

**CORYNEBACTERIUM GLUTAMICUM GENES ENCODING PROTEINS
INVOLVED IN DNA REPLICATION, PROTEIN SYNTHESIS, AND
PATHOGENESIS**

5 **Related Applications**

 This application claims priority to prior filed U.S. Provisional Patent Application Serial No. 60/144448, filed July 16, 1999, and U.S. Provisional Patent Application Serial No.60/149402, filed August 17, 1999. The entire contents of both of the above referenced applications is hereby incorporated by this reference.

10

Background of the Invention

 Certain products and by-products of naturally-occurring metabolic processes in cells have utility in a wide array of industries, including the food, feed, cosmetics, and pharmaceutical industries. These molecules, collectively termed 'fine chemicals',
15 include organic acids, both proteinogenic and non-proteinogenic amino acids, nucleotides and nucleosides, lipids and fatty acids, diols, carbohydrates, aromatic compounds, vitamins and cofactors, and enzymes. Their production is most conveniently performed through the large-scale culture of bacteria developed to produce and secrete large quantities of one or more desired molecules. One particularly useful
20 organism for this purpose is *Corynebacterium glutamicum*, a gram positive bacterium lacking human pathogenicity. Through strain selection, a number of mutant strains have been developed which produce an array of desirable compounds. However, selection of strains improved for the production of a particular molecule is a time-consuming and difficult process.

25

Summary of the Invention

 The invention provides novel bacterial nucleic acid molecules which have a variety of uses. These uses include the identification of microorganisms which can be used to produce fine chemicals, the modulation of fine chemical production in *C.*
30 *glutamicum* or related bacteria, the typing or identification of *C. glutamicum* or related bacteria, as reference points for mapping the *C. glutamicum* genome, and as markers for transformation. These novel nucleic acid molecules encode proteins, referred to herein as DNA replication, ribosome and pathogenesis (RRP) proteins.

C. glutamicum is a gram positive, aerobic bacterium which is commonly used in
35 industry for the large-scale production of a variety of fine chemicals, and also for the degradation of hydrocarbons (such as in petroleum spills) and for the oxidation of terpenoids. The RRP nucleic acid molecules of the invention, therefore, can be used to

identify microorganisms which can be used to produce fine chemicals, *e.g.*, by fermentation processes. Modulation of the expression of the RRP nucleic acids of the invention, or modification of the sequence of the RRP nucleic acid molecules of the invention, can be used to modulate the production of one or more fine chemicals from a microorganism (*e.g.*, to improve the yield or production of one or more fine chemicals from a *Corynebacterium* or *Brevibacterium* species).

The RRP nucleic acids of the invention may also be used to identify an organism as being *Corynebacterium glutamicum* or a close relative thereof, or to identify the presence of *C. glutamicum* or a relative thereof in a mixed population of microorganisms. The invention provides the nucleic acid sequences of a number of *C. glutamicum* genes; by probing the extracted genomic DNA of a culture of a unique or mixed population of microorganisms under stringent conditions with a probe spanning a region of a *C. glutamicum* gene which is unique to this organism, one can ascertain whether this organism is present. Although *Corynebacterium glutamicum* itself is nonpathogenic, it is related to species pathogenic in humans, such as *Corynebacterium diphtheriae* (the causative agent of diphtheria); the detection of such organisms is of significant clinical relevance.

The RRP nucleic acid molecules of the invention may also serve as reference points for mapping of the *C. glutamicum* genome, or of genomes of related organisms. Similarly, these molecules, or variants or portions thereof, may serve as markers for genetically engineered *Corynebacterium* or *Brevibacterium* species.

The RRP proteins encoded by the novel nucleic acid molecules of the invention are capable of, for example, performing a function in *C. glutamicum* involved in the replication of DNA, in protein synthesis, or of contributing to the pathogenicity of the microorganism. Given the availability of cloning vectors for use in *Corynebacterium glutamicum*, such as those disclosed in Sinskey *et al.*, U.S. Patent No. 4,649,119, and techniques for genetic manipulation of *C. glutamicum* and the related *Brevibacterium* species (*e.g.*, *lactofermentum*) (Yoshihama *et al.*, *J. Bacteriol.* 162: 591-597 (1985); Katsumata *et al.*, *J. Bacteriol.* 159: 306-311 (1984); and Santamaria *et al.*, *J. Gen. Microbiol.* 130: 2237-2246 (1984)), the nucleic acid molecules of the invention may be utilized in the genetic engineering of this organism to make it a better or more efficient producer of one or more fine chemicals. This improved production or efficiency of production of a fine chemical may be due to a direct effect of manipulation of a gene of the invention, or it may be due to an indirect effect of such manipulation.

There are a number of mechanisms by which the alteration of an RRP protein of the invention may affect the yield, production, and/or efficiency of production of a fine chemical from a *C. glutamicum* strain incorporating such an altered protein. For

example, by improving the rate at which DNA replication occurs (*e.g.*, by optimizing the activity of one or more DNA polymerase, or by improving the rate at which the topoisomerases or helicases of the invention unwind DNA) it may be possible to increase the rate of cell division, which in turn increases the number of viable fine-chemical-producing *C. glutamicum* cells present in large-scale culture settings.

5 Similarly, by improving the rate at which mRNA is translated to protein (*e.g.*, by optimizing the activity of one or more of the ribosomal proteins) it may be possible to increase the number of proteins in the cell which participate in the synthesis of one or more desired fine chemicals, or in an overall increase in the rate of cell division (due to

10 increased growth and metabolism), both of which should lead to increased production of one or more fine chemicals from large-scale fermentor cultures of these microorganisms. Alterations in the DNA replication proteins of the invention may also permit increased fidelity in the replicative process, thereby increasing the genetic stability and viability of the microorganism and lessening the chance that another

15 engineered mutation improving fine chemical production from the microorganism will not be inadvertently mutagenized by error-prone replication. The RRP proteins of the invention involved in pathogenesis are themselves fine chemicals; by increasing the number or by engineering the corresponding genes such that the expression of these proteins is removed from cellular repression pathways, or by mutagenizing the proteins

20 such that feedback regulatory regions are removed, it may be possible to increase the yield, production, and/or efficiency of production of these proteins from large-scale fermentor culture of organisms containing such mutations.

The invention provides novel nucleic acid molecules which encode proteins, referred to herein as RRP proteins, which are capable of, for example, performing a

25 function in *C. glutamicum* involved in the replication of DNA, in protein synthesis, or of contributing to the pathogenicity of the microorganism. Nucleic acid molecules encoding an RRP protein are referred to herein as RRP nucleic acid molecules. In a preferred embodiment, an RRP protein participates in *C. glutamicum* DNA replication, ribosome function, or in the pathogenesis of the organism, or possesses a *C. glutamicum*

30 enzymatic or proteolytic activity. Examples of such proteins include those encoded by the genes set forth in Table 1.

Accordingly, one aspect of the invention pertains to isolated nucleic acid molecules (*e.g.*, cDNAs, DNAs, or RNAs) comprising a nucleotide sequence encoding an RRP protein or biologically active portions thereof, as well as nucleic acid fragments

35 suitable as primers or hybridization probes for the detection or amplification of RRP-encoding nucleic acids (*e.g.*, DNA or mRNA). In particularly preferred embodiments, the isolated nucleic acid molecule comprises one of the nucleotide sequences set forth in

Appendix A or the coding region or a complement thereof of one of these nucleotide sequences. In other particularly preferred embodiments, the isolated nucleic acid molecule of the invention comprises a nucleotide sequence which hybridizes to or is at least about 50%, preferably at least about 60%, more preferably at least about 70%, 80%
5 or 90%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to a nucleotide sequence set forth in Appendix A, or a portion thereof. In other preferred embodiments, the isolated nucleic acid molecule encodes one of the amino acid sequences set forth in Appendix B. The preferred RRP proteins of the present invention also preferably possess at least one of the RRP activities described
10 herein.

In another embodiment, the isolated nucleic acid molecule encodes a protein or portion thereof wherein the protein or portion thereof includes an amino acid sequence which is sufficiently homologous to an amino acid sequence of Appendix B, *e.g.*, sufficiently homologous to an amino acid sequence of Appendix B such that the protein
15 or portion thereof maintains an RRP activity. Preferably, the protein or portion thereof encoded by the nucleic acid molecule maintains the ability to participate in the replication of DNA, in protein synthesis, or in the pathogenicity of the microorganism. In one embodiment, the protein encoded by the nucleic acid molecule is at least about 50%, preferably at least about 60%, and more preferably at least about 70%, 80%, or
20 90% and most preferably at least about 95%, 96%, 97%, 98%, or 99% or more homologous to an amino acid sequence of Appendix B (*e.g.*, an entire amino acid sequence selected from those sequences set forth in Appendix B). In another preferred embodiment, the protein is a full length *C. glutamicum* protein which is substantially homologous to an entire amino acid sequence of Appendix B (encoded by an open
25 reading frame shown in Appendix A).

In another preferred embodiment, the isolated nucleic acid molecule is derived from *C. glutamicum* and encodes a protein (*e.g.*, an RRP fusion protein) which includes a biologically active domain which is at least about 50% or more homologous to one of the amino acid sequences of Appendix B and is able to participate in the replication of
30 *C. glutamicum* DNA, in *C. glutamicum* protein synthesis, or may contribute to the pathogenicity of the microorganism, or has one or more of the activities set forth in Table 1, and which also includes heterologous nucleic acid sequences encoding a heterologous polypeptide or regulatory regions.

In another embodiment, the isolated nucleic acid molecule is at least 15
35 nucleotides in length and hybridizes under stringent conditions to a nucleic acid molecule comprising a nucleotide sequence of Appendix A. Preferably, the isolated nucleic acid molecule corresponds to a naturally-occurring nucleic acid molecule. More

preferably, the isolated nucleic acid encodes a naturally-occurring *C. glutamicum* RRP protein, or a biologically active portion thereof.

Another aspect of the invention pertains to vectors, *e.g.*, recombinant expression vectors, containing the nucleic acid molecules of the invention, and host cells into which
5 such vectors have been introduced. In one embodiment, such a host cell is used to produce an RRP protein by culturing the host cell in a suitable medium. The RRP protein can be then isolated from the medium or the host cell.

Yet another aspect of the invention pertains to a genetically altered microorganism in which an RRP gene has been introduced or altered. In one
10 embodiment, the genome of the microorganism has been altered by introduction of a nucleic acid molecule of the invention encoding wild-type or mutated RRP sequence as a transgene. In another embodiment, an endogenous RRP gene within the genome of the microorganism has been altered, *e.g.*, functionally disrupted, by homologous recombination with an altered RRP gene. In another embodiment, an endogenous or
15 introduced RRP gene in a microorganism has been altered by one or more point mutations, deletions, or inversions, but still encodes a functional RRP protein. In still another embodiment, one or more of the regulatory regions (*e.g.*, a promoter, repressor, or inducer) of an RRP gene in a microorganism has been altered (*e.g.*, by deletion, truncation, inversion, or point mutation) such that the expression of the RRP gene is
20 modulated. In a preferred embodiment, the microorganism belongs to the genus *Corynebacterium* or *Brevibacterium*, with *Corynebacterium glutamicum* being particularly preferred. In a preferred embodiment, the microorganism is also utilized for the production of a desired compound, such as an amino acid, with lysine being particularly preferred.

25 In another aspect, the invention provides a method of identifying the presence or activity of *Corynebacterium diphtheriae* in a subject. This method includes detection of one or more of the nucleic acid or amino acid sequences of the invention (*e.g.*, the sequences set forth in Appendix A or Appendix B) in a subject, thereby detecting the presence or activity of *Corynebacterium diphtheriae* in the subject.

30 Still another aspect of the invention pertains to an isolated RRP protein or a portion, *e.g.*, a biologically active portion, thereof. In a preferred embodiment, the isolated RRP protein or portion thereof can participate in the replication of *C. glutamicum* DNA, in *C. glutamicum* protein synthesis, or may contribute to the pathogenicity of the microorganism. In another preferred embodiment, the isolated RRP
35 protein or portion thereof is sufficiently homologous to an amino acid sequence of Appendix B such that the protein or portion thereof maintains the ability to participate in

the replication of *C. glutamicum* DNA, to participate in *C. glutamicum* protein synthesis, or may contribute to the pathogenicity of the microorganism.

The invention also provides an isolated preparation of an RRP protein. In preferred embodiments, the RRP protein comprises an amino acid sequence of

5 Appendix B. In another preferred embodiment, the invention pertains to an isolated full length protein which is substantially homologous to an entire amino acid sequence of Appendix B (encoded by an open reading frame set forth in Appendix A). In yet another embodiment, the protein is at least about 50%, preferably at least about 60%, and more preferably at least about 70%, 80%, or 90%, and most preferably at least about

10 95%, 96%, 97%, 98%, or 99% or more homologous to an entire amino acid sequence of Appendix B. In other embodiments, the isolated RRP protein comprises an amino acid sequence which is at least about 50% or more homologous to one of the amino acid sequences of Appendix B and is able to participate in the replication of *C. glutamicum* DNA, to participate in *C. glutamicum* protein synthesis, or may contribute to the

15 pathogenicity of the microorganism, or has one or more of the activities set forth in Table 1.

Alternatively, the isolated RRP protein can comprise an amino acid sequence which is encoded by a nucleotide sequence which hybridizes, *e.g.*, hybridizes under stringent conditions, or is at least about 50%, preferably at least about 60%, more

20 preferably at least about 70%, 80%, or 90%, and even more preferably at least about 95%, 96%, 97%, 98%, or 99% or more homologous, to a nucleotide sequence of Appendix B. It is also preferred that the preferred forms of RRP proteins also have one or more of the RRP bioactivities described herein.

The RRP polypeptide, or a biologically active portion thereof, can be operatively

25 linked to a non-RRP polypeptide to form a fusion protein. In preferred embodiments, this fusion protein has an activity which differs from that of the RRP protein alone. In other preferred embodiments, this fusion protein participates in the replication of *C. glutamicum* DNA, participates in *C. glutamicum* protein synthesis, or contributes to the pathogenicity of the microorganism. In particularly preferred embodiments, integration

30 of this fusion protein into a host cell modulates production of a desired compound from the cell.

In another aspect, the invention provides methods for screening molecules which modulate the activity of an RRP protein, either by interacting with the protein itself or a substrate or binding partner of the RRP protein, or by modulating the transcription or

35 translation of an RRP nucleic acid molecule of the invention.

Another aspect of the invention pertains to a method for producing a fine chemical. This method involves the culturing of a cell containing a vector directing the

expression of an RRP nucleic acid molecule of the invention, such that a fine chemical is produced. In a preferred embodiment, this method further includes the step of obtaining a cell containing such a vector, in which a cell is transfected with a vector directing the expression of an RRP nucleic acid. In another preferred embodiment, this method further includes the step of recovering the fine chemical from the culture. In a particularly preferred embodiment, the cell is from the genus *Corynebacterium* or *Brevibacterium*, or is selected from those strains set forth in Table 3.

Another aspect of the invention pertains to methods for modulating production of a molecule from a microorganism. Such methods include contacting the cell with an agent which modulates RRP protein activity or RRP nucleic acid expression such that a cell associated activity is altered relative to this same activity in the absence of the agent. In a preferred embodiment, the cell is modulated for one or more *C. glutamicum* processes involved in the replication of *C. glutamicum* DNA, in *C. glutamicum* protein synthesis, or in the pathogenicity of the microorganism. The agent which modulates RRP protein activity can be an agent which stimulates RRP protein activity or RRP nucleic acid expression. Examples of agents which stimulate RRP protein activity or RRP nucleic acid expression include small molecules, active RRP proteins, and nucleic acids encoding RRP proteins that have been introduced into the cell. Examples of agents which inhibit RRP activity or expression include small molecules and antisense RRP nucleic acid molecules.

Another aspect of the invention pertains to methods for modulating yields of a desired compound from a cell, involving the introduction of a wild-type or mutant RRP gene into a cell, either maintained on a separate plasmid or integrated into the genome of the host cell. If integrated into the genome, such integration can be random, or it can take place by homologous recombination such that the native gene is replaced by the introduced copy, causing the production of the desired compound from the cell to be modulated. In a preferred embodiment, said yields are increased. In another preferred embodiment, said chemical is a fine chemical. In a particularly preferred embodiment, said fine chemical is an amino acid. In especially preferred embodiments, said amino acid is L-lysine.

Detailed Description of the Invention

The present invention provides RRP nucleic acid and protein molecules which are involved in *C. glutamicum* DNA replication, protein synthesis, or pathogenesis. The molecules of the invention may be utilized in the modulation of production of fine chemicals from microorganisms, such as *C. glutamicum*, either directly (*e.g.*, where increased activity of a ribosome permits increased production of fine chemical

biosynthetic proteins, which may result in increased yields, production, or efficiency of production of one or more fine chemicals from the modified *C. glutamicum*), or may have an indirect impact which nonetheless results in an increase of yield, production, and/or efficiency of production of the desired compound (*e.g.*, where modulation of the activity or number of copies of a *C. glutamicum* DNA synthesis protein results in an increase in the rate of *C. glutamicum* cell division, resulting in greater numbers of viable cells in culture, which in turn permits increased production in a large-scale culture setting). Aspects of the invention are further explicated below.

10 I. Fine Chemicals

The term 'fine chemical' is art-recognized and includes molecules produced by an organism which have applications in various industries, such as, but not limited to, the pharmaceutical, agriculture, and cosmetics industries. Such compounds include organic acids, such as tartaric acid, itaconic acid, and diaminopimelic acid, both proteinogenic and non-proteinogenic amino acids, purine and pyrimidine bases, nucleosides, and nucleotides (as described *e.g.* in Kuninaka, A. (1996) Nucleotides and related compounds, p. 561-612, in Biotechnology vol. 6, Rehm *et al.*, eds. VCH: Weinheim, and references contained therein), lipids, both saturated and unsaturated fatty acids (*e.g.*, arachidonic acid), diols (*e.g.*, propane diol, and butane diol), carbohydrates (*e.g.*, hyaluronic acid and trehalose), aromatic compounds (*e.g.*, aromatic amines, vanillin, and indigo), vitamins and cofactors (as described in Ullmann's Encyclopedia of Industrial Chemistry, vol. A27, "Vitamins", p. 443-613 (1996) VCH: Weinheim and references therein; and Ong, A.S., Niki, E. & Packer, L. (1995) "Nutrition, Lipids, Health, and Disease" Proceedings of the UNESCO/Confederation of Scientific and Technological Associations in Malaysia, and the Society for Free Radical Research – Asia, held Sept. 1-3, 1994 at Penang, Malaysia, AOCS Press, (1995)), enzymes, polyketides (Cane *et al.* (1998) *Science* 282: 63-68), toxins, and all other chemicals described in Gutcho (1983) Chemicals by Fermentation, Noyes Data Corporation, ISBN: 0818805086 and references therein. The metabolism and uses of certain of these fine chemicals are further explicated below.

A. *Amino Acid Metabolism and Uses*

Amino acids comprise the basic structural units of all proteins, and as such are essential for normal cellular functioning in all organisms. The term "amino acid" is art-recognized. The proteinogenic amino acids, of which there are 20 species, serve as structural units for proteins, in which they are linked by peptide bonds, while the nonproteinogenic amino acids (hundreds of which are known) are not normally found in

proteins (see Ulmann's Encyclopedia of Industrial Chemistry, vol. A2, p. 57-97 VCH: Weinheim (1985)). Amino acids may be in the D- or L- optical configuration, though L-amino acids are generally the only type found in naturally-occurring proteins.

Biosynthetic and degradative pathways of each of the 20 proteinogenic amino acids
5 have been well characterized in both prokaryotic and eukaryotic cells (see, for example, Stryer, L. Biochemistry, 3rd edition, pages 578-590 (1988)). The 'essential' amino acids (histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine), so named because they are generally a nutritional requirement due to the complexity of their biosyntheses, are readily converted by simple biosynthetic pathways
10 to the remaining 11 'nonessential' amino acids (alanine, arginine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, and tyrosine). Higher animals do retain the ability to synthesize some of these amino acids, but the essential amino acids must be supplied from the diet in order for normal protein synthesis to occur.

Aside from their function in protein biosynthesis, these amino acids are
15 interesting chemicals in their own right, and many have been found to have various applications in the food, feed, chemical, cosmetics, agriculture, and pharmaceutical industries. Lysine is an important amino acid in the nutrition not only of humans, but also of monogastric animals such as poultry and swine. Glutamate is most commonly used as a flavor additive (mono-sodium glutamate, MSG) and is widely used throughout
20 the food industry, as are aspartate, phenylalanine, glycine, and cysteine. Glycine, L-methionine and tryptophan are all utilized in the pharmaceutical industry. Glutamine, valine, leucine, isoleucine, histidine, arginine, proline, serine and alanine are of use in both the pharmaceutical and cosmetics industries. Threonine, tryptophan, and D/ L-methionine are common feed additives. (Leuchtenberger, W. (1996) Amino acids –
25 technical production and use, p. 466-502 in Rehm *et al.* (eds.) Biotechnology vol. 6, chapter 14a, VCH: Weinheim). Additionally, these amino acids have been found to be useful as precursors for the synthesis of synthetic amino acids and proteins, such as N-acetylcysteine, S-carboxymethyl-L-cysteine, (S)-5-hydroxytryptophan, and others described in Ulmann's Encyclopedia of Industrial Chemistry, vol. A2, p. 57-97, VCH:
30 Weinheim, 1985.

The biosynthesis of these natural amino acids in organisms capable of producing them, such as bacteria, has been well characterized (for review of bacterial amino acid biosynthesis and regulation thereof, see Umbarger, H.E.(1978) *Ann. Rev. Biochem.* 47: 533-606). Glutamate is synthesized by the reductive amination of α -
35 ketoglutarate, an intermediate in the citric acid cycle. Glutamine, proline, and arginine are each subsequently produced from glutamate. The biosynthesis of serine is a three-step process beginning with 3-phosphoglycerate (an intermediate in glycolysis), and

resulting in this amino acid after oxidation, transamination, and hydrolysis steps. Both cysteine and glycine are produced from serine; the former by the condensation of homocysteine with serine, and the latter by the transferal of the side-chain β -carbon atom to tetrahydrofolate, in a reaction catalyzed by serine transhydroxymethylase.

- 5 Phenylalanine, and tyrosine are synthesized from the glycolytic and pentose phosphate pathway precursors erythrose 4-phosphate and phosphoenolpyruvate in a 9-step biosynthetic pathway that differ only at the final two steps after synthesis of prephenate. Tryptophan is also produced from these two initial molecules, but its synthesis is an 11-step pathway. Tyrosine may also be synthesized from phenylalanine, in a reaction
10 catalyzed by phenylalanine hydroxylase. Alanine, valine, and leucine are all biosynthetic products of pyruvate, the final product of glycolysis. Aspartate is formed from oxaloacetate, an intermediate of the citric acid cycle. Asparagine, methionine, threonine, and lysine are each produced by the conversion of aspartate. Isoleucine is formed from threonine. A complex 9-step pathway results in the production of histidine
15 from 5-phosphoribosyl-1-pyrophosphate, an activated sugar.

Amino acids in excess of the protein synthesis needs of the cell cannot be stored, and are instead degraded to provide intermediates for the major metabolic pathways of the cell (for review see Stryer, L. Biochemistry 3rd ed. Ch. 21 "Amino Acid Degradation and the Urea Cycle" p. 495-516 (1988)). Although the cell is able to convert unwanted
20 amino acids into useful metabolic intermediates, amino acid production is costly in terms of energy, precursor molecules, and the enzymes necessary to synthesize them. Thus it is not surprising that amino acid biosynthesis is regulated by feedback inhibition, in which the presence of a particular amino acid serves to slow or entirely stop its own production (for overview of feedback mechanisms in amino acid biosynthetic pathways,
25 see Stryer, L. Biochemistry, 3rd ed. Ch. 24: "Biosynthesis of Amino Acids and Heme" p. 575-600 (1988)). Thus, the output of any particular amino acid is limited by the amount of that amino acid present in the cell.

B. Vitamin, Cofactor, and Nutraceutical Metabolism and Uses

- 30 Vitamins, cofactors, and nutraceuticals comprise another group of molecules which the higher animals have lost the ability to synthesize and so must ingest, although they are readily synthesized by other organisms such as bacteria. These molecules are either bioactive substances themselves, or are precursors of biologically active substances which may serve as electron carriers or intermediates in a variety of
35 metabolic pathways. Aside from their nutritive value, these compounds also have significant industrial value as coloring agents, antioxidants, and catalysts or other processing aids. (For an overview of the structure, activity, and industrial applications

of these compounds, see, for example, Ullman's Encyclopedia of Industrial Chemistry, "Vitamins" vol. A27, p. 443-613, VCH: Weinheim, 1996.) The term "vitamin" is art-recognized, and includes nutrients which are required by an organism for normal functioning, but which that organism cannot synthesize by itself. The group of vitamins
5 may encompass cofactors and nutraceutical compounds. The language "cofactor" includes nonproteinaceous compounds required for a normal enzymatic activity to occur. Such compounds may be organic or inorganic; the cofactor molecules of the invention are preferably organic. The term "nutraceutical" includes dietary supplements having health benefits in plants and animals, particularly humans. Examples of such
10 molecules are vitamins, antioxidants, and also certain lipids (*e.g.*, polyunsaturated fatty acids).

The biosynthesis of these molecules in organisms capable of producing them, such as bacteria, has been largely characterized (Ullman's Encyclopedia of Industrial Chemistry, "Vitamins" vol. A27, p. 443-613, VCH: Weinheim, 1996; Michal, G. (1999)
15 Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology, John Wiley & Sons; Ong, A.S., Niki, E. & Packer, L. (1995) "Nutrition, Lipids, Health, and Disease" Proceedings of the UNESCO/Confederation of Scientific and Technological Associations in Malaysia, and the Society for Free Radical Research – Asia, held Sept. 1-3, 1994 at Penang, Malaysia, AOCS Press: Champaign, IL X, 374 S).

20 Thiamin (vitamin B₁) is produced by the chemical coupling of pyrimidine and thiazole moieties. Riboflavin (vitamin B₂) is synthesized from guanosine-5'-triphosphate (GTP) and ribose-5'-phosphate. Riboflavin, in turn, is utilized for the synthesis of flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD). The family of compounds collectively termed 'vitamin B₆' (*e.g.*, pyridoxine, pyridoxamine, pyridoxa-
25 5'-phosphate, and the commercially used pyridoxin hydrochloride) are all derivatives of the common structural unit, 5-hydroxy-6-methylpyridine. Pantothenate (pantothenic acid, (R)-(+)-N-(2,4-dihydroxy-3,3-dimethyl-1-oxobutyl)- β -alanine) can be produced either by chemical synthesis or by fermentation. The final steps in pantothenate biosynthesis consist of the ATP-driven condensation of β -alanine and pantoic acid. The
30 enzymes responsible for the biosynthesis steps for the conversion to pantoic acid, to β -alanine and for the condensation to pantothenic acid are known. The metabolically active form of pantothenate is Coenzyme A, for which the biosynthesis proceeds in 5 enzymatic steps. Pantothenate, pyridoxal-5'-phosphate, cysteine and ATP are the precursors of Coenzyme A. These enzymes not only catalyze the formation of
35 panthothante, but also the production of (R)-pantoic acid, (R)-pantolacton, (R)-panthenol (provitamin B₅), pantetheine (and its derivatives) and coenzyme A.

Biotin biosynthesis from the precursor molecule pimeloyl-CoA in microorganisms has been studied in detail and several of the genes involved have been identified. Many of the corresponding proteins have been found to also be involved in Fe-cluster synthesis and are members of the *nifS* class of proteins. Lipoic acid is
5 derived from octanoic acid, and serves as a coenzyme in energy metabolism, where it becomes part of the pyruvate dehydrogenase complex and the α -ketoglutarate dehydrogenase complex. The folates are a group of substances which are all derivatives of folic acid, which in turn is derived from L-glutamic acid, p-amino-benzoic acid and 6-methylpterin. The biosynthesis of folic acid and its derivatives, starting from the
10 metabolism intermediates guanosine-5'-triphosphate (GTP), L-glutamic acid and p-amino-benzoic acid has been studied in detail in certain microorganisms.

Corrinoids (such as the cobalamines and particularly vitamin B₁₂) and porphyrines belong to a group of chemicals characterized by a tetrapyrrole ring system. The biosynthesis of vitamin B₁₂ is sufficiently complex that it has not yet been
15 completely characterized, but many of the enzymes and substrates involved are now known. Nicotinic acid (nicotinate), and nicotinamide are pyridine derivatives which are also termed 'niacin'. Niacin is the precursor of the important coenzymes NAD (nicotinamide adenine dinucleotide) and NADP (nicotinamide adenine dinucleotide phosphate) and their reduced forms.

20 The large-scale production of these compounds has largely relied on cell-free chemical syntheses, though some of these chemicals have also been produced by large-scale culture of microorganisms, such as riboflavin, Vitamin B₆, pantothenate, and biotin. Only Vitamin B₁₂ is produced solely by fermentation, due to the complexity of its synthesis. *In vitro* methodologies require significant inputs of materials and time,
25 often at great cost.

C. Purine, Pyrimidine, Nucleoside and Nucleotide Metabolism and Uses

Purine and pyrimidine metabolism genes and their corresponding proteins are important targets for the therapy of tumor diseases and viral infections. The language
30 "purine" or "pyrimidine" includes the nitrogenous bases which are constituents of nucleic acids, co-enzymes, and nucleotides. The term "nucleotide" includes the basic structural units of nucleic acid molecules, which are comprised of a nitrogenous base, a pentose sugar (in the case of RNA, the sugar is ribose; in the case of DNA, the sugar is D-deoxyribose), and phosphoric acid. The language "nucleoside" includes molecules
35 which serve as precursors to nucleotides, but which are lacking the phosphoric acid moiety that nucleotides possess. By inhibiting the biosynthesis of these molecules, or their mobilization to form nucleic acid molecules, it is possible to inhibit RNA and DNA

synthesis; by inhibiting this activity in a fashion targeted to cancerous cells, the ability of tumor cells to divide and replicate may be inhibited. Additionally, there are nucleotides which do not form nucleic acid molecules, but rather serve as energy stores (*i.e.*, AMP) or as coenzymes (*i.e.*, FAD and NAD).

5 Several publications have described the use of these chemicals for these medical indications, by influencing purine and/or pyrimidine metabolism (*e.g.* Christopherson, R.I. and Lyons, S.D. (1990) "Potent inhibitors of *de novo* pyrimidine and purine biosynthesis as chemotherapeutic agents." *Med. Res. Reviews* 10: 505-548). Studies of enzymes involved in purine and pyrimidine metabolism have been focused on the
10 development of new drugs which can be used, for example, as immunosuppressants or anti-proliferants (Smith, J.L., (1995) "Enzymes in nucleotide synthesis." *Curr. Opin. Struct. Biol.* 5: 752-757; (1995) *Biochem Soc. Transact.* 23: 877-902). However, purine and pyrimidine bases, nucleosides and nucleotides have other utilities: as intermediates in the biosynthesis of several fine chemicals (*e.g.*, thiamine, S-adenosyl-methionine,
15 folates, or riboflavin), as energy carriers for the cell (*e.g.*, ATP or GTP), and for chemicals themselves, commonly used as flavor enhancers (*e.g.*, IMP or GMP) or for several medicinal applications (see, for example, Kuninaka, A. (1996) *Nucleotides and Related Compounds in Biotechnology* vol. 6, Rehm *et al.*, eds. VCH: Weinheim, p. 561-612). Also, enzymes involved in purine, pyrimidine, nucleoside, or nucleotide
20 metabolism are increasingly serving as targets against which chemicals for crop protection, including fungicides, herbicides and insecticides, are developed.

 The metabolism of these compounds in bacteria has been characterized (for reviews see, for example, Zalkin, H. and Dixon, J.E. (1992) "*de novo* purine nucleotide biosynthesis", in: *Progress in Nucleic Acid Research and Molecular Biology*, vol. 42, Academic Press, p. 259-287; and Michal, G. (1999) "Nucleotides and Nucleosides",
25 Chapter 8 in: *Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology*, Wiley: New York). Purine metabolism has been the subject of intensive research, and is essential to the normal functioning of the cell. Impaired purine metabolism in higher animals can cause severe disease, such as gout. Purine nucleotides are synthesized from
30 ribose-5-phosphate, in a series of steps through the intermediate compound inosine-5'-phosphate (IMP), resulting in the production of guanosine-5'-monophosphate (GMP) or adenosine-5'-monophosphate (AMP), from which the triphosphate forms utilized as nucleotides are readily formed. These compounds are also utilized as energy stores, so their degradation provides energy for many different biochemical processes in the cell.
35 Pyrimidine biosynthesis proceeds by the formation of uridine-5'-monophosphate (UMP) from ribose-5-phosphate. UMP, in turn, is converted to cytidine-5'-triphosphate (CTP). The deoxy- forms of all of these nucleotides are produced in a one step reduction

reaction from the diphosphate ribose form of the nucleotide to the diphosphate deoxyribose form of the nucleotide. Upon phosphorylation, these molecules are able to participate in DNA synthesis.

5 *D. Trehalose Metabolism and Uses*

Trehalose consists of two glucose molecules, bound in α , α -1,1 linkage. It is commonly used in the food industry as a sweetener, an additive for dried or frozen foods, and in beverages. However, it also has applications in the pharmaceutical, cosmetics and biotechnology industries (see, for example, Nishimoto *et al.*, (1998) U.S. Patent No. 5,759,610; Singer, M.A. and Lindquist, S. (1998) *Trends Biotech.* 16: 460-467; Paiva, C.L.A. and Panek, A.D. (1996) *Biotech. Ann. Rev.* 2: 293-314; and Shiosaka, M. (1997) *J. Japan* 172: 97-102). Trehalose is produced by enzymes from many microorganisms and is naturally released into the surrounding medium, from which it can be collected using methods known in the art.

15 II. Activities of the Genes of the Invention

In order for a population of a particular type of bacterial cells to survive in an environment, at least three activities are necessary. First, the cells must be able to divide efficiently, such that the population is at least maintained, if not increased. Second, the cells must be able to efficiently express those genes encoding proteins necessary for normal cellular functioning. Finally, the cells must be able to influence their interaction with the surrounding environment, either by adaptation to the prevailing environmental conditions, by physical movement to preferred surroundings, or by directly altering the surrounding environment such that their own viability is improved. Critical processes involved in each of the aforementioned activities include replication of the bacterial genome, the action of the ribosome in protein synthesis, and anticellular or cell lytic activities (such as those involved in the pathogenesis of an organism).

25 *A. DNA Replication*

In order for a cell (*e.g.*, a bacterial cell) to divide to form viable progeny cells, the cellular genome must be replicated. This is a multistep process, in which the tightly packaged DNA must first be locally freed from topological constraints, the two strands of the double helix must be unwound, a DNA polymerase must synthesize a new strand of DNA complementary to one of the original strands, and both the old and the new strands must be repackaged. Each of these steps is described in greater detail in the following section (see, *e.g.*, Michal, G. (1999) *Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology*, Wiley: New York, and references therein; and

Griffiths, A.J.F. *et al.*, (1993) *An Introduction to Genetic Analysis*, 5th ed., Freeman: New York p. 304-332 and references therein).

The general structure of genomic DNA in bacterial cells has been characterized. Bacterial chromosomes are usually circular in nature, and bacterial cells may also
5 contain one or more different types of plasmids (also circular pieces of DNA, although usually significantly smaller in size than the bacterial chromosome) which may be replicated and incorporated into the daughter cell simultaneously with the chromosome. Replication of either of these circular pieces of genetic information typically begins at a single designated origin of replication (*ori*). Replication of the DNA may then take place
10 either in one direction around the circle (rolling circle replication) until the origin is again reached, or it may occur in both directions simultaneously (θ -mechanism).

The *ori* site has a particular structure which permits the initiation of replication. First, the *ori* region typically contains multiple sequences which serve as binding sites for initiator proteins. The binding of the initiator proteins (*e.g.*, DnaA in *E. coli*) to these
15 binding sites at the origin takes place in an ATP-dependent fashion. Upon ATP hydrolysis, the DNA bends around these DNA-associated molecules, and the two strands of DNA at the site separate, forming an open complex.

The molecule responsible for the actual synthesis of the new DNA molecule is a DNA polymerase. For replication purposes, the DNA polymerase utilized by the cell is
20 the DNA polymerase III (Pol III) holoenzyme. This complex comprises 10 molecules, each of which has a different function in the complex. For example, the dimeric γ subunit acts to associate the β subunit with a primed DNA template in an ATP-dependent fashion. The β subunit is the 'processivity factor' – the portion of the holoenzyme which specifically associates with the DNA template and which permits the
25 template to 'slide' along the DNA due to its ring-like structure. The α subunit catalyzes the reaction which adds the new dNTP to the nascent nucleotide strand, and the ϵ subunit contains the 3'-5' exonuclease activity.

A significant topological barrier to DNA synthesis exists due to the structure of a DNA molecule and to that of the bacterial chromosome. Not only must the double helix
30 of the DNA molecule be split such that a single strand may be replicated, but this unwinding process results in increased positive supercoiling of the chromosome. Two types of enzymes permit these processes to occur despite the topological constraints: helicase unwinds the double helix in an ATP-dependent fashion, introducing positive supercoils into the bacterial chromosome. Gyrase introduces negative supercoils into
35 the bacterial genome (in an ATP-dependent fashion), counteracting the positive supercoils introduced by the helicase. The result of their combined is a replication fork: a split between the two strands of DNA in which replication of each strand of the DNA

can occur. Single-stranded binding proteins (SSBs) bind to the unwound DNA molecules to prevent them from reassociating.

In order for Pol III to initiate DNA synthesis, it must have a sequence from which to prime synthesis. Primase (*E. coli* DnaG) synthesizes RNA primers as starting sequences for Pol III. The Pol III complex gamma subunit associates with the newly synthesized primers and subsequently associates with the dimeric beta Pol III subunits, initiating DNA synthesis. Replication of each strand takes place simultaneously, but because Pol III polymerizes dNTPs only in the 5'-3' direction, only one strand (the 3'-5' leading strand) can be continuously replicated. The other strand (the complementary lagging strand) is replicated in short fragments (Okazaki fragments), due to the lack of progressivity of the polymerase in this direction. These fragments are subsequently ligated by DNA ligase to form a single strand. Incorrectly added bases are excised by the 3'-5' exonuclease activity of Pol III and the nick sealed by DNA ligase.

Bacterial DNA replication is terminated at a site opposite to the origin at which terminator proteins bind. The association of these proteins with the DNA prevents the replication fork from progressing. The RNA primer used to initiate DNA synthesis is degraded by DNA polymerase I (Pol I) or ribonuclease H (RnaseH), and Pol I adds the appropriate dNTPs to the gap. Finally, DNA ligase seals the nicks. To achieve semiconservative replication, the two strands of the parental bacterial chromosome are separated by topoisomerases and are each paired with the complementary daughter strand.

B. Protein Synthesis

Protein synthesis is a multistep process which converts mRNA to the corresponding polypeptide chain (see, e.g., Michal, G. (1999) *Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology*, Wiley: New York, and references therein; and Griffiths, A.J.F. *et al.*, (1993) *An Introduction to Genetic Analysis*, 5th ed., Freeman: New York p. 391-398 and references therein). As the initiator codon (AUG, encoding methionine) first becomes accessible after being transcribed from the DNA by RNA polymerase, a translation initiation complex forms. This complex is comprised of the mRNA molecule itself, an initiation tRNA molecule (charged with methionine, corresponding to the first AUG codon of the mRNA molecule, and which has also been formylated to form the N-terminus of the nascent polypeptide), initiation factors, and the ribosome itself.

The bacterial ribosome (the 70S ribosome) contains two subunits. The first subunit is large (50S) while the second is small (30S). Each subunit contains a complex of RNA and protein molecules which assemble soon after or during their synthesis.

These complexes are globular in shape, and the large subunit contains a long channel through which it is believed that the nascent polypeptide chain leaves the ribosome. There are at least three known sites of activity in the bacterial ribosome: one to bind a charged tRNA (aminoacyl tRNA), one to bind a tRNA associated with the nascent polypeptide chain, and the third to expel the uncharged tRNA from the complex. Ribosomes may occur singly or in groups, termed 'polyribosomes' or 'polysomes'. These complexes are plentiful within the cell; one *E. coli* cell may contain as many as 15,000 ribosomes, constituting up to one quarter of the total biomass of the cell.

Upon the binding of the initiator tRNA^{met} in complex with the initiation factor IF-2 and GTP, the 30S ribosomal subunit binds such that the tRNA anticodon is associated with the peptidyl site in this molecule. The binding of the 50S subunit to this complex causes hydrolysis of the bound GTP, with concomitant release of the initiation factors. The amino-acid-charged tRNA corresponding to the second codon of the mRNA is positioned in the aminoacyl tRNA site in the ribosome (by the action of the elongation factor EF-Tu). The methionine attached to the tRNA in the peptidyl site and the amino acid bound to the tRNA in the aminoacyl site react to form a peptide bond, catalyzed by the peptidyltransferase activity of the 23S rRNA in the complex. Two simultaneous translocation steps subsequently occur in a GTP-dependent fashion: the nascent polypeptide-bound (peptidyl) tRNA remaining in the aminoacyl site is translocated to the peptidyl site of the ribosome (with concomitant displacement of the now uncharged tRNA in the peptidyl site to the ejection site), and the mRNA moves one codon site relative to the ribosome such that the next codon is exposed to the aminoacyl-tRNA site on the ribosome.

This cycle of amino acid addition and elongation of the peptide chain continues until a stop codon (UAA, UGA, UAG) is reached. There do not exist tRNA molecules specific for these stop codons; thus, no amino acid can be added. Instead, one of two release factors (specific to the particular codon in question) binds to the mRNA at the stop codon in a complex with release factor 3 and GTP. The release of the nascent polypeptide chain is accomplished by the hydrolysis of this GTP, and the remaining bound ribosomal subunits are dissociated through the activity of the ribosomal recycling factor.

C. Pathogenesis

Bacteria possess numerous mechanisms by which they are able to survive and even to adapt to environments with suboptimal growth conditions. These include protective elements (*e.g.*, the cell wall, which prevents osmotic lysis), the ability to switch to the utilization of different nutrient sources (*e.g.*, inorganic compounds, or

carbon sources), and the ability to adjust to different stresses (*e.g.*, temperature stress, osmotic stress, pH stress, or oxygen stress) by the activation of a sigma factor regulatory cascade. Under growth conditions in a complex environment containing cells other than the bacterium, many bacteria are capable of another survival mechanism: pathogenesis.

- 5 In order to survive in a host (*e.g.*, a plant, animal, or human host), bacteria must be able to not only defend themselves against killing or removal by host immune systems, but also to proliferate. Many bacteria have developed multiple mechanisms by which each goal may be accomplished (see, *e.g.*, Stanier *et al.* (1986) *The Microbial World* 5th ed., Prentice Hall: Englewood Cliffs and references therein; and Hacker, J.
- 10 (1999) "Prokaryotes in Medicine" in "Biology of the Prokaryotes, Lengeler *et al.*, eds., Thieme Verlag: Stuttgart, p. 815-849, and references therein). Many bacteria produce peptide or protein toxins (*e.g.*, hemolysins, or diphtheria toxin from *Corynebacterium diphtheriae*) which act to specifically or nonspecifically destroy host cells. Frequently these toxins are directed to immune cells which would otherwise act to remove the
- 15 bacteria from the host. Such toxins may exert their lethal effect in a variety of ways, including by inhibition of protein synthesis in the target cell (*e.g.*, exotoxin A from *Pseudomonas aeruginosa* or diphtheria toxin), by interfering with cellular signal transduction in the target cell (*e.g.*, anthrax lethal toxin, cholera toxin), or by simply creating holes in the target cell membrane which lead to cell lysis (*e.g.*, hemolysins).
- 20 These toxic activities manifest as a disease, for example, diphtheria, tuberculosis (*Mycobacterium bovis* or *M. tuberculosis*), anthrax (*Bacillus anthracis*).

Proliferation (*i.e.*, colonization) of the bacterial cells depends on special factors termed adhesion factors or adhesins. These frequently proteinaceous molecules at the cell surface of the bacterium permit the bacterium to bind to one or more specific host

25 cells or surfaces. This not only permits the bacterium to not be removed by circulatory and excretory processes, but it also limits the exposure of the bacterium to the host immune system, since the bacteria remain stationary and sometimes even inaccessible once adhered to a surface.

Corynebacterium glutamicum is a soil bacterium not known to be pathogenic,

30 but its genome surprisingly includes several genes which are typically associated with bacterial pathogenesis, but the expression of which has never been observed. Similar situations have been observed in other bacteria: a bacterial species may have stains which are virulent (disease causing) and avirulent (nonpathogenic). A classic example of this is *E. coli*, from which both virulent (*e.g.*, enteropathogenic species) and avirulent

35 (*e.g.*, K-12 strains) are well known. Certain bacteria are typically not pathogenic, but may still contain within their genome genes encoding proteins involved in pathogenicity, such as adhesins or toxins. These may be a evolutionary remnant, or may

simply only be expressed under specific conditions which the bacterium rarely encounters.

III. Elements and Methods of the Invention

5 The present invention is based, at least in part, on the discovery of novel molecules, referred to herein as RRP nucleic acid and protein molecules, which participate in *C. glutamicum* DNA replication, protein synthesis, or pathogenesis. In one embodiment, the RRP molecules participate in the replication of *C. glutamicum* DNA, in *C. glutamicum* ribosome activity, or in the pathogenicity of the microorganism. In a
10 preferred embodiment, the activity of the RRP molecules of the present invention with regard to DNA replication, protein synthesis, or pathogenesis has an impact on the production of a desired fine chemical by this organism. In a particularly preferred embodiment, the RRP molecules of the invention are modulated in activity, such that the *C. glutamicum* cellular processes in which the RRP molecules participate (*e.g.*, DNA
15 replication, protein synthesis, or pathogenesis) are also altered in activity, resulting either directly or indirectly in a modulation of the yield, production, and/or efficiency of production of a desired fine chemical by *C. glutamicum*.

 The language, "RRP protein" or "RRP polypeptide" includes proteins which participate in a number of cellular processes related to *C. glutamicum* DNA replication, protein synthesis, or pathogenesis. For example, an RRP protein may be involved in the
20 replication of *C. glutamicum* DNA, in *C. glutamicum* ribosome activity, or in the pathogenicity of the microorganism. Examples of RRP proteins include those encoded by the RRP genes set forth in Table 1 and Appendix A. The terms "RRP gene" or "RRP nucleic acid sequence" include nucleic acid sequences encoding an RRP protein, which
25 consist of a coding region and also corresponding untranslated 5' and 3' sequence regions. Examples of RRP genes include those set forth in Table 1. The terms "production" or "productivity" are art-recognized and include the concentration of the fermentation product (for example, the desired fine chemical) formed within a given time and a given fermentation volume (*e.g.*, kg product per hour per liter). The term
30 "efficiency of production" includes the time required for a particular level of production to be achieved (for example, how long it takes for the cell to attain a particular rate of output of a fine chemical). The term "yield" or "product/carbon yield" is art-recognized and includes the efficiency of the conversion of the carbon source into the product (*i.e.*, fine chemical). This is generally written as, for example, kg product per kg carbon
35 source. By increasing the yield or production of the compound, the quantity of recovered molecules, or of useful recovered molecules of that compound in a given amount of culture over a given amount of time is increased. The terms "biosynthesis" or

a "biosynthetic pathway" are art-recognized and include the synthesis of a compound, preferably an organic compound, by a cell from intermediate compounds in what may be a multistep and highly regulated process. The terms "degradation" or a "degradation pathway" are art-recognized and include the breakdown of a compound, preferably an organic compound, by a cell to degradation products (generally speaking, smaller or less complex molecules) in what may be a multistep and highly regulated process. The language "metabolism" is art-recognized and includes the totality of the biochemical reactions that take place in an organism. The metabolism of a particular compound, then, (*e.g.*, the metabolism of an amino acid such as glycine) comprises the overall biosynthetic, modification, and degradation pathways in the cell related to this compound. The language "pathogenicity" or "pathogenesis" is art-recognized and includes the activity of an organism, such as a bacterial organism, to bring about a disease state in a host (*e.g.*, cholera, diphtheria, or anthrax). Such disease states are typically the result of cell lytic activity of the organism, which may occur through the expression and release of cytotoxins (*e.g.*, cholera toxin, diphtheria toxin, or anthrax toxin). Other bacterial proteins or peptides not pertaining specifically to cell lysis but contributing to the colonization of the host by the bacterium may also be considered pathogenesis proteins, such as, but not limited to, adhesins. The term "DNA replication" is art-recognized and includes all of the activities associated with the replication of DNA *in vivo* or *in vitro*, and for the purposes of the invention, particularly within bacterial cells. These activities include but are not limited to the assembly of DNA polymerases, the unwinding of DNA, the incorporation of new dNTPs into the nascent DNA strand, the excision and replacement of erroneous bases, and the termination of replication. The term "protein synthesis" is art-recognized and includes the process of converting mRNA codons into amino acids in a growing polypeptide chain, as catalyzed by the ribosome. The term "ribosome function" or "ribosome activity" is art-recognized and includes all of the functions of a ribosome, including, but not limited to, the binding of mRNA, the binding of an aminoacyl-tRNA and a peptidyl-tRNA, and the catalysis of the addition of the next amino acid to the growing polypeptide chain.

In another embodiment, the RRP molecules of the invention are capable of modulating the production of a desired molecule, such as a fine chemical, in a microorganism such as *C. glutamicum*. There are a number of mechanisms by which the alteration of an RRP protein of the invention may affect the yield, production, and/or efficiency of production of a fine chemical from a *C. glutamicum* strain incorporating such an altered protein. For example, by improving the rate at which DNA replication occurs (*e.g.*, by optimizing the activity of one or more DNA polymerase, or by

improving the rate at which the topoisomerases or helicases of the invention unwind DNA) it may be possible to increase the rate of cell division, which in turn increases the number of viable fine-chemical-producing *C. glutamicum* cells present in large-scale culture settings. Similarly, by improving the rate at which mRNA is translated to protein (*e.g.*, by optimizing the activity of one or more of the ribosomal proteins) it may be possible to increase the number of proteins in the cell which participate in the synthesis of one or more desired fine chemicals, or in an overall increase in the rate of cell division (due to increased growth and metabolism), both of which should lead to increased production of one or more fine chemicals from large-scale fermentor cultures of these microorganisms. Alterations in the DNA replication proteins of the invention may also permit increased fidelity in the replicative process, thereby increasing the genetic stability and viability of the microorganism and lessening the chance that another engineered mutation improving fine chemical production will not be inadvertently mutagenized by error-prone replication. The RRP proteins of the invention involved in pathogenesis are themselves fine chemicals; by increasing the number or by engineering the corresponding genes such that the expression of these proteins is removed from cellular repression pathways, or by mutagenizing the proteins such that feedback regulatory regions are removed, it may be possible to increase the yield, production, and/or efficiency of production of these proteins from large-scale fermentor culture of organisms containing such mutations.

The isolated nucleic acid sequences of the invention are contained within the genome of a *Corynebacterium glutamicum* strain available through the American Type Culture Collection, given designation ATCC 13032. The nucleotide sequence of the isolated *C. glutamicum* RRP DNAs and the predicted amino acid sequences of the *C. glutamicum* RRP proteins are shown in Appendices A and B, respectively. Computational analyses were performed which classified and/or identified these nucleotide sequences as sequences which encode proteins that participate in the replication of *C. glutamicum* DNA, in *C. glutamicum* ribosome activity, or in the pathogenicity of this microorganism.

The present invention also pertains to proteins which have an amino acid sequence which is substantially homologous to an amino acid sequence of Appendix B. As used herein, a protein which has an amino acid sequence which is substantially homologous to a selected amino acid sequence is least about 50% homologous to the selected amino acid sequence, *e.g.*, the entire selected amino acid sequence. A protein which has an amino acid sequence which is substantially homologous to a selected amino acid sequence can also be least about 50-60%, preferably at least about 60-70%, and more preferably at least about 70-80%, 80-90%, or 90-95%, and most preferably at

least about 96%, 97%, 98%, 99% or more homologous to the selected amino acid sequence.

The RRP protein or a biologically active portion or fragment thereof of the invention can participate in *C. glutamicum* DNA replication, in *C. glutamicum* protein synthesis, or in the pathogenicity of this microorganism, or have one or more of the activities set forth in Table 1.

Various aspects of the invention are described in further detail in the following subsections.

10 A. Isolated Nucleic Acid Molecules

One aspect of the invention pertains to isolated nucleic acid molecules that encode RRP polypeptides or biologically active portions thereof, as well as nucleic acid fragments sufficient for use as hybridization probes or primers for the identification or amplification of RRP-encoding nucleic acid (*e.g.*, RRP DNA). As used herein, the term "nucleic acid molecule" is intended to include DNA molecules (*e.g.*, cDNA or genomic DNA) and RNA molecules (*e.g.*, mRNA) and analogs of the DNA or RNA generated using nucleotide analogs. This term also encompasses untranslated sequence located at both the 3' and 5' ends of the coding region of the gene: at least about 100 nucleotides of sequence upstream from the 5' end of the coding region and at least about 20 nucleotides of sequence downstream from the 3' end of the coding region of the gene. The nucleic acid molecule can be single-stranded or double-stranded, but preferably is double-stranded DNA. An "isolated" nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an "isolated" nucleic acid is free of sequences which naturally flank the nucleic acid (*i.e.*, sequences located at the 5' and 3' ends of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated RRP nucleic acid molecule can contain less than about 5 kb, 4kb, 3kb, 2kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell from which the nucleic acid is derived (*e.g.*, a *C. glutamicum* cell). Moreover, an "isolated" nucleic acid molecule, such as a DNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or chemical precursors or other chemicals when chemically synthesized.

A nucleic acid molecule of the present invention, *e.g.*, a nucleic acid molecule having a nucleotide sequence of Appendix A, or a portion thereof, can be isolated using standard molecular biology techniques and the sequence information provided herein. For example, a *C. glutamicum* RRP DNA can be isolated from a *C. glutamicum* library

using all or portion of one of the sequences of Appendix A as a hybridization probe and standard hybridization techniques (*e.g.*, as described in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual. 2nd, ed.*, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).

- 5 Moreover, a nucleic acid molecule encompassing all or a portion of one of the sequences of Appendix A can be isolated by the polymerase chain reaction using oligonucleotide primers designed based upon this sequence (*e.g.*, a nucleic acid molecule encompassing all or a portion of one of the sequences of Appendix A can be isolated by the polymerase chain reaction using oligonucleotide primers designed based upon this same sequence of
- 10 Appendix A). For example, mRNA can be isolated from normal endothelial cells (*e.g.*, by the guanidinium-thiocyanate extraction procedure of Chirgwin *et al.* (1979) *Biochemistry* 18: 5294-5299) and DNA can be prepared using reverse transcriptase (*e.g.*, Moloney MLV reverse transcriptase, available from Gibco/BRL, Bethesda, MD; or AMV reverse transcriptase, available from Seikagaku America, Inc., St. Petersburg, FL).
- 15 Synthetic oligonucleotide primers for polymerase chain reaction amplification can be designed based upon one of the nucleotide sequences shown in Appendix A. A nucleic acid of the invention can be amplified using cDNA or, alternatively, genomic DNA, as a template and appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an
- 20 appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to an RRP nucleotide sequence can be prepared by standard synthetic techniques, *e.g.*, using an automated DNA synthesizer.

In a preferred embodiment, an isolated nucleic acid molecule of the invention comprises one of the nucleotide sequences shown in Appendix A. The sequences of

25 Appendix A correspond to the *Corynebacterium glutamicum* RRP DNAs of the invention. This DNA comprises sequences encoding RRP proteins (*i.e.*, the "coding region", indicated in each sequence in Appendix A), as well as 5' untranslated sequences and 3' untranslated sequences, also indicated in Appendix A. Alternatively, the nucleic acid molecule can comprise only the coding region of any of the sequences in Appendix

30 A.

For the purposes of this application, it will be understood that each of the sequences set forth in Appendix A has an identifying RXA or RXN number having the designation "RXA", or "RXN" followed by 5 digits (*i.e.*, RXA00823 or RXN00625). Each of these sequences comprises up to three parts: a 5' upstream region, a coding

35 region, and a downstream region. Each of these three regions is identified by the same RXA or RXN designation to eliminate confusion. The recitation "one of the sequences in Appendix A", then, refers to any of the sequences in Appendix A, which may be

distinguished by their differing RXA or RXN designations. The coding region of each of these sequences is translated into a corresponding amino acid sequence, which is set forth in Appendix B. The sequences of Appendix B are identified by the same RXA or RXN designations as Appendix A, such that they can be readily correlated. For
5 example, the amino acid sequences in Appendix B designated RXA00823 and RXN00625 are translations of the coding regions of the nucleotide sequence of nucleic acid molecules RXA00823 and RXN00625, respectively, in Appendix A. Each of the RXA and RXN nucleotide and amino acid sequences of the invention has also been assigned a SEQ ID NO, as indicated in Table 1. For example, as set forth in Table 1, the
10 nucleic acid sequence of RXA01064 is SEQ ID NO:13, and the amino acid sequence of RXA01064 is SEQ ID NO:14.

Several of the genes of the invention are "F-designated genes". An F-designated gene includes those genes set forth in Table 1 which have an 'F' in front of the RXA or RXN designation. For example, SEQ ID NO:3, designated, as indicated on Table 1, as
15 "F RXA00625", is an F-designated gene, as are SEQ ID NOs: 7, 17, and 25 (designated on Table 1 as "F RXA00538", "F RXA01594", and "F RXA00562", respectively).

In one embodiment, the nucleic acid molecules of the present invention are not intended to include those compiled in Table 2. In the case of the *dapD* gene, a sequence for this gene was published in Wehrmann, A., *et al.* (1998) *J. Bacteriol.* 180(12): 3159-
20 3165. However, the sequence obtained by the inventors of the present application is significantly longer than the published version. It is believed that the published version relied on an incorrect start codon, and thus represents only a fragment of the actual coding region.

In another preferred embodiment, an isolated nucleic acid molecule of the
25 invention comprises a nucleic acid molecule which is a complement of one of the nucleotide sequences shown in Appendix A, or a portion thereof. A nucleic acid molecule which is complementary to one of the nucleotide sequences shown in Appendix A is one which is sufficiently complementary to one of the nucleotide sequences shown in Appendix A such that it can hybridize to one of the nucleotide
30 sequences shown in Appendix A, thereby forming a stable duplex.

In still another preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleotide sequence which is at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%, more preferably at least about 71%, 72%,
35 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to a nucleotide sequence shown

in Appendix A, or a portion thereof. Ranges and identity values intermediate to the above-recited ranges, (*e.g.*, 70-90% identical or 80-95% identical) are also intended to be encompassed by the present invention. For example, ranges of identity values using a combination of any of the above values recited as upper and/or lower limits are intended to be included. In an additional preferred embodiment, an isolated nucleic acid molecule of the invention comprises a nucleotide sequence which hybridizes, *e.g.*, hybridizes under stringent conditions, to one of the nucleotide sequences shown in Appendix A, or a portion thereof.

Moreover, the nucleic acid molecule of the invention can comprise only a portion of the coding region of one of the sequences in Appendix A, for example a fragment which can be used as a probe or primer or a fragment encoding a biologically active portion of an RRP protein. The nucleotide sequences determined from the cloning of the RRP genes from *C. glutamicum* allows for the generation of probes and primers designed for use in identifying and/or cloning RRP homologues in other cell types and organisms, as well as RRP homologues from other *Corynebacteria* or related species. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, preferably about 25, more preferably about 40, 50 or 75 consecutive nucleotides of a sense strand of one of the sequences set forth in Appendix A, an anti-sense sequence of one of the sequences set forth in Appendix A, or naturally occurring mutants thereof. Primers based on a nucleotide sequence of Appendix A can be used in PCR reactions to clone RRP homologues. Probes based on the RRP nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In preferred embodiments, the probe further comprises a label group attached thereto, *e.g.* the label group can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells which misexpress an RRP protein, such as by measuring a level of an RRP-encoding nucleic acid in a sample of cells, *e.g.*, detecting RRP mRNA levels or determining whether a genomic RRP gene has been mutated or deleted.

In one embodiment, the nucleic acid molecule of the invention encodes a protein or portion thereof which includes an amino acid sequence which is sufficiently homologous to an amino acid sequence of Appendix B such that the protein or portion thereof maintains the ability to participate in the replication of *C. glutamicum* DNA, in *C. glutamicum* protein synthesis, or in the pathogenicity of this microorganism. As used herein, the language "sufficiently homologous" refers to proteins or portions thereof which have amino acid sequences which include a minimum number of identical or

equivalent (*e.g.*, an amino acid residue which has a similar side chain as an amino acid residue in one of the sequences of Appendix B) amino acid residues to an amino acid sequence of Appendix B such that the protein or portion thereof is able to participate in the replication of *C. glutamicum* DNA, in *C. glutamicum* protein synthesis, or in the pathogenicity of this microorganism. Proteins involved in *C. glutamicum* DNA replication, in ribosome function/activity, or in the pathogenesis of this microorganism, as described herein, may play a role in the production and secretion of one or more fine chemicals. Examples of such activities are also described herein. Thus, "the function of an RRP protein" contributes either directly or indirectly to the yield, production, and/or efficiency of production of one or more fine chemicals. Examples of RRP protein activities are set forth in Table 1.

In another embodiment, the protein is at least about 50-60%, preferably at least about 60-70%, and more preferably at least about 70-80%, 80-90%, 90-95%, and most preferably at least about 96%, 97%, 98%, 99% or more homologous to an entire amino acid sequence of Appendix B.

Portions of proteins encoded by the RRP nucleic acid molecules of the invention are preferably biologically active portions of one of the RRP proteins. As used herein, the term "biologically active portion of an RRP protein" is intended to include a portion, *e.g.*, a domain/motif, of an RRP protein that can participate in the replication of *C. glutamicum* DNA, in *C. glutamicum* protein synthesis, or in the pathogenicity of this microorganism, or has an activity as set forth in Table 1. To determine whether an RRP protein or a biologically active portion thereof can participate in the replication of *C. glutamicum* DNA, in *C. glutamicum* protein synthesis, or in the pathogenicity of this microorganism, an assay of enzymatic/protein activity may be performed. Such assay methods are well known to those of ordinary skill in the art, as detailed in Example 8 of the Exemplification.

Additional nucleic acid fragments encoding biologically active portions of an RRP protein can be prepared by isolating a portion of one of the sequences in Appendix B, expressing the encoded portion of the RRP protein or peptide (*e.g.*, by recombinant expression *in vitro*) and assessing the activity of the encoded portion of the RRP protein or peptide.

The invention further encompasses nucleic acid molecules that differ from one of the nucleotide sequences shown in Appendix A (and portions thereof) due to degeneracy of the genetic code and thus encode the same RRP protein as that encoded by the nucleotide sequences shown in Appendix A. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence shown in Appendix B. In a still further embodiment, the nucleic

acid molecule of the invention encodes a full length *C. glutamicum* protein which is substantially homologous to an amino acid sequence of Appendix B (encoded by an open reading frame shown in Appendix A).

It will be understood by one of ordinary skill in the art that in one embodiment the sequences of the invention are not meant to include the sequences of the prior art, such as those Genbank sequences set forth in Tables 2 or 4 which were available prior to the present invention. In one embodiment, the invention includes nucleotide and amino acid sequences having a percent identity to a nucleotide or amino acid sequence of the invention which is greater than that of a sequence of the prior art (*e.g.*, a Genbank sequence (or the protein encoded by such a sequence) set forth in Tables 2 or 4). For example, the invention includes a nucleotide sequence which is greater than and/or at least 38% identical to the nucleotide sequence designated RXA00823 (SEQ ID NO:9), a nucleotide sequence which is greater than and/or at least 40% identical to the nucleotide sequence designated RXA01064 (SEQ ID NO:13), and a nucleotide sequence which is greater than and/or at least 45% identical to the nucleotide sequence designated RXA02363 (SEQ ID NO:35). One of ordinary skill in the art would be able to calculate the lower threshold of percent identity for any given sequence of the invention by examining the GAP-calculated percent identity scores set forth in Table 4 for each of the three top hits for the given sequence, and by subtracting the highest GAP-calculated percent identity from 100 percent. One of ordinary skill in the art will also appreciate that nucleic acid and amino acid sequences having percent identities greater than the lower threshold so calculated (*e.g.*, at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%, more preferably at least about 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more identical) are also encompassed by the invention.

In addition to the *C. glutamicum* RRP nucleotide sequences shown in Appendix A, it will be appreciated by those of ordinary skill in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of RRP proteins may exist within a population (*e.g.*, the *C. glutamicum* population). Such genetic polymorphism in the RRP gene may exist among individuals within a population due to natural variation. As used herein, the terms "gene" and "recombinant gene" refer to nucleic acid molecules comprising an open reading frame encoding an RRP protein, preferably a *C. glutamicum* RRP protein. Such natural variations can typically result in 1-5% variance in the nucleotide sequence of the RRP gene. Any and all such nucleotide variations and resulting amino acid polymorphisms in RRP that are the result of natural

variation and that do not alter the functional activity of RRP proteins are intended to be within the scope of the invention.

Nucleic acid molecules corresponding to natural variants and non-*C. glutamicum* homologues of the *C. glutamicum* RRP DNA of the invention can be isolated based on their homology to the *C. glutamicum* RRP nucleic acid disclosed herein using the *C. glutamicum* DNA, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions. Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 15 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising a nucleotide sequence of Appendix A. In other embodiments, the nucleic acid is at least 30, 50, 100, 250 or more nucleotides in length. As used herein, the term "hybridizes under stringent conditions" is intended to describe conditions for hybridization and washing under which nucleotide sequences at least 60% homologous to each other typically remain hybridized to each other. Preferably, the conditions are such that sequences at least about 65%, more preferably at least about 70%, and even more preferably at least about 75% or more homologous to each other typically remain hybridized to each other. Such stringent conditions are known to those of ordinary skill in the art and can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. A preferred, non-limiting example of stringent hybridization conditions are hybridization in 6X sodium chloride/sodium citrate (SSC) at about 45°C, followed by one or more washes in 0.2 X SSC, 0.1% SDS at 50-65°C. Preferably, an isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to a sequence of Appendix A corresponds to a naturally-occurring nucleic acid molecule. As used herein, a "naturally-occurring" nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (*e.g.*, encodes a natural protein). In one embodiment, the nucleic acid encodes a natural *C. glutamicum* RRP protein.

In addition to naturally-occurring variants of the RRP sequence that may exist in the population, the one of ordinary skill in the art will further appreciate that changes can be introduced by mutation into a nucleotide sequence of Appendix A, thereby leading to changes in the amino acid sequence of the encoded RRP protein, without altering the functional ability of the RRP protein. For example, nucleotide substitutions leading to amino acid substitutions at "non-essential" amino acid residues can be made in a sequence of Appendix A. A "non-essential" amino acid residue is a residue that can be altered from the wild-type sequence of one of the RRP proteins (Appendix B) without altering the activity of said RRP protein, whereas an "essential" amino acid residue is required for RRP protein activity. Other amino acid residues, however, (*e.g.*,

those that are not conserved or only semi-conserved in the domain having RRP activity) may not be essential for activity and thus are likely to be amenable to alteration without altering RRP activity.

Accordingly, another aspect of the invention pertains to nucleic acid molecules
5 encoding RRP proteins that contain changes in amino acid residues that are not essential for RRP activity. Such RRP proteins differ in amino acid sequence from a sequence contained in Appendix B yet retain at least one of the RRP activities described herein. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about
10 50% homologous to an amino acid sequence of Appendix B and is capable of participating in the replication of *C. glutamicum* DNA, in *C. glutamicum* protein synthesis, or in the pathogenicity of this microorganism, or has one or more of the activities set forth in Table 1. Preferably, the protein encoded by the nucleic acid molecule is at least about 50-60% homologous to one of the sequences in Appendix B,
15 more preferably at least about 60-70% homologous to one of the sequences in Appendix B, even more preferably at least about 70-80%, 80-90%, 90-95% homologous to one of the sequences in Appendix B, and most preferably at least about 96%, 97%, 98%, or 99% homologous to one of the sequences in Appendix B.

To determine the percent homology of two amino acid sequences (*e.g.*, one of
20 the sequences of Appendix B and a mutant form thereof) or of two nucleic acids, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in the sequence of one protein or nucleic acid for optimal alignment with the other protein or nucleic acid). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in one sequence
25 (*e.g.*, one of the sequences of Appendix B) is occupied by the same amino acid residue or nucleotide as the corresponding position in the other sequence (*e.g.*, a mutant form of the sequence selected from Appendix B), then the molecules are homologous at that position (*i.e.*, as used herein amino acid or nucleic acid "homology" is equivalent to amino acid or nucleic acid "identity"). The percent homology between the two
30 sequences is a function of the number of identical positions shared by the sequences (*i.e.*, % homology = # of identical positions/total # of positions x 100).

An isolated nucleic acid molecule encoding an RRP protein homologous to a protein sequence of Appendix B can be created by introducing one or more nucleotide substitutions, additions or deletions into a nucleotide sequence of Appendix A such that
35 one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced into one of the sequences of Appendix A by standard techniques, such as site-directed mutagenesis and PCR-mediated

mutagenesis. Preferably, conservative amino acid substitutions are made at one or more predicted non-essential amino acid residues. A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in an RRP protein is preferably replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of an RRP coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for an RRP activity described herein to identify mutants that retain RRP activity. Following mutagenesis of one of the sequences of Appendix A, the encoded protein can be expressed recombinantly and the activity of the protein can be determined using, for example, assays described herein (see Example 8 of the Exemplification).

In addition to the nucleic acid molecules encoding RRP proteins described above, another aspect of the invention pertains to isolated nucleic acid molecules which are antisense thereto. An "antisense" nucleic acid comprises a nucleotide sequence which is complementary to a "sense" nucleic acid encoding a protein, *e.g.*, complementary to the coding strand of a double-stranded DNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can hydrogen bond to a sense nucleic acid. The antisense nucleic acid can be complementary to an entire RRP coding strand, or to only a portion thereof. In one embodiment, an antisense nucleic acid molecule is antisense to a "coding region" of the coding strand of a nucleotide sequence encoding an RRP protein. The term "coding region" refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues (*e.g.*, the entire coding region of SEQ ID NO:5 (RXN02943) comprises nucleotides 1 to 1668). In another embodiment, the antisense nucleic acid molecule is antisense to a "noncoding region" of the coding strand of a nucleotide sequence encoding RRP. The term "noncoding region" refers to 5' and 3' sequences which flank the coding region that are not translated into amino acids (*i.e.*, also referred to as 5' and 3' untranslated regions).

Given the coding strand sequences encoding RRP disclosed herein (*e.g.*, the sequences set forth in Appendix A), antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of RRP mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of RRP mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of RRP mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (*e.g.*, an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, *e.g.*, phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (*v*), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (*v*), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (*i.e.*, RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).

The antisense nucleic acid molecules of the invention are typically administered to a cell or generated *in situ* such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding an RRP protein to thereby inhibit expression of the protein, *e.g.*, by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the

case of an antisense nucleic acid molecule which binds to DNA duplexes, through specific interactions in the major groove of the double helix. The antisense molecule can be modified such that it specifically binds to a receptor or an antigen expressed on a selected cell surface, *e.g.*, by linking the antisense nucleic acid molecule to a peptide or an antibody which binds to a cell surface receptor or antigen. The antisense nucleic acid molecule can also be delivered to cells using the vectors described herein. To achieve sufficient intracellular concentrations of the antisense molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong prokaryotic, viral, or eukaryotic promoter are preferred.

In yet another embodiment, the antisense nucleic acid molecule of the invention is an α -anomeric nucleic acid molecule. An α -anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gaultier *et al.* (1987) *Nucleic Acids Res.* 15:6625-6641). The antisense nucleic acid molecule can also comprise a 2'-*o*-methylribonucleotide (Inoue *et al.* (1987) *Nucleic Acids Res.* 15:6131-6148) or a chimeric RNA-DNA analogue (Inoue *et al.* (1987) *FEBS Lett.* 215:327-330).

In still another embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity which are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (*e.g.*, hammerhead ribozymes (described in Haselhoff and Gerlach (1988) *Nature* 334:585-591)) can be used to catalytically cleave RRP mRNA transcripts to thereby inhibit translation of RRP mRNA. A ribozyme having specificity for an RRP-encoding nucleic acid can be designed based upon the nucleotide sequence of an RRP DNA molecule disclosed herein (*i.e.*, SEQ ID NO:9 (RXA00823 in Appendix A)). For example, a derivative of a *Tetrahymena* L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in an RRP-encoding mRNA. See, *e.g.*, Cech *et al.* U.S. Patent No. 4,987,071 and Cech *et al.* U.S. Patent No. 5,116,742. Alternatively, RRP mRNA can be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, *e.g.*, Bartel, D. and Szostak, J.W. (1993) *Science* 261:1411-1418.

Alternatively, RRP gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of an RRP nucleotide sequence (*e.g.*, an RRP promoter and/or enhancers) to form triple helical structures that prevent transcription of an RRP gene in target cells. See generally, Helene, C. (1991) *Anticancer Drug Des.* 6(6):569-84; Helene, C. *et al.* (1992) *Ann. N.Y. Acad. Sci.* 660:27-36; and Maher, L.J. (1992) *Bioassays* 14(12):807-15.

B. Recombinant Expression Vectors and Host Cells

Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding an RRP protein (or a portion thereof). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which are operatively linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, "operably linked" is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (*e.g.*, in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements (*e.g.*, polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells. Preferred regulatory sequences are, for example, promoters such as cos-, tac-, trp-, tet-, trp-tet-, lpp-, lac-, lpp-lac-, lacI^q-, T7-, T5-, T3-, gal-, trc-, ara-, SP6-, any, SPO2, λ-P_R-

or λ P_L, which are used preferably in bacteria. Additional regulatory sequences are, for example, promoters from yeasts and fungi, such as ADC1, MF α , AC, P-60, CYC1, GAPDH, TEF, rp28, ADH, promoters from plants such as CaMV/35S, SSU, OCS, lib4, usp, STLS1, B33, nos or ubiquitin- or phaseolin-promoters. It is also possible to use artificial promoters. It will be appreciated by one of ordinary skill in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., RRP proteins, mutant forms of RRP proteins, fusion proteins, etc.).

The recombinant expression vectors of the invention can be designed for expression of RRP proteins in prokaryotic or eukaryotic cells. For example, RRP genes can be expressed in bacterial cells such as *C. glutamicum*, insect cells (using baculovirus expression vectors), yeast and other fungal cells (see Romanos, M.A. *et al.* (1992) "Foreign gene expression in yeast: a review", *Yeast* 8: 423-488; van den Hondel, C.A.M.J.J. *et al.* (1991) "Heterologous gene expression in filamentous fungi" in: More Gene Manipulations in Fungi, J.W. Bennet & L.L. Lasure, eds., p. 396-428: Academic Press: San Diego; and van den Hondel, C.A.M.J.J. & Punt, P.J. (1991) "Gene transfer systems and vector development for filamentous fungi, in: Applied Molecular Genetics of Fungi, Peberdy, J.F. *et al.*, eds., p. 1-28, Cambridge University Press: Cambridge), algae and multicellular plant cells (see Schmidt, R. and Willmitzer, L. (1988) High efficiency *Agrobacterium tumefaciens* -mediated transformation of *Arabidopsis thaliana* leaf and cotyledon explants" *Plant Cell Rep.*: 583-586), or mammalian cells. Suitable host cells are discussed further in Goeddel, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Alternatively, the recombinant expression vector can be transcribed and translated *in vitro*, for example using T7 promoter regulatory sequences and T7 polymerase.

Expression of proteins in prokaryotes is most often carried out with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein but also to the C-terminus or fused within suitable regions in the proteins. Such fusion vectors typically serve three purposes: 1) to increase expression of recombinant protein; 2) to increase the solubility of the recombinant protein; and 3) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein

from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase.

Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith, D.B. and Johnson, K.S. (1988) *Gene* 67:31-40), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein. In one embodiment, the coding sequence of the RRP protein is cloned into a pGEX expression vector to create a vector encoding a fusion protein comprising, from the N-terminus to the C-terminus, GST-thrombin cleavage site-X protein. The fusion protein can be purified by affinity chromatography using glutathione-agarose resin. Recombinant RRP protein unfused to GST can be recovered by cleavage of the fusion protein with thrombin.

Examples of suitable inducible non-fusion *E. coli* expression vectors include pTrc (Amann *et al.*, (1988) *Gene* 69:301-315) pLG338, pACYC184, pBR322, pUC18, pUC19, pKC30, pRep4, pHS1, pHS2, pPLc236, pMBL24, pLG200, pUR290, pIN-III113-B1, λ gt11, pBdCl, and pET 11d (Studier *et al.*, *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 60-89; and Pouwels *et al.*, eds. (1985) *Cloning Vectors*. Elsevier: New York ISBN 0 444 904018). Target gene expression from the pTrc vector relies on host RNA polymerase transcription from a hybrid trp-lac fusion promoter. Target gene expression from the pET 11d vector relies on transcription from a T7 gn10-lac fusion promoter mediated by a coexpressed viral RNA polymerase (T7 gn1). This viral polymerase is supplied by host strains BL21(DE3) or HMS174(DE3) from a resident λ prophage harboring a T7 gn1 gene under the transcriptional control of the lacUV 5 promoter. For transformation of other varieties of bacteria, appropriate vectors may be selected. For example, the plasmids pIJ101, pIJ364, pIJ702 and pIJ361 are known to be useful in transforming *Streptomyces*, while plasmids pUB110, pC194, or pBD214 are suited for transformation of *Bacillus* species. Several plasmids of use in the transfer of genetic information into *Corynebacterium* include pHM1519, pBL1, pSA77, or pAJ667 (Pouwels *et al.*, eds. (1985) *Cloning Vectors*. Elsevier: New York ISBN 0 444 904018). One strategy to maximize recombinant protein expression is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein (Gottesman, S., *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, California (1990) 119-128). Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in the bacterium chosen for expression, such as *C. glutamicum* (Wada *et al.* (1992) *Nucleic Acids Res.*

20: 2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.

In another embodiment, the RRP protein expression vector is a yeast expression vector. Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1
5 (Baldari, *et al.*, (1987) *Embo J.* 6:229-234), 2 μ , pAG-1, Yep6, Yep13, pEMBLYe23, pMFa (Kurjan and Herskowitz, (1982) *Cell* 30:933-943), pJRY88 (Schultz *et al.*, (1987) *Gene* 54:113-123), and pYES2 (Invitrogen Corporation, San Diego, CA). Vectors and methods for the construction of vectors appropriate for use in other fungi, such as the filamentous fungi, include those detailed in: van den Hondel, C.A.M.J.J. & Punt, P.J.
10 (1991) "Gene transfer systems and vector development for filamentous fungi, in: Applied Molecular Genetics of Fungi, J.F. Peberdy, *et al.*, eds., p. 1-28, Cambridge University Press: Cambridge, and Pouwels *et al.*, eds. (1985) Cloning Vectors. Elsevier: New York (ISBN 0 444 904018).

Alternatively, the RRP proteins of the invention can be expressed in insect cells
15 using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (*e.g.*, Sf 9 cells) include the pAc series (Smith *et al.* (1983) *Mol. Cell Biol.* 3:2156-2165) and the pVL series (Lucklow and Summers (1989) *Virology* 170:31-39).

In another embodiment, the RRP proteins of the invention may be expressed in
20 unicellular plant cells (such as algae) or in plant cells from higher plants (*e.g.*, the spermatophytes, such as crop plants). Examples of plant expression vectors include those detailed in: Becker, D., Kemper, E., Schell, J. and Masterson, R. (1992) "New plant binary vectors with selectable markers located proximal to the left border", *Plant Mol. Biol.* 20: 1195-1197; and Bevan, M.W. (1984) "Binary *Agrobacterium* vectors for
25 plant transformation", *Nucl. Acid. Res.* 12: 8711-8721, and include pLGV23, pGHlac+, pBIN19, pAK2004, and pDH51 (Pouwels *et al.*, eds. (1985) Cloning Vectors. Elsevier: New York ISBN 0 444 904018). In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, B. (1987) *Nature*
30 329:840) and pMT2PC (Kaufman *et al.* (1987) *EMBO J.* 6:187-195). When used in mammalian cells, the expression vector's control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see chapters 16 and 17 of
35 Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.

In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert *et al.* (1987) *Genes Dev.* 1:268-277), lymphoid-specific promoters (Calame and Eaton (1988) *Adv. Immunol.* 43:235-275), in particular promoters of T cell receptors (Winoto and Baltimore (1989) *EMBO J.* 8:729-733) and immunoglobulins (Banerji *et al.* (1983) *Cell* 33:729-740; Queen and Baltimore (1983) *Cell* 33:741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle (1989) *PNAS* 86:5473-5477), pancreas-specific promoters (Edlund *et al.* (1985) *Science* 230:912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Patent No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, for example the murine hox promoters (Kessel and Gruss (1990) *Science* 249:374-379) and the α -fetoprotein promoter (Campes and Tilghman (1989) *Genes Dev.* 3:537-546).

The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively linked to a regulatory sequence in a manner which allows for expression (by transcription of the DNA molecule) of an RNA molecule which is antisense to RRP mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen which direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen which direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see Weintraub, H. *et al.*, Antisense RNA as a molecular tool for genetic analysis, *Reviews - Trends in Genetics*, Vol. 1(1) (1986).

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be

identical to the parent cell, but are still included within the scope of the term as used herein.

5 A host cell can be any prokaryotic or eukaryotic cell. For example, an RRP protein can be expressed in bacterial cells such as *C. glutamicum*, insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to one of ordinary skill in the art. Microorganisms related to *Corynebacterium glutamicum* which may be conveniently used as host cells for the nucleic acid and protein molecules of the invention are set forth in Table 3.

10 Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms "transformation" and "transfection", "conjugation" and "transduction" are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (*e.g.*, linear DNA or RNA (*e.g.*, a linearized vector or a gene construct alone without a vector) or nucleic acid in the form of a vector (*e.g.*, a plasmid, phage, phasmid, phagemid, 15 transposon or other DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, natural competence, chemical-mediated transfer, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, *et al.* (*Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), and other laboratory manuals. 20

For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (*e.g.*, resistance to antibiotics) is 25 generally introduced into the host cells along with the gene of interest. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding an RRP protein or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by, for example, drug selection (*e.g.*, cells that have incorporated 30 the selectable marker gene will survive, while the other cells die).

To create a homologous recombinant microorganism, a vector is prepared which contains at least a portion of an RRP gene into which a deletion, addition or substitution has been introduced to thereby alter, *e.g.*, functionally disrupt, the RRP gene. 35 Preferably, this RRP gene is a *Corynebacterium glutamicum* RRP gene, but it can be a homologue from a related bacterium or even from a mammalian, yeast, or insect source. In a preferred embodiment, the vector is designed such that, upon homologous

recombination, the endogenous RRP gene is functionally disrupted (*i.e.*, no longer encodes a functional protein; also referred to as a “knock out” vector). Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous RRP gene is mutated or otherwise altered but still encodes functional protein (*e.g.*, the upstream regulatory region can be altered to thereby alter the expression of the endogenous RRP protein). In the homologous recombination vector, the altered portion of the RRP gene is flanked at its 5’ and 3’ ends by additional nucleic acid of the RRP gene to allow for homologous recombination to occur between the exogenous RRP gene carried by the vector and an endogenous RRP gene in a microorganism. The additional flanking RRP nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5’ and 3’ ends) are included in the vector (see *e.g.*, Thomas, K.R., and Capecchi, M.R. (1987) Cell 51: 503 for a description of homologous recombination vectors). The vector is introduced into a microorganism (*e.g.*, by electroporation) and cells in which the introduced RRP gene has homologously recombined with the endogenous RRP gene are selected, using art-known techniques.

In another embodiment, recombinant microorganisms can be produced which contain selected systems which allow for regulated expression of the introduced gene. For example, inclusion of an RRP gene on a vector placing it under control of the lac operon permits expression of the RRP gene only in the presence of IPTG. Such regulatory systems are well known in the art.

In another embodiment, an endogenous RRP gene in a host cell is disrupted (*e.g.*, by homologous recombination or other genetic means known in the art) such that expression of its protein product does not occur. In another embodiment, an endogenous or introduced RRP gene in a host cell has been altered by one or more point mutations, deletions, or inversions, but still encodes a functional RRP protein. In still another embodiment, one or more of the regulatory regions (*e.g.*, a promoter, repressor, or inducer) of an RRP gene in a microorganism has been altered (*e.g.*, by deletion, truncation, inversion, or point mutation) such that the expression of the RRP gene is modulated. One of ordinary skill in the art will appreciate that host cells containing more than one of the described RRP gene and protein modifications may be readily produced using the methods of the invention, and are meant to be included in the present invention.

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (*i.e.*, express) an RRP protein. Accordingly, the invention further provides methods for producing RRP proteins using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of

invention (into which a recombinant expression vector encoding an RRP protein has been introduced, or into which genome has been introduced a gene encoding a wild-type or altered RRP protein) in a suitable medium until RRP protein is produced. In another embodiment, the method further comprises isolating RRP proteins from the medium or the host cell.

C. Isolated RRP Proteins

Another aspect of the invention pertains to isolated RRP proteins, and biologically active portions thereof. An "isolated" or "purified" protein or biologically active portion thereof is substantially free of cellular material when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. The language "substantially free of cellular material" includes preparations of RRP protein in which the protein is separated from cellular components of the cells in which it is naturally or recombinantly produced. In one embodiment, the language "substantially free of cellular material" includes preparations of RRP protein having less than about 30% (by dry weight) of non-RRP protein (also referred to herein as a "contaminating protein"), more preferably less than about 20% of non-RRP protein, still more preferably less than about 10% of non-RRP protein, and most preferably less than about 5% non-RRP protein. When the RRP protein or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, *i.e.*, culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the protein preparation. The language "substantially free of chemical precursors or other chemicals" includes preparations of RRP protein in which the protein is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. In one embodiment, the language "substantially free of chemical precursors or other chemicals" includes preparations of RRP protein having less than about 30% (by dry weight) of chemical precursors or non-RRP chemicals, more preferably less than about 20% chemical precursors or non-RRP chemicals, still more preferably less than about 10% chemical precursors or non-RRP chemicals, and most preferably less than about 5% chemical precursors or non-RRP chemicals. In preferred embodiments, isolated proteins or biologically active portions thereof lack contaminating proteins from the same organism from which the RRP protein is derived. Typically, such proteins are produced by recombinant expression of, for example, a *C. glutamicum* RRP protein in a microorganism such as *C. glutamicum*.

An isolated RRP protein or a portion thereof of the invention can participate in the replication of *C. glutamicum* DNA, in *C. glutamicum* protein synthesis, or in the

pathogenicity of this microorganism, or has one or more of the activities set forth in Table 1. In preferred embodiments, the protein or portion thereof comprises an amino acid sequence which is sufficiently homologous to an amino acid sequence of Appendix B such that the protein or portion thereof maintains the ability to participate in the replication of *C. glutamicum* DNA, in *C. glutamicum* protein synthesis, or in the pathogenicity of this microorganism. The portion of the protein is preferably a biologically active portion as described herein. In another preferred embodiment, an RRP protein of the invention has an amino acid sequence shown in Appendix B. In yet another preferred embodiment, the RRP protein has an amino acid sequence which is encoded by a nucleotide sequence which hybridizes, *e.g.*, hybridizes under stringent conditions, to a nucleotide sequence of Appendix A. In still another preferred embodiment, the RRP protein has an amino acid sequence which is encoded by a nucleotide sequence that is at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%, more preferably at least about 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to one of the nucleic acid sequences of Appendix A, or a portion thereof. Ranges and identity values intermediate to the above-recited values, (*e.g.*, 70-90% identical or 80-95% identical) are also intended to be encompassed by the present invention. For example, ranges of identity values using a combination of any of the above values recited as upper and/or lower limits are intended to be included. The preferred RRP proteins of the present invention also preferably possess at least one of the RRP activities described herein. For example, a preferred RRP protein of the present invention includes an amino acid sequence encoded by a nucleotide sequence which hybridizes, *e.g.*, hybridizes under stringent conditions, to a nucleotide sequence of Appendix A, and which can participate in the replication of *C. glutamicum* DNA, in *C. glutamicum* protein synthesis, or in the pathogenicity of this microorganism, or which has one or more of the activities set forth in Table 1.

In other embodiments, the RRP protein is substantially homologous to an amino acid sequence of Appendix B and retains the functional activity of the protein of one of the sequences of Appendix B yet differs in amino acid sequence due to natural variation or mutagenesis, as described in detail in subsection I above. Accordingly, in another embodiment, the RRP protein is a protein which comprises an amino acid sequence which is at least about 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, or 60%, preferably at least about 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, or 70%, more preferably at least about 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%,

or 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, or 90%, or 91%, 92%, 93%, 94%, and even more preferably at least about 95%, 96%, 97%, 98%, 99% or more homologous to an entire amino acid sequence of Appendix B and which has at least one of the RRP activities described herein. Ranges and identity values intermediate to the
5 above-recited values, (*e.g.*, 70-90% identical or 80-95% identical) are also intended to be encompassed by the present invention. For example, ranges of identity values using a combination of any of the above values recited as upper and/or lower limits are intended to be included. In another embodiment, the invention pertains to a full length *C. glutamicum* protein which is substantially homologous to an entire amino acid sequence
10 of Appendix B.

Biologically active portions of an RRP protein include peptides comprising amino acid sequences derived from the amino acid sequence of an RRP protein, *e.g.*, an amino acid sequence shown in Appendix B or the amino acid sequence of a protein homologous to an RRP protein, which include fewer amino acids than a full length RRP
15 protein or the full length protein which is homologous to an RRP protein, and exhibit at least one activity of an RRP protein. Typically, biologically active portions (peptides, *e.g.*, peptides which are, for example, 5, 10, 15, 20, 30, 35, 36, 37, 38, 39, 40, 50, 100 or more amino acids in length) comprise a domain or motif with at least one activity of an RRP protein. Moreover, other biologically active portions, in which other regions of the
20 protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the activities described herein. Preferably, the biologically active portions of an RRP protein include one or more selected domains/motifs or portions thereof having biological activity.

RRP proteins are preferably produced by recombinant DNA techniques. For
25 example, a nucleic acid molecule encoding the protein is cloned into an expression vector (as described above), the expression vector is introduced into a host cell (as described above) and the RRP protein is expressed in the host cell. The RRP protein can then be isolated from the cells by an appropriate purification scheme using standard protein purification techniques. Alternative to recombinant expression, an RRP protein,
30 polypeptide, or peptide can be synthesized chemically using standard peptide synthesis techniques. Moreover, native RRP protein can be isolated from cells (*e.g.*, endothelial cells), for example using an anti-RRP antibody, which can be produced by standard techniques utilizing an RRP protein or fragment thereof of this invention.

The invention also provides RRP chimeric or fusion proteins. As used herein, an
35 RRP "chimeric protein" or "fusion protein" comprises an RRP polypeptide operatively linked to a non-RRP polypeptide. An "RRP polypeptide" refers to a polypeptide having an amino acid sequence corresponding to an RRP protein, whereas a "non-RRP

polypeptide" refers to a polypeptide having an amino acid sequence corresponding to a protein which is not substantially homologous to the RRP protein, *e.g.*, a protein which is different from the RRP protein and which is derived from the same or a different organism. Within the fusion protein, the term "operatively linked" is intended to

5 indicate that the RRP polypeptide and the non-RRP polypeptide are fused in-frame to each other. The non-RRP polypeptide can be fused to the N-terminus or C-terminus of the RRP polypeptide. For example, in one embodiment the fusion protein is a GST-RRP fusion protein in which the RRP sequences are fused to the C-terminus of the GST sequences. Such fusion proteins can facilitate the purification of recombinant RRP

10 proteins. In another embodiment, the fusion protein is an RRP protein containing a heterologous signal sequence at its N-terminus. In certain host cells (*e.g.*, mammalian host cells), expression and/or secretion of an RRP protein can be increased through use of a heterologous signal sequence.

Preferably, an RRP chimeric or fusion protein of the invention is produced by

15 standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, for example by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid

20 undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed and reamplified to generate a chimeric

25 gene sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel *et al.* John Wiley & Sons: 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (*e.g.*, a GST polypeptide). An RRP-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the RRP protein.

30 Homologues of the RRP protein can be generated by mutagenesis, *e.g.*, discrete point mutation or truncation of the RRP protein. As used herein, the term "homologue" refers to a variant form of the RRP protein which acts as an agonist or antagonist of the activity of the RRP protein. An agonist of the RRP protein can retain substantially the same, or a subset, of the biological activities of the RRP protein. An antagonist of the

35 RRP protein can inhibit one or more of the activities of the naturally occurring form of the RRP protein, by, for example, competitively binding to a downstream or upstream member of a biochemical cascade which includes the RRP protein, by binding to a target

molecule with which the RRP protein interacts, such that no functional interaction is possible, or by binding directly to the RRP protein and inhibiting its normal activity.

In an alternative embodiment, homologues of the RRP protein can be identified by screening combinatorial libraries of mutants, *e.g.*, truncation mutants, of the RRP protein for RRP protein agonist or antagonist activity. In one embodiment, a variegated library of RRP variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of RRP variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential RRP sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (*e.g.*, for phage display) containing the set of RRP sequences therein. There are a variety of methods which can be used to produce libraries of potential RRP homologues from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential RRP sequences. Methods for synthesizing degenerate oligonucleotides are known in the art (see, *e.g.*, Narang, S.A. (1983) *Tetrahedron* 39:3; Itakura *et al.* (1984) *Annu. Rev. Biochem.* 53:323; Itakura *et al.* (1984) *Science* 198:1056; Ike *et al.* (1983) *Nucleic Acid Res.* 11:477).

In addition, libraries of fragments of the RRP protein coding can be used to generate a variegated population of RRP fragments for screening and subsequent selection of homologues of an RRP protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of an RRP coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double stranded DNA which can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S1 nuclease, and ligating the resulting fragment library into an expression vector. By this method, an expression library can be derived which encodes N-terminal, C-terminal and internal fragments of various sizes of the RRP protein.

Several techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of RRP homologues. The most widely used techniques, which are amenable to high through-put analysis, for screening large gene libraries typically include cloning the gene library into

replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique which enhances the
5 frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify RRP homologues (Arkin and Yourvan (1992) *PNAS* 89:7811-7815; Delgrave *et al.* (1993) *Protein Engineering* 6(3):327-331).

In another embodiment, cell based assays can be exploited to analyze a variegated RRP library, using methods well known in the art.

10

D. Uses and Methods of the Invention

The nucleic acid molecules, proteins, protein homologues, fusion proteins, primers, vectors, and host cells described herein can be used in one or more of the following methods: identification of *C. glutamicum* and related organisms; mapping of
15 genomes of organisms related to *C. glutamicum*; identification and localization of *C. glutamicum* sequences of interest; evolutionary studies; determination of RRP protein regions required for function; modulation of an RRP protein activity; modulation of DNA synthesis; modulation of protein synthesis; modulation of *C. glutamicum* pathogenesis; and modulation of cellular production of a desired compound, such as a
20 fine chemical.

The RRP nucleic acid molecules of the invention have a variety of uses. First, they may be used to identify an organism as being *Corynebacterium glutamicum* or a close relative thereof. Also, they may be used to identify the presence of *C. glutamicum* or a relative thereof in a mixed population of microorganisms. The invention provides
25 the nucleic acid sequences of a number of *C. glutamicum* genes; by probing the extracted genomic DNA of a culture of a unique or mixed population of microorganisms under stringent conditions with a probe spanning a region of a *C. glutamicum* gene which is unique to this organism, one can ascertain whether this organism is present.

Although *Corynebacterium glutamicum* itself is not pathogenic in humans, it is
30 related to species which are human pathogens, such as *Corynebacterium diphtheriae*. *Corynebacterium diphtheriae* is the causative agent of diphtheria, a rapidly developing, acute, febrile infection which involves both local and systemic pathology. In this disease, a local lesion develops in the upper respiratory tract and involves necrotic injury to epithelial cells; the bacilli secrete toxin which is disseminated through this lesion to
35 distal susceptible tissues of the body. Degenerative changes brought about by the inhibition of protein synthesis in these tissues, which include heart, muscle, peripheral nerves, adrenals, kidneys, liver and spleen, result in the systemic pathology of the

disease. Diphtheria continues to have high incidence in many parts of the world, including Africa, Asia, Eastern Europe and the independent states of the former Soviet Union. An ongoing epidemic of diphtheria in the latter two regions has resulted in at least 5,000 deaths since 1990.

5 In one embodiment, the invention provides a method of identifying the presence or activity of *Corynebacterium diphtheriae* in a subject. This method includes detection of one or more of the nucleic acid or amino acid sequences of the invention (*e.g.*, the sequences set forth in Appendix A or Appendix B) in a subject, thereby detecting the presence or activity of *Corynebacterium diphtheriae* in the subject. *C. glutamicum* and
10 *C. diphtheriae* are related bacteria, and many of the nucleic acid and protein molecules in *C. glutamicum* are homologous to *C. diphtheriae* nucleic acid and protein molecules, and can therefore be used to detect *C. diphtheriae* in a subject.

The nucleic acid and protein molecules of the invention may also serve as markers for specific regions of the genome. This has utility not only in the mapping of
15 the genome, but also for functional studies of *C. glutamicum* proteins. For example, to identify the region of the genome to which a particular *C. glutamicum* DNA-binding protein binds, the *C. glutamicum* genome could be digested, and the fragments incubated with the DNA-binding protein. Those which bind the protein may be additionally probed with the nucleic acid molecules of the invention, preferably with readily detectable
20 labels; binding of such a nucleic acid molecule to the genome fragment enables the localization of the fragment to the genome map of *C. glutamicum*, and, when performed multiple times with different enzymes, facilitates a rapid determination of the nucleic acid sequence to which the protein binds. Further, the nucleic acid molecules of the invention may be sufficiently homologous to the sequences of related species such that
25 these nucleic acid molecules may serve as markers for the construction of a genomic map in related bacteria, such as *Brevibacterium lactofermentum*.

The RRP nucleic acid molecules encoding proteins involved in the pathogenicity of *C. glutamicum* are also useful for purposes of genetic engineering of this microorganism. Frequently, the insertion of genetic information into the genome of an
30 organism is a disruptive process, which may inadvertently impair the regulation or coding regions of multiple different genes. The RRP pathogenicity genes of the invention are not necessary for the continued survival of the organism in an artificial culture setting, and are not likely to add any benefit to the productivity of the organism for one or more fine chemicals. These genes, then, may serve as useful insertion points
35 for the addition of genetic material to the genome of *C. glutamicum*, since their disruption should not affect the viability or the productivity of this microorganism.

The RRP nucleic acid molecules of the invention are also useful for evolutionary and protein structural studies. The processes involved in DNA replication, protein synthesis and pathogenesis in which the molecules of the invention participate are utilized by a wide variety of species; by comparing the sequences of the nucleic acid molecules of the present invention to those encoding similar enzymes from other organisms, the evolutionary relatedness of the organisms can be assessed. Similarly, such a comparison permits an assessment of which regions of the sequence are conserved and which are not, which may aid in determining those regions of the protein which are essential for the functioning of the enzyme. This type of determination is of value for protein engineering studies and may give an indication of what the protein can tolerate in terms of mutagenesis without losing function.

Manipulation of the RRP nucleic acid molecules of the invention may result in the production of RRP proteins having functional differences from the wild-type RRP proteins. These proteins may be improved in efficiency or activity, may be present in greater numbers in the cell than is usual, or may be decreased in efficiency or activity.

The invention provides methods for screening molecules which modulate the activity of an RRP protein, either by interacting with the protein itself or a substrate or binding partner of the RRP protein, or by modulating the transcription or translation of an RRP nucleic acid molecule of the invention. In such methods, a microorganism expressing one or more RRP proteins of the invention is contacted with one or more test compounds, and the effect of each test compound on the activity or level of expression of the RRP protein is assessed.

The alteration of activity or number of one or more of the RRP proteins of the invention involved in DNA replication may affect fine chemical production from a *C. glutamicum* (or related bacterial) cell containing such mutations. For example, by improving the rate at which a DNA polymerase of the invention synthesizes DNA, it may be possible to improve the overall replication rate of the genomic DNA. Similarly, by optimizing the activity of the topoisomerases or gyrases of the invention, it may be possible to more quickly unwind the DNA, thereby permitting increased progressivity of the polymerase complex along the bacterial chromosome. Further, it may be possible to engineer one or more of the proteins involved in DNA replication such that they are improved for function under conditions of high temperature and nonoptimal pH, such as those found in large-scale fermentor culture (e.g., amino acid replacements may be made such that the resulting structure of one of these proteins retains activity but is improved for stability at high temperature or acidic/basic pH). Improving the rate of DNA synthesis in *C. glutamicum* or related bacteria may permit more rapid rates of cell division, leading to increased numbers of cells present in large-scale cultures of the

bacterium. Relatively increased numbers of cells, each of which is producing one or more desired fine chemicals, should result in relatively increased yield, production, or efficiency of production of one or more fine chemicals from the culture.

Also, by manipulating one or more of the RRP genes of the invention, it may be possible to increase the overall fidelity of replication in *C. glutamicum* or related bacterial cells. For example, the 3'-5' exonuclease activities of Pol III or Pol I (which are responsible for excising inappropriately incorporated bases from the growing DNA strand) may be optimized such that more incorrect bases are detected and removed. Similarly, the polymerization activity of the DNA polymerases of the invention may be improved such that the error rate in base incorporation is decreased. Both such modifications should result in improved fidelity in the replicated DNA, which in turn should decrease the rate of introduced mutations. Fewer introduced mutations not only helps to ensure that any other engineered genes will not be undesirably altered by random mutation, but also may permit increased viability of the cells in culture, since random mutations may impair the activity of genes necessary for cell survival. As before, increased numbers of viable cells in culture should result in increased yield, production, and/or efficiency of production of one or more fine chemicals produced by those cells.

Mutations in genes and proteins involved in protein synthesis (*e.g.*, ribosomal genes and proteins) may also have a significant effect on the production of one or more fine chemicals from *C. glutamicum* or related bacterial cultures. For example, by improving the rate of protein synthesis (*e.g.*, by improving the rate of assembly of the ribosome, by improving the progressivity of the ribosome, or by increasing the rate at which the ribosome is able to productively bind to mRNA, all of which may be accomplished by altering the binding sites for the various ribosomal components such that binding and association of ribosomal proteins to each other or to tRNAs or to mRNAs are improved) it may be possible to increase the rate at which proteins involved in the synthesis of desired fine chemicals are produced, thereby potentially improving the production of one or more of these fine chemicals. This increased protein production may also permit increased growth and cell division of the cell, since increased cellular metabolism (which may occur due to the presence of increased numbers of metabolic proteins) may also result in more rapid cell division, thereby increasing the number of cells in a culture of the bacterium containing such mutation(s). Increased numbers of viable cells in large-scale fermentor culture, each of which is producing one or more desired fine chemicals, should result in an increase in yield, production, and/or efficiency of production of these fine chemicals.

Alteration of the number of the RRP proteins of the invention involved in the pathogenicity of *C. glutamicum* (e.g., hemolysin and invasins) may also increase the yield, production, and/or efficiency of production of one or more fine chemicals from *C. glutamicum* cells containing such mutations. These pathogenesis proteins may be of utility for the survival of *C. glutamicum* cells in their natural environments. However, in the artificial environment of fermentor culture, nutrients are typically supplied in excess, and there should be no other organisms with which these bacteria need to compete. Thus, the synthesis of these pathogenesis proteins represents the utilization of energy and biomaterials which could instead be shifted to the production of one or more desired fine chemicals. Thus, by decreasing the number of such pathogenesis genes in *C. glutamicum*, it may be possible to increase the available intermediate compounds (e.g., nucleotides, amino acids, or energy molecules such as ATP) such that metabolism in general, and fine chemical production in particular is increased.

These RRP proteins involved in pathogenesis may themselves also be considered desirable fine chemicals. These proteins may have significant pharmaceutical applications, as, for example, antimicrobial or antifungal agents. Further, although *C. glutamicum* is not a human pathogen, its pathogenesis proteins (e.g., hemolysins or adhesins) may be similar in structure and activity to those from bacterial species which are significant human pathogens (e.g., *E. coli* or *Pseudomonas* spp.) These *C. glutamicum* pathogenesis proteins may thus serve as useful targets for the development of vaccines or therapeutics against various human pathogens. By mutagenizing the genes encoding these proteins such that their synthesis and/or translation is no longer repressed by cellular regulatory mechanisms, or such that their production is no longer subject to feedback inhibition (e.g., by mutagenizing regulatory regions upstream or downstream of the gene, or by mutagenizing regulatory regions on the protein itself) greater numbers of these proteins may be able to be expressed and harvested from culture.

The aforementioned mutagenesis strategies for RRP proteins to result in increased yields of a fine chemical from *C. glutamicum* are not meant to be limiting; variations on these strategies will be readily apparent to one of ordinary skill in the art. Using such strategies, and incorporating the mechanisms disclosed herein, the nucleic acid and protein molecules of the invention may be utilized to generate *C. glutamicum* or related strains of bacteria expressing mutated RRP nucleic acid and protein molecules such that the yield, production, and/or efficiency of production of a desired compound is improved. This desired compound may be any product produced by *C. glutamicum*, which includes the final products of biosynthesis pathways and intermediates of naturally-occurring metabolic pathways, as well as molecules which do not naturally

occur in the metabolism of *C. glutamicum*, but which are produced by a *C. glutamicum* strain of the invention.

5 This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patent applications, patents, published patent applications, Tables, Appendices, and the sequence listing cited throughout this application are hereby incorporated by reference.

Exemplification

10

Example 1: Preparation of total genomic DNA of *Corynebacterium glutamicum* ATCC 13032

A culture of *Corynebacterium glutamicum* (ATCC 13032) was grown overnight at 30°C with vigorous shaking in BHI medium (Difco). The cells were harvested by
15 centrifugation, the supernatant was discarded and the cells were resuspended in 5 ml buffer-I (5% of the original volume of the culture — all indicated volumes have been calculated for 100 ml of culture volume). Composition of buffer-I: 140.34 g/l sucrose, 2.46 g/l MgSO₄ x 7H₂O, 10 ml/l KH₂PO₄ solution (100 g/l, adjusted to pH 6.7 with KOH), 50 ml/l M12 concentrate (10 g/l (NH₄)₂SO₄, 1 g/l NaCl, 2 g/l MgSO₄ x 7H₂O,
20 0.2 g/l CaCl₂, 0.5 g/l yeast extract (Difco), 10 ml/l trace-elements-mix (200 mg/l FeSO₄ x H₂O, 10 mg/l ZnSO₄ x 7 H₂O, 3 mg/l MnCl₂ x 4 H₂O, 30 mg/l H₃BO₃, 20 mg/l CoCl₂ x 6 H₂O, 1 mg/l NiCl₂ x 6 H₂O, 3 mg/l Na₂MoO₄ x 2 H₂O, 500 mg/l complexing agent (EDTA or critic acid), 100 ml/l vitamins-mix (0.2 mg/l biotin, 0.2 mg/l folic acid, 20 mg/l p-amino benzoic acid, 20 mg/l riboflavin, 40 mg/l ca-panthothenate, 140 mg/l
25 nicotinic acid, 40 mg/l pyridoxole hydrochloride, 200 mg/l myo-inositol). Lysozyme was added to the suspension to a final concentration of 2.5 mg/ml. After an approximately 4 h incubation at 37°C, the cell wall was degraded and the resulting protoplasts are harvested by centrifugation. The pellet was washed once with 5 ml buffer-I and once with 5 ml TE-buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8). The
30 pellet was resuspended in 4 ml TE-buffer and 0.5 ml SDS solution (10%) and 0.5 ml NaCl solution (5 M) are added. After adding of proteinase K to a final concentration of 200 µg/ml, the suspension is incubated for ca.18 h at 37°C. The DNA was purified by extraction with phenol, phenol-chloroform-isoamylalcohol and chloroform-isoamylalcohol using standard procedures. Then, the DNA was precipitated by adding
35 1/50 volume of 3 M sodium acetate and 2 volumes of ethanol, followed by a 30 min incubation at -20°C and a 30 min centrifugation at 12,000 rpm in a high speed centrifuge using a SS34 rotor (Sorvall). The DNA was dissolved in 1 ml TE-buffer containing 20

µg/ml RNaseA and dialysed at 4°C against 1000 ml TE-buffer for at least 3 hours. During this time, the buffer was exchanged 3 times. To aliquots of 0.4 ml of the dialysed DNA solution, 0.4 ml of 2 M LiCl and 0.8 ml of ethanol are added. After a 30 min incubation at -20°C, the DNA was collected by centrifugation (13,000 rpm, Biofuge
5 Fresco, Heraeus, Hanau, Germany). The DNA pellet was dissolved in TE-buffer. DNA prepared by this procedure could be used for all purposes, including southern blotting or construction of genomic libraries.

10 **Example 2: Construction of genomic libraries in *Escherichia coli* of *Corynebacterium glutamicum* ATCC13032.**

Using DNA prepared as described in Example 1, cosmid and plasmid libraries were constructed according to known and well established methods (*see e.g.*, Sambrook, J. *et al.* (1989) "Molecular Cloning : A Laboratory Manual", Cold Spring Harbor Laboratory Press, or Ausubel, F.M. *et al.* (1994) "Current Protocols in Molecular Biology", John Wiley &
15 Sons.)

Any plasmid or cosmid could be used. Of particular use were the plasmids pBR322 (Sutcliffe, J.G. (1979) *Proc. Natl. Acad. Sci. USA*, 75:3737-3741); pACYC177 (Change & Cohen (1978) *J. Bacteriol* 134:1141-1156), plasmids of the pBS series (pBSSK+, pBSSK- and others; Stratagene, LaJolla, USA), or cosmids as SuperCos1 (Stratagene, LaJolla, USA) or
20 Lorist6 (Gibson, T.J., Rosenthal A. and Waterson, R.H. (1987) *Gene* 53:283-286. Gene libraries specifically for use in *C. glutamicum* may be constructed using plasmid pSL109 (Lee, H.-S. and A. J. Sinskey (1994) *J. Microbiol. Biotechnol.* 4: 256-263).

Example 3: DNA Sequencing and Computational Functional Analysis

25 *Sub G2* Genomic libraries as described in Example 2 were used for DNA sequencing according to standard methods, in particular by the chain termination method using ABI377 sequencing machines (*see e.g.*, Fleischman, R.D. *et al.* (1995) "Whole-genome Random Sequencing and Assembly of Haemophilus Influenzae Rd., Science, 269:496-512). Sequencing primers with the following nucleotide sequences were used: 5'-
30 GGAAACAGTATGACCATG-3' or 5'-GTAAAACGACGGCCAGT-3'.

Example 4: *In vivo* Mutagenesis

In vivo mutagenesis of *Corynebacterium glutamicum* can be performed by passage of plasmid (or other vector) DNA through *E. coli* or other microorganisms (*e.g.* *Bacillus* spp. or
35 yeasts such as *Saccharomyces cerevisiae*) which are impaired in their capabilities to maintain the integrity of their genetic information. Typical mutator strains have mutations in the genes for the DNA repair system (*e.g.*, mutHLS, mutD, mutT, etc.; for reference, see Rupp, W.D.

(1996) DNA repair mechanisms, in: *Escherichia coli* and *Salmonella*, p. 2277-2294, ASM: Washington.) Such strains are well known to one of ordinary skill in the art. The use of such strains is illustrated, for example, in Greener, A. and Callahan, M. (1994) Strategies 7: 32-34.

5 Example 5: DNA Transfer Between *Escherichia coli* and *Corynebacterium glutamicum*

Several *Corynebacterium* and *Brevibacterium* species contain endogenous plasmids (as e.g.; pHM1519 or pBL1) which replicate autonomously (for review see, e.g., Martin, J.F. *et al.* (1987) *Biotechnology*, 5:137-146). Shuttle vectors for *Escherichia coli* and *Corynebacterium glutamicum* can be readily constructed by using standard vectors for *E. coli* (Sambrook, J. *et al.* (1989), "Molecular Cloning: A Laboratory Manual", Cold Spring Harbor Laboratory Press or Ausubel, F.M. *et al.* (1994) "Current Protocols in Molecular Biology", John Wiley & Sons) to which a origin or replication for and a suitable marker from *Corynebacterium glutamicum* is added. Such origins of replication are preferably taken from endogenous plasmids isolated from *Corynebacterium* and *Brevibacterium* species. Of particular use as transformation markers for these species are genes for kanamycin resistance (such as those derived from the Tn5 or Tn903 transposons) or chloramphenicol (Winnacker, E.L. (1987) "From Genes to Clones — Introduction to Gene Technology, VCH, Weinheim). There are numerous examples in the literature of the construction of a wide variety of shuttle vectors which replicate in both *E. coli* and *C. glutamicum*, and which can be used for several purposes, including gene over-expression (for reference, see e.g., Yoshihama, M. *et al.* (1985) *J. Bacteriol.* 162:591-597, Martin J.F. *et al.* (1987) *Biotechnology*, 5:137-146 and Eikmanns, B.J. *et al.* (1991) *Gene*, 102:93-98).

Using standard methods, it is possible to clone a gene of interest into one of the shuttle vectors described above and to introduce such a hybrid vectors into strains of *Corynebacterium glutamicum*. Transformation of *C. glutamicum* can be achieved by protoplast transformation (Kastsumata, R. *et al.* (1984) *J. Bacteriol.* 159:306-311), electroporation (Liebl, E. *et al.* (1989) *FEMS Microbiol. Letters*, 53:399-303) and in cases where special vectors are used, also by conjugation (as described e.g. in Schäfer, A *et al.* (1990) *J. Bacteriol.* 172:1663-1666). It is also possible to transfer the shuttle vectors for *C. glutamicum* to *E. coli* by preparing plasmid DNA from *C. glutamicum* (using standard methods well-known in the art) and transforming it into *E. coli*. This transformation step can be performed using standard methods, but it is advantageous to use an Mcr-deficient *E. coli* strain, such as NM522 (Gough & Murray (1983) *J. Mol. Biol.* 166:1-19).

Genes may be overexpressed in *C. glutamicum* strains using plasmids which comprise pCG1 (U.S. Patent No. 4,617,267) or fragments thereof, and optionally the

gene for kanamycin resistance from TN903 (Grindley, N.D. and Joyce, C.M. (1980) *Proc. Natl. Acad. Sci. USA* 77(12): 7176-7180). In addition, genes may be overexpressed in *C. glutamicum* strains using plasmid pSL109 (Lee, H.-S. and A. J. Sinskey (1994) *J. Microbiol. Biotechnol.* 4: 256-263).

5 Aside from the use of replicative plasmids, gene overexpression can also be achieved by integration into the genome. Genomic integration in *C. glutamicum* or other *Corynebacterium* or *Brevibacterium* species may be accomplished by well-known methods, such as homologous recombination with genomic region(s), restriction endonuclease mediated integration (REMI) (see, *e.g.*, DE Patent 19823834), or through
10 the use of transposons. It is also possible to modulate the activity of a gene of interest by modifying the regulatory regions (*e.g.*, a promoter, a repressor, and/or an enhancer) by sequence modification, insertion, or deletion using site-directed methods (such as homologous recombination) or methods based on random events (such as transposon mutagenesis or REMI). Nucleic acid sequences which function as transcriptional
15 terminators may also be inserted 3' to the coding region of one or more genes of the invention; such terminators are well-known in the art and are described, for example, in Winnacker, E.L. (1987) *From Genes to Clones – Introduction to Gene Technology*. VCH: Weinheim.

20 **Example 6: Assessment of the Expression of the Mutant Protein**

Observations of the activity of a mutated protein in a transformed host cell rely on the fact that the mutant protein is expressed in a similar fashion and in a similar quantity to that of the wild-type protein. A useful method to ascertain the level of transcription of the mutant gene (an indicator of the amount of mRNA available for translation to the gene
25 product) is to perform a Northern blot (for reference see, for example, Ausubel *et al.* (1988) *Current Protocols in Molecular Biology*, Wiley: New York), in which a primer designed to bind to the gene of interest is labeled with a detectable tag (usually radioactive or chemiluminescent), such that when the total RNA of a culture of the organism is extracted, run on gel, transferred to a stable matrix and incubated with this probe, the
30 binding and quantity of binding of the probe indicates the presence and also the quantity of mRNA for this gene. This information is evidence of the degree of transcription of the mutant gene. Total cellular RNA can be prepared from *Corynebacterium glutamicum* by several methods, all well-known in the art, such as that described in Bormann, E.R. *et al.* (1992) *Mol. Microbiol.* 6: 317-326.

35 To assess the presence or relative quantity of protein translated from this mRNA, standard techniques, such as a Western blot, may be employed (see, for example, Ausubel *et al.* (1988) *Current Protocols in Molecular Biology*, Wiley: New York). In this process,

total cellular proteins are extracted, separated by gel electrophoresis, transferred to a matrix such as nitrocellulose, and incubated with a probe, such as an antibody, which specifically binds to the desired protein. This probe is generally tagged with a chemiluminescent or colorimetric label which may be readily detected. The presence and
5 quantity of label observed indicates the presence and quantity of the desired mutant protein present in the cell.

Example 7: Growth of Genetically Modified *Corynebacterium glutamicum* — Media and Culture Conditions

10 Genetically modified *Corynebacteria* are cultured in synthetic or natural growth media. A number of different growth media for *Corynebacteria* are both well-known and readily available (Lieb *et al.* (1989) Appl. Microbiol. Biotechnol., 32:205-210; von der Osten *et al.* (1998) Biotechnology Letters, 11:11-16; Patent DE 4,120,867; Liebl (1992) "The Genus *Corynebacterium*, in: The Prokaryotes, Volume II, Balows, A. *et al.*, eds.
15 Springer-Verlag). These media consist of one or more carbon sources, nitrogen sources, inorganic salts, vitamins and trace elements. Preferred carbon sources are sugars, such as mono-, di-, or polysaccharides. For example, glucose, fructose, mannose, galactose, ribose, sorbose, ribulose, lactose, maltose, sucrose, raffinose, starch or cellulose serve as very good carbon sources. It is also possible to supply sugar to the media via complex
20 compounds such as molasses or other by-products from sugar refinement. It can also be advantageous to supply mixtures of different carbon sources. Other possible carbon sources are alcohols and organic acids, such as methanol, ethanol, acetic acid or lactic acid. Nitrogen sources are usually organic or inorganic nitrogen compounds, or materials which contain these compounds. Exemplary nitrogen sources include ammonia gas or
25 ammonia salts, such as NH_4Cl or $(\text{NH}_4)_2\text{SO}_4$, NH_4OH , nitrates, urea, amino acids or complex nitrogen sources like corn steep liquor, soy bean flour, soy bean protein, yeast extract, meat extract and others.

Inorganic salt compounds which may be included in the media include the chloride-, phosphorous- or sulfate- salts of calcium, magnesium, sodium, cobalt,
30 molybdenum, potassium, manganese, zinc, copper and iron. Chelating compounds can be added to the medium to keep the metal ions in solution. Particularly useful chelating compounds include dihydroxyphenols, like catechol or protocatechuate, or organic acids, such as citric acid. It is typical for the media to also contain other growth factors, such as vitamins or growth promoters, examples of which include biotin, riboflavin, thiamin, folic
35 acid, nicotinic acid, pantothenate and pyridoxin. Growth factors and salts frequently originate from complex media components such as yeast extract, molasses, corn steep liquor and others. The exact composition of the media compounds depends strongly on

the immediate experiment and is individually decided for each specific case. Information about media optimization is available in the textbook "Applied Microbiol. Physiology, A Practical Approach (*eds.* P.M. Rhodes, P.F. Stanbury, IRL Press (1997) pp. 53-73, ISBN 0 19 963577 3). It is also possible to select growth media from commercial suppliers, like
5 standard 1 (Merck) or BHI (grain heart infusion, DIFCO) or others.

All medium components are sterilized, either by heat (20 minutes at 1.5 bar and 121°C) or by sterile filtration. The components can either be sterilized together or, if necessary, separately. All media components can be present at the beginning of growth, or they can optionally be added continuously or batchwise.

10 Culture conditions are defined separately for each experiment. The temperature should be in a range between 15°C and 45°C. The temperature can be kept constant or can be altered during the experiment. The pH of the medium should be in the range of 5 to 8.5, preferably around 7.0, and can be maintained by the addition of buffers to the media. An exemplary buffer for this purpose is a potassium phosphate buffer. Synthetic buffers
15 such as MOPS, HEPES, ACES and others can alternatively or simultaneously be used. It is also possible to maintain a constant culture pH through the addition of NaOH or NH₄OH during growth. If complex medium components such as yeast extract are utilized, the necessity for additional buffers may be reduced, due to the fact that many complex compounds have high buffer capacities. If a fermentor is utilized for culturing the micro-
20 organisms, the pH can also be controlled using gaseous ammonia.

The incubation time is usually in a range from several hours to several days. This time is selected in order to permit the maximal amount of product to accumulate in the broth. The disclosed growth experiments can be carried out in a variety of vessels, such as microtiter plates, glass tubes, glass flasks or glass or metal fermentors of different sizes.
25 For screening a large number of clones, the microorganisms should be cultured in microtiter plates, glass tubes or shake flasks, either with or without baffles. Preferably 100 ml shake flasks are used, filled with 10% (by volume) of the required growth medium. The flasks should be shaken on a rotary shaker (amplitude 25 mm) using a speed-range of 100 – 300 rpm. Evaporation losses can be diminished by the maintenance
30 of a humid atmosphere; alternatively, a mathematical correction for evaporation losses should be performed.

If genetically modified clones are tested, an unmodified control clone or a control clone containing the basic plasmid without any insert should also be tested. The medium is inoculated to an OD₆₀₀ of 0.5 – 1.5 using cells grown on agar plates, such as CM plates
35 (10 g/l glucose, 2,5 g/l NaCl, 2 g/l urea, 10 g/l polypeptone, 5 g/l yeast extract, 5 g/l meat extract, 22 g/l NaCl, 2 g/l urea, 10 g/l polypeptone, 5 g/l yeast extract, 5 g/l meat extract, 22 g/l agar, pH 6.8 with 2M NaOH) that had been incubated at 30°C. Inoculation of the

media is accomplished by either introduction of a saline suspension of *C. glutamicum* cells from CM plates or addition of a liquid preculture of this bacterium.

Example 8 – *In vitro* Analysis of the Function of Mutant Proteins

5 The determination of activities and kinetic parameters of enzymes is well established in the art. Experiments to determine the activity of any given altered enzyme must be tailored to the specific activity of the wild-type enzyme, which is well within the ability of one of ordinary skill in the art. Overviews about enzymes in general, as well as specific details concerning structure, kinetics, principles, methods, applications and examples for the determination of many enzyme activities may be found, for example, in the following references: Dixon, M., and Webb, E.C., (1979) *Enzymes*. Longmans: London; Fersht, (1985) *Enzyme Structure and Mechanism*. Freeman: New York; Walsh, (1979) *Enzymatic Reaction Mechanisms*. Freeman: San Francisco; Price, N.C., Stevens, L. (1982) *Fundamentals of Enzymology*. Oxford Univ. Press: Oxford; Boyer, P.D., ed. (1983) *The Enzymes*, 3rd ed. Academic Press: New York; Bisswanger, H., (1994) *Enzymkinetik*, 2nd ed. VCH: Weinheim (ISBN 3527300325); Bergmeyer, H.U., Bergmeyer, J., Graßl, M., eds. (1983-1986) *Methods of Enzymatic Analysis*, 3rd ed., vol. I-XII, Verlag Chemie: Weinheim; and Ullmann's Encyclopedia of Industrial Chemistry (1987) vol. A9, "Enzymes". VCH: Weinheim, p. 352-363.

20 The activity of proteins which bind to DNA can be measured by several well-established methods, such as DNA band-shift assays (also called gel retardation assays). The effect of such proteins on the expression of other molecules can be measured using reporter gene assays (such as that described in Kolmar, H. *et al.* (1995) *EMBO J.* 14: 3895-3904 and references cited therein). Reporter gene test systems are well known and established for applications in both pro- and eukaryotic cells, using enzymes such as beta-galactosidase, green fluorescent protein, and several others.

25 The determination of activity of membrane-transport proteins can be performed according to techniques such as those described in Gennis, R.B. (1989) "Pores, Channels and Transporters", in *Biomembranes, Molecular Structure and Function*, Springer: Heidelberg, p. 85-137; 199-234; and 270-322.

Example 9: Analysis of Impact of Mutant Protein on the Production of the Desired Product

35 The effect of the genetic modification in *C. glutamicum* on production of a desired compound (such as an amino acid) can be assessed by growing the modified microorganism under suitable conditions (such as those described above) and analyzing

the medium and/or the cellular component for increased production of the desired product (*i.e.*, an amino acid). Such analysis techniques are well known to one of ordinary skill in the art, and include spectroscopy, thin layer chromatography, staining methods of various kinds, enzymatic and microbiological methods, and analytical chromatography such as high performance liquid chromatography (see, for example, Ullman, Encyclopedia of Industrial Chemistry, vol. A2, p. 89-90 and p. 443-613, VCH: Weinheim (1985); Fallon, A. *et al.*, (1987) "Applications of HPLC in Biochemistry" in: Laboratory Techniques in Biochemistry and Molecular Biology, vol. 17; Rehm *et al.* (1993) Biotechnology, vol. 3, Chapter III: "Product recovery and purification", page 469-714, VCH: Weinheim; Belter, P.A. *et al.* (1988) Bioseparations: downstream processing for biotechnology, John Wiley and Sons; Kennedy, J.F. and Cabral, J.M.S. (1992) Recovery processes for biological materials, John Wiley and Sons; Shaeiwitz, J.A. and Henry, J.D. (1988) Biochemical separations, in: Ulmann's Encyclopedia of Industrial Chemistry, vol. B3, Chapter 11, page 1-27, VCH: Weinheim; and Dechow, F.J. (1989) Separation and purification techniques in biotechnology, Noyes Publications.)

In addition to the measurement of the final product of fermentation, it is also possible to analyze other components of the metabolic pathways utilized for the production of the desired compound, such as intermediates and side-products, to determine the overall efficiency of production of the compound. Analysis methods include measurements of nutrient levels in the medium (*e.g.*, sugars, hydrocarbons, nitrogen sources, phosphate, and other ions), measurements of biomass composition and growth, analysis of the production of common metabolites of biosynthetic pathways, and measurement of gasses produced during fermentation. Standard methods for these measurements are outlined in Applied Microbial Physiology, A Practical Approach, P.M. Rhodes and P.F. Stanbury, eds., IRL Press, p. 103-129; 131-163; and 165-192 (ISBN: 0199635773) and references cited therein.

Example 10: Purification of the Desired Product from *C. glutamicum* Culture

Recovery of the desired product from the *C. glutamicum* cells or supernatant of the above-described culture can be performed by various methods well known in the art. If the desired product is not secreted from the cells, the cells can be harvested from the culture by low-speed centrifugation, the cells can be lysed by standard techniques, such as mechanical force or sonication. The cellular debris is removed by centrifugation, and the supernatant fraction containing the soluble proteins is retained for further purification of the desired compound. If the product is secreted from the *C. glutamicum*

cells, then the cells are removed from the culture by low-speed centrifugation, and the supernate fraction is retained for further purification.

The supernatant fraction from either purification method is subjected to chromatography with a suitable resin, in which the desired molecule is either retained on a chromatography resin while many of the impurities in the sample are not, or where the impurities are retained by the resin while the sample is not. Such chromatography steps may be repeated as necessary, using the same or different chromatography resins. One of ordinary skill in the art would be well-versed in the selection of appropriate chromatography resins and in their most efficacious application for a particular molecule to be purified. The purified product may be concentrated by filtration or ultrafiltration, and stored at a temperature at which the stability of the product is maximized.

There are a wide array of purification methods known to the art and the preceding method of purification is not meant to be limiting. Such purification techniques are described, for example, in Bailey, J.E. & Ollis, D.F. *Biochemical Engineering Fundamentals*, McGraw-Hill: New York (1986).

The identity and purity of the isolated compounds may be assessed by techniques standard in the art. These include high-performance liquid chromatography (HPLC), spectroscopic methods, staining methods, thin layer chromatography, NIRS, enzymatic assay, or microbiologically. Such analysis methods are reviewed in: Patek *et al.* (1994) *Appl. Environ. Microbiol.* 60: 133-140; Malakhova *et al.* (1996) *Biotekhnologiya* 11: 27-32; and Schmidt *et al.* (1998) *Bioprocess Engineer.* 19: 67-70. *Ulmann's Encyclopedia of Industrial Chemistry*, (1996) vol. A27, VCH: Weinheim, p. 89-90, p. 521-540, p. 540-547, p. 559-566, 575-581 and p. 581-587; Michal, G. (1999) *Biochemical Pathways: An Atlas of Biochemistry and Molecular Biology*, John Wiley and Sons; Fallon, A. *et al.* (1987) *Applications of HPLC in Biochemistry in: Laboratory Techniques in Biochemistry and Molecular Biology*, vol. 17.

Example 11: Analysis of the Gene Sequences of the Invention

The comparison of sequences and determination of percent homology between two sequences are art-known techniques, and can be accomplished using a mathematical algorithm, such as the algorithm of Karlin and Altschul (1990) *Proc. Natl. Acad. Sci. USA* 87:2264-68, modified as in Karlin and Altschul (1993) *Proc. Natl. Acad. Sci. USA* 90:5873-77. Such an algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0) of Altschul, *et al.* (1990) *J. Mol. Biol.* 215:403-10. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to RRP nucleic acid molecules of the invention. BLAST protein searches can be performed with the

XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to RRP protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.*, (1997) *Nucleic Acids Res.* 25(17):3389-3402. When utilizing BLAST and Gapped
5 BLAST programs, one of ordinary skill in the art will know how to optimize the parameters of the program (*e.g.*, XBLAST and NBLAST) for the specific sequence being analyzed.

Another example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Meyers and Miller ((1988) *Comput. Appl. Biosci.* 4: 11-
10 17). Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. Additional algorithms for sequence analysis are known in the art, and include ADVANCE and ADAM. described
15 in Torelli and Robotti (1994) *Comput. Appl. Biosci.* 10:3-5; and FASTA, described in Pearson and Lipman (1988) *P.N.A.S.* 85:2444-8.

The percent homology between two amino acid sequences can also be accomplished using the GAP program in the GCG software package (available at <http://www.gcg.com>), using either a Blosum 62 matrix or a PAM250 matrix, and a gap
20 weight of 12, 10, 8, 6, or 4 and a length weight of 2, 3, or 4. The percent homology between two nucleic acid sequences can be accomplished using the GAP program in the GCG software package, using standard parameters, such as a gap weight of 50 and a length weight of 3.

A comparative analysis of the gene sequences of the invention with those present
25 in Genbank has been performed using techniques known in the art (see, *e.g.*, Bexevanis and Ouellette, eds. (1998) *Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins*. John Wiley and Sons: New York). The gene sequences of the invention were compared to genes present in Genbank in a three-step process. In a first step, a BLASTN analysis (*e.g.*, a local alignment analysis) was performed for each of the
30 sequences of the invention against the nucleotide sequences present in Genbank, and the top 500 hits were retained for further analysis. A subsequent FASTA search (*e.g.*, a combined local and global alignment analysis, in which limited regions of the sequences are aligned) was performed on these 500 hits. Each gene sequence of the invention was subsequently globally aligned to each of the top three FASTA hits, using the GAP
35 program in the GCG software package (using standard parameters). In order to obtain correct results, the length of the sequences extracted from Genbank were adjusted to the length of the query sequences by methods well-known in the art. The results of this

analysis are set forth in Table 4. The resulting data is identical to that which would have been obtained had a GAP (global) analysis alone been performed on each of the genes of the invention in comparison with each of the references in Genbank, but required significantly reduced computational time as compared to such a database-wide GAP (global) analysis. Sequences of the invention for which no alignments above the cutoff values were obtained are indicated on Table 4 by the absence of alignment information. It will further be understood by one of ordinary skill in the art that the GAP alignment homology percentages set forth in Table 4 under the heading "% homology (GAP)" are listed in the European numerical format, wherein a ',' represents a decimal point. For example, a value of "40,345" in this column represents "40.345%".

Example 12: Construction and Operation of DNA Microarrays

The sequences of the invention may additionally be used in the construction and application of DNA microarrays (the design, methodology, and uses of DNA arrays are well known in the art, and are described, for example, in Schena, M. *et al.* (1995) *Science* 270: 467-470; Wodicka, L. *et al.* (1997) *Nature Biotechnology* 15: 1359-1367; DeSaizieu, A. *et al.* (1998) *Nature Biotechnology* 16: 45-48; and DeRisi, J.L. *et al.* (1997) *Science* 278: 680-686).

DNA microarrays are solid or flexible supports consisting of nitrocellulose, nylon, glass, silicone, or other materials. Nucleic acid molecules may be attached to the surface in an ordered manner. After appropriate labeling, other nucleic acids or nucleic acid mixtures can be hybridized to the immobilized nucleic acid molecules, and the label may be used to monitor and measure the individual signal intensities of the hybridized molecules at defined regions. This methodology allows the simultaneous quantification of the relative or absolute amount of all or selected nucleic acids in the applied nucleic acid sample or mixture. DNA microarrays, therefore, permit an analysis of the expression of multiple (as many as 6800 or more) nucleic acids in parallel (see, *e.g.*, Schena, M. (1996) *BioEssays* 18(5): 427-431).

The sequences of the invention may be used to design oligonucleotide primers which are able to amplify defined regions of one or more *C. glutamicum* genes by a nucleic acid amplification reaction such as the polymerase chain reaction. The choice and design of the 5' or 3' oligonucleotide primers or of appropriate linkers allows the covalent attachment of the resulting PCR products to the surface of a support medium described above (and also described, for example, Schena, M. *et al.* (1995) *Science* 270: 467-470).

Nucleic acid microarrays may also be constructed by *in situ* oligonucleotide synthesis as described by Wodicka, L. *et al.* (1997) *Nature Biotechnology* 15: 1359-

1367. By photolithographic methods, precisely defined regions of the matrix are exposed to light. Protective groups which are photolabile are thereby activated and undergo nucleotide addition, whereas regions that are masked from light do not undergo any modification. Subsequent cycles of protection and light activation permit the synthesis of different oligonucleotides at defined positions. Small, defined regions of the genes of the invention may be synthesized on microarrays by solid phase oligonucleotide synthesis.

The nucleic acid molecules of the invention present in a sample or mixture of nucleotides may be hybridized to the microarrays. These nucleic acid molecules can be labeled according to standard methods. In brief, nucleic acid molecules (*e.g.*, mRNA molecules or DNA molecules) are labeled by the incorporation of isotopically or fluorescently labeled nucleotides, *e.g.*, during reverse transcription or DNA synthesis. Hybridization of labeled nucleic acids to microarrays is described (*e.g.*, in Schena, M. *et al.* (1995) *supra*; Wodicka, L. *et al.* (1997), *supra*; and DeSaizieu A. *et al.* (1998), *supra*). The detection and quantification of the hybridized molecule are tailored to the specific incorporated label. Radioactive labels can be detected, for example, as described in Schena, M. *et al.* (1995) *supra*) and fluorescent labels may be detected, for example, by the method of Shalon *et al.* (1996) *Genome Research* 6: 639-645).

The application of the sequences of the invention to DNA microarray technology, as described above, permits comparative analyses of different strains of *C. glutamicum* or other Corynebacteria. For example, studies of inter-strain variations based on individual transcript profiles and the identification of genes that are important for specific and/or desired strain properties such as pathogenicity, productivity and stress tolerance are facilitated by nucleic acid array methodologies. Also, comparisons of the profile of expression of genes of the invention during the course of a fermentation reaction are possible using nucleic acid array technology.

Example 13: Analysis of the Dynamics of Cellular Protein Populations (Proteomics)

The genes, compositions, and methods of the invention may be applied to study the interactions and dynamics of populations of proteins, termed 'proteomics'. Protein populations of interest include, but are not limited to, the total protein population of *C. glutamicum* (*e.g.*, in comparison with the protein populations of other organisms), those proteins which are active under specific environmental or metabolic conditions (*e.g.*, during fermentation, at high or low temperature, or at high or low pH), or those proteins which are active during specific phases of growth and development.

Protein populations can be analyzed by various well-known techniques, such as gel electrophoresis. Cellular proteins may be obtained, for example, by lysis or extraction, and may be separated from one another using a variety of electrophoretic techniques. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) separates proteins largely on the basis of their molecular weight. Isoelectric focusing polyacrylamide gel electrophoresis (IEF-PAGE) separates proteins by their isoelectric point (which reflects not only the amino acid sequence but also posttranslational modifications of the protein). Another, more preferred method of protein analysis is the consecutive combination of both IEF-PAGE and SDS-PAGE, known as 2-D-gel electrophoresis (described, for example, in Hermann *et al.* (1998) *Electrophoresis* 19: 3217-3221; Fountoulakis *et al.* (1998) *Electrophoresis* 19: 1193-1202; Langen *et al.* (1997) *Electrophoresis* 18: 1184-1192; Antelmann *et al.* (1997) *Electrophoresis* 18: 1451-1463). Other separation techniques may also be utilized for protein separation, such as capillary gel electrophoresis; such techniques are well known in the art.

Proteins separated by these methodologies can be visualized by standard techniques, such as by staining or labeling. Suitable stains are known in the art, and include Coomassie Brilliant Blue, silver stain, or fluorescent dyes such as Sypro Ruby (Molecular Probes). The inclusion of radioactively labeled amino acids or other protein precursors (*e.g.*, ^{35}S -methionine, ^{35}S -cysteine, ^{14}C -labelled amino acids, ^{15}N -amino acids, $^{15}\text{NO}_3$ or $^{15}\text{NH}_4^+$ or ^{13}C -labelled amino acids) in the medium of *C. glutamicum* permits the labeling of proteins from these cells prior to their separation. Similarly, fluorescent labels may be employed. These labeled proteins can be extracted, isolated and separated according to the previously described techniques.

Proteins visualized by these techniques can be further analyzed by measuring the amount of dye or label used. The amount of a given protein can be determined quantitatively using, for example, optical methods and can be compared to the amount of other proteins in the same gel or in other gels. Comparisons of proteins on gels can be made, for example, by optical comparison, by spectroscopy, by image scanning and analysis of gels, or through the use of photographic films and screens. Such techniques are well-known in the art.

To determine the identity of any given protein, direct sequencing or other standard techniques may be employed. For example, N- and/or C-terminal amino acid sequencing (such as Edman degradation) may be used, as may mass spectrometry (in particular MALDI or ESI techniques (see, *e.g.*, Langen *et al.* (1997) *Electrophoresis* 18: 1184-1192)). The protein sequences provided herein can be used for the identification of *C. glutamicum* proteins by these techniques.

The information obtained by these methods can be used to compare patterns of protein presence, activity, or modification between different samples from various biological conditions (*e.g.*, different organisms, time points of fermentation, media conditions, or different biotopes, among others). Data obtained from such experiments alone, or in combination with other techniques, can be used for various applications, such as to compare the behavior of various organisms in a given (*e.g.*, metabolic) situation, to increase the productivity of strains which produce fine chemicals or to increase the efficiency of the production of fine chemicals.

10 **Equivalents**

Those skilled of ordinary skill in the art will recognize, or will be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

TABLE 1: Genes in the Application

Nucleic Acid SEQ ID NO	Amino Acid SEQ ID NO	Identification Code	Contig.	NT Start	NT Stop	Function
1	2	RXN00625	VV0135	5	946	(D90902) extracellular nuclease [Synecocystis sp.]
3	4	F RXA00625	GR00163	9320	8982	(D90902) extracellular nuclease [Synecocystis sp.]
5	6	RXN02943	VV0103	1671	4	(D90902) extracellular nuclease [Synecocystis sp.]
7	8	F RXA00538	GR00139	1272	4	(D90902) extracellular nuclease [Synecocystis sp.]
9	10	RXA00823	GR00221	3566	4345	ENDONUCLEASE III (EC 4.2.99.18)
11	12	RXA02145	GR00639	12248	13864	ENDONUCLEASE III (EC 4.2.99.18)
13	14	RXA01064	GR00297	937	1572	TERMONUCLEASE PRECURSOR (EC 3.1.31.1)
15	16	RXN01594	VV0229	12195	11377	HEMOLYSIN
17	18	F RXA01594	GR00447	2580	3323	HEMOLYSIN
19	20	RXA01718	GR00488	540	55	HEMOLYSIN
21	22	RXN03148	VV0146	626	991	HEMOLYSIN
23	24	RXN00562	VV0103	5761	6483	HEMOLYSIN III
25	26	F RXA00562	GR00150	405	1034	HEMOLYSIN III
27	28	RXN00890	VV0099	18771	20069	HEMOLYSIN
29	30	F RXA00890	GR00242	15953	17227	HEMOLYSIN
Nucleic Acid SEQ ID NO	Amino Acid SEQ ID NO	Identification Code	Contig.	NT Start	NT Stop	Function
31	32	RXN01772	VV0050	28644	33581	/K/J Superfamily II DNA and RNA helicases
33	34	F RXA01772	GR00502	4731	2368	/K/J Superfamily II DNA and RNA helicases
35	36	RXA02363	GR00685	10755	15554	/K/J Superfamily II DNA and RNA helicases
37	38	RXN01606	VV0137	5576	2901	Hypothetical ATP-Dependent RNA Helicase
39	40	F RXA01797	GR00508	1249	542	/L Superfamily II DNA and RNA(?) helicases (SNF2 family)
41	42	RXN01030	VV0015	32429	33604	Hypothetical ATP-dependent RNA helicase
43	44	F RXA01030	GR00295	2007	3182	/L Superfamily II DNA and RNA(?) helicases (SNF2 family)
45	46	RXA01739	GR00493	4702	5298	Superfamily I DNA and RNA helicases
47	48	RXA02359	GR00685	1666	3534	Superfamily I DNA and RNA helicases
49	50	RXN02764	VV0317	2787	4	DNA HELICASE II (EC 3.6.1.-)
51	52	F RXA02764	GR00769	2787	4	Superfamily I DNA and RNA helicases
53	54	RXA01736	GR00493	3	2870	(A1021646) putative ATP-dependent DNA helicase [Mycobacterium tuberculosis]
55	56	RXA00095	GR00014	4677	2389	DNA HELICASE II (EC 3.6.1.-)
57	58	RXN02819	VV0088	6162	5116	ATP-DEPENDENT DNA HELICASE
59	60	F RXA02819	GR00800	615	4	ATP-DEPENDENT DNA HELICASE
61	62	RXA01157	GR00328	1610	6	ATP-DEPENDENT DNA HELICASE
63	64	RXN01876	VV0145	188	2038	ATP-DEPENDENT DNA HELICASE REP (EC 3.6.1.-)
65	66	F RXA01876	GR00536	2796	1324	ATP-DEPENDENT DNA HELICASE REP (EC 3.6.1.-)

Genes involved in DNA replication, topology, and packaging

<u>Nucleic Acid SEQ ID NO</u>	<u>Amino Acid SEQ ID NO</u>	<u>Identification Code</u>	<u>Contig.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
67	68	RXA00544	GR00140	1639	3168	REPLICATIVE DNA HELICASE (EC 3.6.1.-)
69	70	RXA01866	GR00533	326	6	ATP-DEPENDENT HELICASE HRP A
71	72	RXA01867	GR00533	853	362	ATP-DEPENDENT HELICASE HRP A
73	74	RXN03166	VV0322	2933	699	ATP-DEPENDENT HELICASE HRP A
75	76	F RXA00361	GR00072	1853	6	ATP-DEPENDENT HELICASE HRP A
77	78	RXN02293	VV0127	19979	22366	ATP-DEPENDENT HELICASE HRPB
79	80	F RXA02293	GR00662	2819	5206	ATP-dependent helicase
81	82	RXA02755	GR00766	951	2945	PROBABLE ATP-DEPENDENT HELICASE DING
83	84	RXN01374	VV0091	7624	8865	Hypothetical ATP-Dependent RNA Helicase
85	86	F RXA01374	GR00400	885	4	PROBABLE ATP-DEPENDENT HELICASE HEPA
87	88	RXN00817	VV0054	35789	33396	PROBABLE ATP-DEPENDENT HELICASE LHR (EC 3.6.1.-)
89	90	F RXA00809	GR00218	514	5	PROBABLE ATP-DEPENDENT HELICASE LHR (EC 3.6.1.-)
91	92	F RXA00817	GR00219	6388	4679	PROBABLE ATP-DEPENDENT HELICASE LHR (EC 3.6.1.-)
93	94	RXN00103	VV0129	11188	15747	PROBABLE ATP-DEPENDENT HELICASE LHR (EC 3.6.1.-)
95	96	F RXA00103	GR00014	15860	11301	PROBABLE ATP-DEPENDENT HELICASE LHR (EC 3.6.1.-)
97	98	RXN02357	VV0051	23376	17077	PROBABLE ATP-DEPENDENT HELICASE LHR (EC 3.6.1.-)
99	100	F RXA01363	GR00395	1408	2106	PROBABLE ATP-DEPENDENT HELICASE LHR (EC 3.6.1.-)
101	102	F RXA02357	GR00685	3	1205	PROBABLE ATP-DEPENDENT HELICASE LHR (EC 3.6.1.-)
103	104	F RXA02785	GR00776	2	3856	PROBABLE ATP-DEPENDENT HELICASE LHR (EC 3.6.1.-)
105	106	RXA01740	GR00493	5314	6735	PROBABLE ATP-DEPENDENT HELICASE LHR (EC 3.6.1.-)
107	108	RXN01683	VV0179	5275	7842	PUTATIVE DNA HELICASE II HOMOLOG (EC 3.6.1.-)
109	110	F RXA01682	GR00468	1	234	DNA GYRASE SUBUNIT A (EC 5.99.1.3)
111	112	F RXA01683	GR00468	146	895	DNA GYRASE SUBUNIT A (EC 5.99.1.3)
113	114	F RXA01684	GR00469	3	875	DNA GYRASE SUBUNIT A (EC 5.99.1.3)
115	116	RXN01688	VV0179	1	930	DNA GYRASE SUBUNIT B (EC 5.99.1.3)
117	118	F RXA01688	GR00471	1	564	DNA GYRASE SUBUNIT B (EC 5.99.1.3)
119	120	RXN01689	VV0221	1920	3035	DNA GYRASE SUBUNIT B (EC 5.99.1.3)
121	122	F RXA01689	GR00472	3	728	DNA GYRASE SUBUNIT B (EC 5.99.1.3)
123	124	F RXA01735	GR00492	1213	1494	DNA GYRASE SUBUNIT B (EC 5.99.1.3)
125	126	RXN03093	VV0054	36970	38808	DNA GYRASE SUBUNIT B (EC 5.99.1.3)
127	128	F RXA00798	GR00213	2525	171	DNA TOPOISOMERASE I (EC 5.99.1.2)
129	130	RXN00990	VV0210	4962	4498	DNA TOPOISOMERASE I (EC 5.99.1.2)
131	132	F RXA00990	GR00281	2	454	ATP-DEPENDENT RNA HELICASE DEAD
133	134	RXN00994	VV0106	356	6	ATP-DEPENDENT RNA HELICASE DEAD
135	136	F RXA00994	GR00282	797	1138	ATP-DEPENDENT RNA HELICASE DEAD
137	138	RXN02468	VV0211	760	1983	ATP-DEPENDENT RNA HELICASE DEAD
141	140	F RXA02463	GR00713	141	254	ATP-DEPENDENT RNA HELICASE DEAD
143	144	RXA00050	GR00714	760	1290	ATP-DEPENDENT RNA HELICASE DEAD
145	146	RXA02682	GR00008	5451	3256	ATP-DEPENDENT RNA HELICASE DEAD
147	148	RXN00542	GR00754	6902	6576	ATP-DEPENDENT RNA HELICASE DEAD
149	150	F RXA00542	VV0079	36158	36832	DNA-BINDING PROTEIN
151	152	RXN02833	GR00140	1	519	SINGLE-STRAND BINDING PROTEIN
153	154	F RXA02833	VV0050	823	41	CHROMOSOMAL REPLICATION INITIATOR PROTEIN DNAA
155	156	RXA01480	GR00822	627	49	CHROMOSOMAL REPLICATION INITIATOR PROTEIN DNAA
157	158	RXN03163	GR00422	14550	12658	DNA PRIMASE (EC 2.7.7.-)
159	160	F RXA02241	VV0204	4514	6010	PRIMOSOMAL PROTEIN N'
			GR00654	8446	10473	PRIMOSOMAL PROTEIN N', replication factor Y

<u>Nucleic Acid SEQ ID NO</u>	<u>Amino Acid SEQ ID NO</u>	<u>Identification Code</u>	<u>Contig.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
161	162	RXND0061	VV0044	4256	1590	DNA POLYMERASE I (EC 2.7.7.7)
163	164	F RXA00060	GR00009	9187	11643	DNA POLYMERASE I (EC 2.7.7.7)
165	166	F RXA00061	GR00009	11643	11852	DNA POLYMERASE I (EC 2.7.7.7)
167	168	RXA02657	GR00752	11033	14614	DNA POLYMERASE III, ALPHA CHAIN (EC 2.7.7.7)
169	170	RXA01238	GR00358	2965	4365	DNA POLYMERASE III, ALPHA CHAIN (EC 2.7.7.7)
171	172	RXND0407	VV0086	55677	58340	DNA POLYMERASE III, ALPHA CHAIN (EC 2.7.7.7)
173	174	F RXA00407	GR00091	3	578	DNA POLYMERASE III, ALPHA CHAIN (EC 2.7.7.7)
175	176	F RXA00415	GR00092	4519	6480	DNA POLYMERASE III, ALPHA CHAIN (EC 2.7.7.7)
177	178	RXND00414	VV0086	55331	55684	DNA POLYMERASE III, ALPHA CHAIN (EC 2.7.7.7)
179	180	F RXA00414	GR00092	4172	4591	DNA POLYMERASE III, ALPHA CHAIN (EC 2.7.7.7)
181	182	RXND0807	VV0009	63097	61856	DNA POLYMERASE III, DELTA SUBUNIT (EC 2.7.7.7)
183	184	F RXA00807	GR00216	423	1541	DNA POLYMERASE III, DELTA SUBUNIT (EC 2.7.7.7)
185	186	RXA00214	GR00032	13046	13756	DNA POLYMERASE III, EPSILON CHAIN (EC 2.7.7.7)
187	188	RXA01255	GR00365	4919	3840	DNA POLYMERASE III, EPSILON CHAIN (EC 2.7.7.7)
189	190	RXND0066	VV0012	816	4	DNA POLYMERASE III SUBUNITS GAMMA AND TAU (EC 2.7.7.7)
191	192	F RXA00066	GR00010	4494	5306	DNA POLYMERASE III SUBUNITS GAMMA AND TAU (EC 2.7.7.7)
193	194	RXND1637	VV0156	666	4	DNA POLYMERASE III SUBUNITS GAMMA AND TAU (EC 2.7.7.7)
195	196	F RXA01637	GR00455	312	4	DNA POLYMERASE III SUBUNITS GAMMA AND TAU (EC 2.7.7.7)
197	198	RXA00212	GR00032	12407	10848	DNA LIGASE (EC 6.5.1.2)
199	200	RXA00213	GR00032	12888	12316	DNA LIGASE (EC 6.5.1.2)
201	202	RXA00789	GR00209	1266	1024	EXODEOXYRIBONUCLEASE SMALL SUBUNIT (EC 3.1.11.6)
203	204	RXND0790	VV0321	1983	3044	EXODEOXYRIBONUCLEASE LARGE SUBUNIT (EC 3.1.11.6)
205	206	F RXA00790	GR00209	2315	1290	EXODEOXYRIBONUCLEASE LARGE SUBUNIT (EC 3.1.11.6)
207	208	RXA00898	GR00245	567	1355	EXODEOXYRIBONUCLEASE III (EC 3.1.11.2)
209	210	RXND3175	VV0331	1248	466	EXODEOXYRIBONUCLEASE III (EC 3.1.11.2)
211	212	F RXA02883	GR10020	779	1690	EXODEOXYRIBONUCLEASE III (EC 3.1.11.2)
213	214	RXA00341	GR00059	3584	4990	EXORIBONUCLEASE II (EC 3.1.13.1)
215	216	RXA02077	GR00628	7779	8174	RIBONUCLEASE III (EC 3.1.26.3)
217	218	RXND1563	VV0191	4413	3205	RIBONUCLEASE D (EC 3.1.26.3)
219	220	F RXA01563	GR00436	1916	1107	RIBONUCLEASE D (EC 3.1.26.3)
221	222	F RXA01713	GR00485	357	4	RIBONUCLEASE D (EC 3.1.26.3)
223	224	RXA02369	GR00687	3191	5479	RIBONUCLEASE E (EC 3.1.4.-)
225	226	RXND2370	VV0102	1338	547	RIBONUCLEASE E (EC 3.1.4.-)
227	228	F RXA02370	GR00687	5463	6254	RIBONUCLEASE E (EC 3.1.4.-)
229	230	RXA01356	GR00393	3731	4357	RIBONUCLEASE HII (EC 3.1.26.4)
231	232	RXND1786	VV0084	11253	10570	RIBONUCLEASE PH (EC 2.7.7.56)
233	234	F RXA01786	GR00505	1878	2318	RIBONUCLEASE PH (EC 2.7.7.56)
235	236	RXND0163	VV0084	10540	9923	RIBONUCLEASE PH (EC 2.7.7.56)
237	238	F RXA00163	GR00024	6432	5872	RIBONUCLEASE PH (EC 2.7.7.56)
239	240	RXA01424	GR00417	988	1296	RIBONUCLEASE PH (EC 2.7.7.56)
241	242	RXA01481	GR00422	14596	15087	RIBONUCLEASE P PROTEIN COMPONENT (EC 3.1.26.5)
243	244	RXND0724	VV0052	1217	3193	GUANYL-SPECIFIC RIBONUCLEASE SA3 (EC 3.1.27.3)
245	246	RXND1979	VV0105	18093	16513	ATP-DEPENDENT DNA HELICASE RECG (EC 3.6.1.-)
247	248	RXND1770	VV0015	50449	54213	ATP-DEPENDENT DNA HELICASE RECG (EC 3.6.1.-)
249	250	RXND1378	VV0091	8756	10510	DNA HELICASE II (EC 3.6.1.-)
251	252	RXND2131	VV0100	23500	25170	Hypothetical ATP-Dependent RNA Helicase
253	254	RXND1066	VV0099	21112	21837	DNA REPAIR HELICASE RAD25 DNA REPAIR PROTEIN RECO

<u>Nucleic Acid SEQ ID NO</u>	<u>Amino Acid SEQ ID NO</u>	<u>Identification Code</u>	<u>Contig.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
255	256	RXND01389	VV0276	1350	667	DNA-DIRECTED RNA POLYMERASE BETA' CHAIN (EC 2.7.7.6)
257	258	RXND02070	VV0222	8319	7198	MRP PROTEIN HOMOLOG
259	260	RXND02082	VV0318	21225	24134	CHROMOSOME SEGREGATION PROTEIN SMC2

Ribosomal genes

<u>Nucleic Acid SEQ ID NO</u>	<u>Amino Acid SEQ ID NO</u>	<u>Identification Code</u>	<u>Contig.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
261	262	RXA01495	GR00423	8970	8524	RIBOSOME-BINDING FACTOR A
263	264	RXA01893	GR00542	871	1425	Ribosome Recycling Factor (RRF)
265	266	RXA01568	GR00437	2764	2330	RIBOSOMAL-PROTEIN-ALANINE ACETYLTRANSFERASE (EC 2.3.1.128)
267	268	RXA01661	GR00462	1132	1797	RNA METHYLTRANSFERASE (EC 2.1.1.-)
269	270	RXA01581	GR00440	777	1589	RNA METHYLTRANSFERASE (EC 2.1.1.-)
271	272	RXA00313	GR00053	3992	3054	RNA METHYLTRANSFERASE (EC 2.1.1.-)
273	274	RXND00460	VV0086	64848	64378	RNA METHYLTRANSFERASE (EC 2.1.1.-)
275	276	F RXA000460	GR00116	382	5	RNA METHYLTRANSFERASE (EC 2.1.1.-)
277	278	RXA02179	GR00641	15353	14526	23S RNA METHYLTRANSFERASE (EC 2.1.1.-)
279	280	RXA02522	GR00725	311	853	16S RNA PROCESSING PROTEIN RIMM
281	282	RXA00717	GR00188	3617	4576	RIBOSOMAL LARGE SUBUNIT PSEUDOURIDINE SYNTHASE B (EC 4.2.1.70)
283	284	RXA02615	GR00744	973	338	RIBOSOMAL-PROTEIN-ALANINE ACETYLTRANSFERASE (EC 2.3.1.128)
285	286	RXND01343	VV0025	33595	34302	LSU ribosomal protein L1P
287	288	F RXA01343	GR00389	13513	12863	LSU ribosomal protein L1P
289	290	RXND01951	GR00561	1218	1778	LSU ribosomal protein L2P
291	292	F RXA01950	GR00561	938	1321	LSU ribosomal protein L2P
293	294	RXA01286	GR00372	730	77	LSU ribosomal protein L3P
295	296	RXA01948	GR00561	3	605	LSU ribosomal protein L1E (= L4P)
297	298	RXND0706	VV0005	2208	2780	LSU ribosomal protein L5P
299	300	F RXA00711	GR00186	660	815	LSU ribosomal protein L5P
301	302	F RXA00706	GR00185	1	267	LSU ribosomal protein L5P
303	304	RXA00695	GR00181	5118	5651	LSU ribosomal protein L6P
305	306	RXA00543	GR00140	579	1004	LSU ribosomal protein L9P
307	308	RXA01335	GR00389	2736	2224	LSU ribosomal protein L10P
309	310	RXND02826	VV0025	33031	33465	LSU ribosomal protein L11P
311	312	F RXA02826	GR00807	67	465	LSU ribosomal protein L11P
313	314	RXA01334	GR00389	2143	1760	LSU ribosomal protein L12P (L7/L12)
315	316	RXA02037	GR00620	1	330	LSU ribosomal protein L13P
317	318	RXA00699	GR00181	6934	7377	LSU ribosomal protein L15P
319	320	RXA02042	GR00622	720	1133	LSU ribosomal protein L16P
321	322	RXA00670	GR00176	2420	1932	LSU ribosomal protein L17P
323	324	RXA00696	GR00181	5658	6059	LSU ribosomal protein L18P
325	326	RXA01353	GR00393	972	1310	LSU ribosomal protein L19P
327	328	RXA02420	GR00705	5954	6334	LSU ribosomal protein L20P
329	330	RXND02371	VV0102	318	4	LSU ribosomal protein L21P
331	332	F RXA02371	GR00687	6483	6752	LSU ribosomal protein L21P
333	334	RXA01949	GR00561	608	910	LSU ribosomal protein L23P

<u>Nucleic Acid SEQ ID NO</u>	<u>Amino Acid SEQ ID NO</u>	<u>Identification Code</u>	<u>Contig.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
335	336	RXN00709	VV0005	1523	1888	LSU ribosomal protein L24P
337	338	F RXA00709	GR00186	2	340	LSU ribosomal protein L24P
339	340	RXA00710	GR00186	346	657	LSU ribosomal protein L24P
341	342	RXA02635	GR00748	7846	8079	LSU ribosomal protein L28P
343	344	RXA02043	GR00622	1136	1276	LSU ribosomal protein L29P
345	346	RXA00698	GR00181	6742	6924	LSU ribosomal protein L30P
347	348	RXA02633	GR00748	5506	5243	LSU ribosomal protein L31P
349	350	RXA02636	GR00748	8085	8246	LSU ribosomal protein L33P
351	352	RXA01423	GR00417	715	855	LSU ribosomal protein L34P
353	354	RXA02419	GR00705	5699	5890	LSU ribosomal protein L36P
355	356	RXA02190	GR00642	1277	2734	SSU ribosomal protein S1P
357	358	RXN01912	VV0150	876	1613	SSU ribosomal protein S2P
359	360	F RXA01912	GR00547	876	1646	SSU ribosomal protein S2P
361	362	RXA02041	GR00622	1	714	SSU ribosomal protein S3P
363	364	RXA00672	GR00176	4215	3613	SSU ribosomal protein S4P
365	366	RXA00697	GR00181	6103	6735	SSU ribosomal protein S5P
367	368	RXN00545	VV0079	35852	36118	SSU ribosomal protein S6P
369	370	F RXA00545	GR00141	562	816	SSU ribosomal protein S6P
371	372	RXA01279	GR00369	3240	2776	SSU ribosomal protein S7P
373	374	RXA00694	GR00181	4700	5095	SSU ribosomal protein S8P
375	376	RXN02038	VV0118	333	701	SSU ribosomal protein S9P
377	378	F RXA02038	GR00620	333	641	SSU ribosomal protein S9P
379	380	RXA01287	GR00372	1068	766	SSU ribosomal protein S10P
381	382	RXA00673	GR00176	4331	4242	SSU ribosomal protein S11P
383	384	RXA01280	GR00369	3615	3250	SSU ribosomal protein S12P
385	386	RXA02637	GR00748	8253	8555	SSU ribosomal protein S14P
387	388	RXA01487	GR00423	1172	906	SSU ribosomal protein S15P
389	390	RXA02752	GR00764	6709	7203	SSU ribosomal protein S16P
391	392	RXA02389	GR00695	504	764	SSU ribosomal protein S20P
393	394	RXA00671	GR00176	3492	2479	DNA-DIRECTED RNA POLYMERASE ALPHA CHAIN (EC 2.7.7.6)
395	396	RXN02981	VV0005	35599	35964	SSU ribosomal protein S13P
397	398	RXN03139	VV0129	35652	36304	SSU ribosomal protein S18P
399	400	RXN00673	VV0005	35970	36371	SSU ribosomal protein S11P
401	402	RXN00714	VV0232	10755	11315	RIBOSOMAL-PROTEIN-ALANINE ACETYLTRANSFERASE (EC 2.3.1.128)
403	404	RXN00897	VV0140	3721	4725	RIBOSOMAL-PROTEIN-ALANINE ACETYLTRANSFERASE (EC 2.3.1.128)
405	406	RXN01380	VV0224	15361	17559	TEX PROTEIN

Genes Involved in Pathogenesis

<u>Nucleic Acid SEQ ID NO</u>	<u>Amino Acid SEQ ID NO</u>	<u>Identification Code</u>	<u>Contig.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
407	408	RXA00157	GR00023	11848	10586	INVASIN 1
409	410	RXA00208	GR00032	7947	7099	VULNIBACTIN UTILIZATION PROTEIN VIUB
411	412	RXA00967	GR00967	1351	989	VIRULENCE-ASSOCIATED PROTEIN I
413	414	RXA01149	GR00323	2501	2758	VIRULENCE-ASSOCIATED PROTEIN I

<u>Nucleic Acid SEQ ID NO</u>	<u>Amino Acid SEQ ID NO</u>	<u>Identification Code</u>	<u>Contig.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
415	416	RXA01305	GR00376	4435	2570	SEROTYPE-SPECIFIC ANTIGEN 1 (EC 3.4.21.-)
417	418	RXA01453	GR00419	2655	2951	VIRULENCE-ASSOCIATED PROTEIN A'
419	420	RXA01824	GR00516	1367	2188	VULNIBACTIN UTILIZATION PROTEIN VIUB
421	422	RXA01832	GR00516	11787	10894	ANNEXIN VII
423	424	RXA02533	GR00726	3775	3209	(D90768) Immunity repressor protein [Escherichia coli]
425	426	RXN02727	VV0017	6287	5376	ANTIGEN 84

Nucleases

<u>Nucleic Acid SEQ ID NO</u>	<u>Amino Acid SEQ ID NO</u>	<u>Identification Code</u>	<u>Contig.</u>	<u>NT Start</u>	<u>NT Stop</u>	<u>Function</u>
427	428	RXN01575	VV0009	50041	49022	RIBONUCLEASE HI (EC 3.1.26.4)
429	430	RXN01966	VV0155	5673	5017	OLIGORIBONUCLEASE (EC 3.1.-.-)

TABLE 2: GENES IDENTIFIED FROM GENBANK

GenBank™ Accession No.	Gene Name	Gene Function	Reference
A09073	ppg	Phosphoenol pyruvate carboxylase	Bachmann, B. et al. "DNA fragment coding for phosphoenolpyruvate carboxylase, recombinant DNA carrying said fragment, strains carrying the recombinant DNA and method for producing L-aminino acids using said strains," Patent: EP 0358940-A 3 03/21/90
A45579, A45581, A45583, A45585 A45587		Threonine dehydratase	Moeckel, B. et al. "Production of L-isoleucine by means of recombinant micro-organisms with deregulated threonine dehydratase," Patent: WO 9519442-A 5 07/20/95
AB03132	murC; ftsQ; ftsZ		Kobayashi, M. et al. "Cloning, sequencing, and characterization of the ftsZ gene from coryneform bacteria," <i>Biochem. Biophys. Res. Commun.</i> , 236(2):383-388 (1997)
AB015023	murC; ftsQ		Wachi, M. et al. "A murC gene from Coryneform bacteria," <i>Appl. Microbiol. Biotechnol.</i> , 51(2):223-228 (1999)
AB018530	dsr		Kimura, E. et al. "Molecular cloning of a novel gene, dsr, which rescues the detergent sensitivity of a mutant derived from <i>Brevibacterium lactofermentum</i> ," <i>Biosci. Biotechnol. Biochem.</i> , 60(10):1565-1570 (1996)
AB018531	dsr1; dsr2		
AB020624	murI	D-glutamate racemase	
AB023377	tkl	transketolase	
AB024708	glbB; glbD	Glutamine 2-oxoglutarate aminotransferase large and small subunits	
AB025424	acn	aconitase	
AB027714	rep	Replication protein	
AB027715	rep; aad	Replication protein; aminoglycoside adenyltransferase	
AF03242	argC	N-acetylglutamate-5-semialdehyde dehydrogenase	
AF005635	glnA	Glutamine synthetase	
AF030405	hisF	cyclase	
AF030520	argG	Argininosuccinate synthetase	
AF031518	argF	Ornithine carbamoyltransferase	
AF036932	aroD	3-dehydroquinate dehydratase	

GenBank™ Accession No.	Gene Name	Gene Function	Reference
AF038548	pyc	Pyruvate carboxylase	
AF038651	dc1AE; apt; rel	Dipeptide-binding protein; adenine phosphoribosyltransferase; GTP pyrophosphokinase	Wehmeier, L. et al. "The role of the <i>Corynebacterium glutamicum</i> rel gene in (p)ppGpp metabolism," <i>Microbiology</i> , 144:1853-1862 (1998)
AF041436	argR	Arginine repressor	
AF045998	impA	Inositol monophosphate phosphatase	
AF048764	argH	Argininosuccinate lyase	
AF049897	argC; argI; argB; argD; argF; argR; argG; argH	N-acetylglutanylphosphate reductase; ornithine acetyltransferase; N-acetylglutamate kinase; acetylornithine transaminase; ornithine carbamoyltransferase; arginine repressor; argininosuccinate synthase; argininosuccinate lyase	
AF050109	inhA	Enoyl-acyl carrier protein reductase	
AF050166	hisG	ATP phosphoribosyltransferase	
AF051846	hisA	Phosphoribosylformimino-5-amino-1-phosphoribosyl-4-imidazolecarboxamide isomerase	
AF052652	metA	Homoserine O-acetyltransferase	Park, S. et al. "Isolation and analysis of metA, a methionine biosynthetic gene encoding homoserine acetyltransferase in <i>Corynebacterium glutamicum</i> ," <i>Mol. Cells</i> , 8(3):286-294 (1998)
AF053071	aroB	Dehydroquinate synthetase	
AF060558	hisH	Glutamine amidotransferase	
AF086704	hisE	Phosphoribosyl-ATP-pyrophosphohydrolase	
AF114233	aroA	5-enolpyruvylshikimate 3-phosphate synthase	
AF116184	panD	L-aspartate-alpha-decarboxylase precursor	Dusch, N. et al. "Expression of the <i>Corynebacterium glutamicum</i> panD gene encoding L-aspartate-alpha-decarboxylase leads to pantothenate overproduction in <i>Escherichia coli</i> ," <i>Appl. Environ. Microbiol.</i> , 65(4):1530-1539 (1999)

GenBank™ Accession No.	Gene Name	Gene Function	Reference
AF124518	aroD; aroE	3-dehydroquinase; shikimate dehydrogenase	
AF124600	aroC; aroK; aroB; pepQ	Chorismate synthase; shikimate kinase; 3-dehydroquinase synthase; putative cytoplasmic peptidase	
AF145897	inhA		
AF145898	inhA		
AJ001436	ectP	Transport of ectoine, glycine betaine, proline	Peter, H. et al. "Corynebacterium glutamicum is equipped with four secondary carriers for compatible solutes: Identification, sequencing, and characterization of the proline/ectoine uptake system, ProP, and the ectoine/proline/glycine betaine carrier, EctP," <i>J. Bacteriol.</i> , 180(22):6005-6012 (1998)
AJ004934	dapD	Tetrahydrodipicolinate succinylase (incomplete)	Wehrmann, A. et al. "Different modes of diaminopimelate synthesis and their role in cell wall integrity: A study with Corynebacterium glutamicum," <i>J. Bacteriol.</i> , 180(12):3159-3165 (1998)
AJ007732	ppc; secG; amt; ocd; soxA	Phosphoenolpyruvate-carboxylase; ?; high affinity ammonium uptake protein; putative ornithine-cyclodecarboxylase; sarcosine oxidase	
AJ010319	ftsY, glnB, glnD; srp; amtP	Involved in cell division; PII protein; uridylyltransferase (uridylyl-removing enzyme); signal recognition particle; low affinity ammonium uptake protein	Jakoby, M. et al. "Nitrogen regulation in Corynebacterium glutamicum; Isolation of genes involved in biochemical characterization of corresponding proteins," <i>FEMS Microbiol.</i> , 173(2):303-310 (1999)
AJ132968	cat	Chloramphenicol acetyl transferase	
AJ224946	mgo	L-malate: quinone oxidoreductase	Molenaar, D. et al. "Biochemical and genetic characterization of the membrane-associated malate dehydrogenase (acceptor) from Corynebacterium glutamicum," <i>Eur. J. Biochem.</i> , 254(2):395-403 (1998)
38250 238703	ndh porA	NADH dehydrogenase Porin	Lichtinger, T. et al. "Biochemical and biophysical characterization of the cell wall porin of Corynebacterium glutamicum: The channel is formed by a low molecular mass polypeptide," <i>Biochemistry</i> , 37(43):15024-15032 (1998)
D17429		Transposable element IS31831	Veres, A.A. et al. "Isolation and characterization of IS31831, a transposable element from Corynebacterium glutamicum," <i>Mol. Microbiol.</i> , 11(4):739-746 (1994)

GenBank™ Accession No.	Gene Name	Gene Function	Reference
D84102	odhA	2-oxoglutarate dehydrogenase	Usuda, Y. et al. "Molecular cloning of the Corynebacterium glutamicum (Brevibacterium lactofermentum AJ12036) odhA gene encoding a novel type of 2-oxoglutarate dehydrogenase," <i>Microbiology</i> , 142:3347-3354 (1996)
E01358	hdh; hk	Homoserine dehydrogenase; homoserine kinase	Katsumata, R. et al. "Production of L-threonine and L-isoleucine," Patent: JP 1987232392-A 1 10/12/87
E01359		Upstream of the start codon of homoserine kinase gene	Katsumata, R. et al. "Production of L-threonine and L-isoleucine," Patent: JP 1987232392-A 2 10/12/87
E01375		Tryptophan operon	
E01376	trpL; trpE	Leader peptide; anthranilate synthase	Matsui, K. et al. "Tryptophan operon, peptide and protein coded thereby, utilization of tryptophan operon gene expression and production of tryptophan," Patent: JP 1987244382-A 1 10/24/87
E01377		Promoter and operator regions of tryptophan operon	Matsui, K. et al. "Tryptophan operon, peptide and protein coded thereby, utilization of tryptophan operon gene expression and production of tryptophan," Patent: JP 1987244382-A 1 10/24/87
E03937		Biotin-synthase	Hatakeyama, K. et al. "DNA fragment containing gene capable of coding biotin synthetase and its utilization," Patent: JP 1992278088-A 1 10/02/92
E04040		Diamino pelargonic acid aminotransferase	Kohama, K. et al. "Gene coding diaminopelargonic acid aminotransferase and deshiobiotin synthetase and its utilization," Patent: JP 1992330284-A 1 11/18/92
E04041		Deshiobiotinsynthetase	Kohama, K. et al. "Gene coding diaminopelargonic acid aminotransferase and deshiobiotin synthetase and its utilization," Patent: JP 1992330284-A 1 11/18/92
E04307		Flavum aspartase	Kurusu, Y. et al. "Gene DNA coding aspartase and utilization thereof," Patent: JP 1993030977-A 1 02/09/93
E04376		Isoctiric acid lyase	Katsumata, R. et al. "Gene manifestation controlling DNA," Patent: JP 1993056782-A 3 03/09/93
377		Isoctiric acid lyase N-terminal fragment	Katsumata, R. et al. "Gene manifestation controlling DNA," Patent: JP 1993056782-A 3 03/09/93
E04484		Prephenate dehydratase	Sotouchi, N. et al. "Production of L-phenylalanine by fermentation," Patent: JP 1993076352-A 2 03/30/93
E05108		Aspartokinase	Fugono, N. et al. "Gene DNA coding Aspartokinase and its use," Patent: JP 1993184366-A 1 07/27/93
E05112		Dihydro-dipichorinate synthetase	Hatakeyama, K. et al. "Gene DNA coding dihydrodipicolinic acid synthetase and its use," Patent: JP 1993184371-A 1 07/27/93

GenBank™ Accession No.	Gene Name	Gene Function	Reference
E05776		Diaminopimelic acid dehydrogenase	Kobayashi, M. et al. "Gene DNA coding Diaminopimelic acid dehydrogenase and its use," Patent: JP 1993284970-A I 11/02/93
E05779		Threonine synthase	Kohama, K. et al. "Gene DNA coding threonine synthase and its use," Patent: JP 1993284972-A I 11/02/93
E06110		Prephenate dehydratase	Kikuchi, T. et al. "Production of L-phenylalanine by fermentation method," Patent: JP 1993344881-A I 12/27/93
E06111		Mutated Prephenate dehydratase	Kikuchi, T. et al. "Production of L-phenylalanine by fermentation method," Patent: JP 1993344881-A I 12/27/93
E06146		Acetohydroxy acid synthetase	Inui, M. et al. "Gene capable of coding Acetohydroxy acid synthetase and its use," Patent: JP 1993344893-A I 12/27/93
E06825		Aspartokinase	Sugimoto, M. et al. "Mutant aspartokinase gene," patent: JP 1994062866-A I 03/08/94
E06826		Mutated aspartokinase alpha subunit	Sugimoto, M. et al. "Mutant aspartokinase gene," patent: JP 1994062866-A I 03/08/94
E06827		Mutated aspartokinase alpha subunit	Sugimoto, M. et al. "Mutant aspartokinase gene," patent: JP 1994062866-A I 03/08/94
E07701	secY		Honno, N. et al. "Gene DNA participating in integration of membraneous protein to membrane," Patent: JP 1994169780-A I 06/21/94
E08177		Aspartokinase	Sato, Y. et al. "Genetic DNA capable of coding Aspartokinase released from feedback inhibition and its utilization," Patent: JP 1994261766-A I 09/20/94
E08178, E08179, E08180, E08181, E08182		Feedback inhibition-released Aspartokinase	Sato, Y. et al. "Genetic DNA capable of coding Aspartokinase released from feedback inhibition and its utilization," Patent: JP 1994261766-A I 09/20/94
E08232		Acetohydroxy-acid isomeroreductase	Inui, M. et al. "Gene DNA coding acetohydroxy acid isomeroreductase," Patent: JP 1994277067-A I 10/04/94
E08234	secE		Asai, Y. et al. "Gene DNA coding for translocation machinery of protein," Patent: JP 1994277073-A I 10/04/94
E08643		FT aminotransferase and deshiobiotin synthetase promoter region	Hatakeyama, K. et al. "DNA fragment having promoter function in coryneform bacterium," Patent: JP 1995031476-A I 02/03/95
E08646		Biotin synthetase	Hatakeyama, K. et al. "DNA fragment having promoter function in coryneform bacterium," Patent: JP 1995031476-A I 02/03/95

GenBank™ Accession No.	Gene Name	Gene Function	Reference
E08649		Aspartase	Kohama, K. et al "DNA fragment having promoter function in coryneform bacterium," Patent: JP 1995031478-A 1 02/03/95
E08900		Dihydropicolinate reductase	Madori, M. et al. "DNA fragment containing gene coding Dihydropicolinate acid reductase and utilization thereof," Patent: JP 1995075578-A 1 03/20/95
E08901		Diaminopimelic acid decarboxylase	Madori, M. et al. "DNA fragment containing gene coding Diaminopimelic acid decarboxylase and utilization thereof," Patent: JP 1995075579-A 1 03/20/95
E12594		Serine hydroxymethyltransferase	Hatakeyama, K. et al. "Production of L-tryptophan," Patent: JP 1997028391-A 1 02/04/97
E12760, E12759, E12758		transposase	Moriya, M. et al. "Amplification of gene using artificial transposon," Patent: JP 1997070291-A 03/18/97
E12764		Arginyl-tRNA synthetase; diaminopimelic acid decarboxylase	Moriya, M. et al. "Amplification of gene using artificial transposon," Patent: JP 1997070291-A 03/18/97
E12767		Dihydropicolinic acid synthetase	Moriya, M. et al. "Amplification of gene using artificial transposon," Patent: JP 1997070291-A 03/18/97
E12770		aspartokinase	Moriya, M. et al. "Amplification of gene using artificial transposon," Patent: JP 1997070291-A 03/18/97
E12773		Dihydropicolinic acid reductase	Moriya, M. et al. "Amplification of gene using artificial transposon," Patent: JP 1997070291-A 03/18/97
E13655		Glucose-6-phosphate dehydrogenase	Hatakeyama, K. et al. "Glucose-6-phosphate dehydrogenase and DNA capable of coding the same," Patent: JP 1997224661-A 1 09/02/97
L01508	ilvA	Threonine dehydratase	Moeckel, B. et al. "Functional and structural analysis of the threonine dehydratase of Corynebacterium glutamicum," <i>J. Bacteriol.</i> , 174:8065-8072 (1992)
L07603	EC 4.2.1.15	3-deoxy-D-arabinoheptulosonate-7-phosphate synthase	Chen, C. et al. "The cloning and nucleotide sequence of Corynebacterium glutamicum 3-deoxy-D-arabinoheptulosonate-7-phosphate synthase gene," <i>FEMS Microbiol. Lett.</i> , 107:223-230 (1993)
L09232	ilvB, ilvN, ilvC	Acetohydroxy acid synthase large subunit; Acetohydroxy acid synthase small subunit; Acetohydroxy acid isomerase	Keilhauer, C. et al. "Isoleucine synthesis in Corynebacterium glutamicum: molecular analysis of the ilvB-ilvN-ilvC operon," <i>J. Bacteriol.</i> , 175(17):5595-5603 (1993)

GenBank™ Accession No.	Gene Name	Gene Function	Reference
L18874	PsmM	Phosphoenolpyruvate sugar phosphotransferase	Fouet, A et al. "Bacillus subtilis sucrose-specific enzyme II of the phosphotransferase system: expression in Escherichia coli and homology to enzymes II from enteric bacteria," <i>PNAS USA</i> , 84(24):8773-8777 (1987); Lee, J.K. et al. "Nucleotide sequence of the gene encoding the Corynebacterium glutamicum mannose enzyme II and analyses of the deduced protein sequence," <i>FEMS Microbiol. Lett.</i> , 119(1-2):137-145 (1994)
L27123	aceB	Malate synthase	Lee, H-S. et al. "Molecular characterization of aceB, a gene encoding malate synthase in Corynebacterium glutamicum," <i>J. Microbiol. Biotechnol.</i> , 4(4):256-263 (1994)
U126		Pyruvate kinase	Jetten, M. S. et al. "Structural and functional analysis of pyruvate kinase from Corynebacterium glutamicum," <i>Appl. Environ. Microbiol.</i> , 60(7):2501-2507 (1994)
L28760	aceA	Isocitrate lyase	
L35906	dxr	Diphtheria toxin repressor	Oguiza, J.A. et al. "Molecular cloning, DNA sequence analysis, and characterization of the Corynebacterium diphtheriae dxr from Brevibacterium lactofermentum," <i>J. Bacteriol.</i> , 177(2):465-467 (1995)
M13774		Prephenate dehydratase	Follette, M.T. et al. "Molecular cloning and nucleotide sequence of the Corynebacterium glutamicum pheA gene," <i>J. Bacteriol.</i> , 167:695-702 (1986)
M16175	5S rRNA		Park, Y-H. et al. "Phylogenetic analysis of the coryneform bacteria by 5S rRNA sequences," <i>J. Bacteriol.</i> , 169:1801-1806 (1987)
M16663	trpE	Anthranilate synthase, 5' end	Sano, K. et al. "Structure and function of the trp operon control regions of Brevibacterium lactofermentum, a glutamic-acid-producing bacterium," <i>Gene</i> , 52:191-200 (1987)
M16664	trpA	Tryptophan synthase, 3' end	Sano, K. et al. "Structure and function of the trp operon control regions of Brevibacterium lactofermentum, a glutamic-acid-producing bacterium," <i>Gene</i> , 52:191-200 (1987)
U5819		Phosphoenolpyruvate carboxylase	O'Regan, M. et al. "Cloning and nucleotide sequence of the Phosphoenolpyruvate carboxylase-coding gene of Corynebacterium glutamicum ATCC13032," <i>Gene</i> , 77(2):237-251 (1989)
M85106		23S rRNA gene insertion sequence	Roller, C. et al. "Gram-positive bacteria with a high DNA G+C content are characterized by a common insertion within their 23S rRNA genes," <i>J. Gen. Microbiol.</i> , 138:1167-1175 (1992)

GenBank™ Accession No.	Gene Name	Gene Function	Reference
M85107, M85108		23S rRNA gene insertion sequence	Roller, C. et al. "Gram-positive bacteria with a high DNA G+C content are characterized by a common insertion within their 23S rRNA genes," <i>J. Gen. Microbiol.</i> , 138:1167-1175 (1992)
M89931	aecD; brnQ; yhbW	Beta C-S lyase; branched-chain amino acid uptake carrier; hypothetical protein yhbW	Rosol, I. et al. "The Corynebacterium glutamicum aecD gene encodes a C-S lyase with alpha, beta-elimination activity that degrades aminoethylcysteine," <i>J. Bacteriol.</i> , 174(9):2968-2977 (1992); Tauch, A. et al. "Isoleucine uptake in Corynebacterium glutamicum ATCC 13032 is directed by the brnQ gene product," <i>Arch. Microbiol.</i> , 169(4):303-312 (1998)
S59299	trp	Leader gene (promoter)	Herry, D.M. et al. "Cloning of the trp gene cluster from a tryptophan-hyperproducing strain of Corynebacterium glutamicum: identification of a mutation in the trp leader sequence," <i>Appl. Environ. Microbiol.</i> , 59(3):791-799 (1993)
U11545	trpD	Anthraniolate phosphoribosyltransferase	O'Gara, J.P. and Dunican, L.K. (1994) Complete nucleotide sequence of the Corynebacterium glutamicum ATCC 21850 trpD gene." Thesis, Microbiology Department, University College Galway, Ireland.
U13922	cgIIIM; cgIIIR; cIglIIR	Putative type II 5-cytosine methyltransferase; putative type II restriction endonuclease; putative type I or type III restriction endonuclease	Schafer, A. et al. "Cloning and characterization of a DNA region encoding a stress-sensitive restriction system from Corynebacterium glutamicum ATCC 13032 and analysis of its role in intergeneric conjugation with Escherichia coli," <i>J. Bacteriol.</i> , 176(23):7309-7319 (1994); Schafer, A. et al. "The Corynebacterium glutamicum cgIIIM gene encoding a 5-cytosine in an McrBC-deficient Escherichia coli strain," <i>Gene</i> , 203(2):95-101 (1997)
U14965	recA		
U31224	ppx		Ankri, S. et al. "Mutations in the Corynebacterium glutamicum proline biosynthetic pathway: A natural bypass of the proA step," <i>J. Bacteriol.</i> , 178(15):4412-4419 (1996)
U31225	proC	L-proline: NADP+ 5-oxido-reductase	Ankri, S. et al. "Mutations in the Corynebacterium glutamicum proline biosynthetic pathway: A natural bypass of the proA step," <i>J. Bacteriol.</i> , 178(15):4412-4419 (1996)
U31230	obg; proB; unkdh	?; gamma glutamyl kinase; similar to D-isomer specific 2-hydroxyacid dehydrogenases	Ankri, S. et al. "Mutations in the Corynebacterium glutamicum proline biosynthetic pathway: A natural bypass of the proA step," <i>J. Bacteriol.</i> , 178(15):4412-4419 (1996)

GenBank™ Accession No.	Gene Name	Gene Function	Reference
U31281	bioB	Biotin synthase	Serebriiskii, I.G., "Two new members of the bio B superfamily: Cloning, sequencing and expression of bio B genes of <i>Methylobacillus flagellatum</i> and <i>Corynebacterium glutamicum</i> ," <i>Gene</i> , 175:15-22 (1996)
U35023	thrR; accBC	Thiosulfate sulfurtransferase; acyl CoA carboxylase	Jager, W. et al. "A <i>Corynebacterium glutamicum</i> gene encoding a two-domain protein similar to biotin carboxylases and biotin-carboxyl-carrier proteins," <i>Arch. Microbiol.</i> , 166(2):76-82 (1996)
U43535	cmr	Multidrug resistance protein	Jager, W. et al. "A <i>Corynebacterium glutamicum</i> gene conferring multidrug resistance in the heterologous host <i>Escherichia coli</i> ," <i>J. Bacteriol.</i> , 179(7):2449-2451 (1997)
3336	clpB	Heat shock ATP-binding protein	
587	aphA-3	3'-5'-aminoglycoside phosphotransferase	
U89648		<i>Corynebacterium glutamicum</i> unidentified sequence involved in histidine biosynthesis, partial sequence	
X04960	trpA; trpB; trpC; trpD; trpE; trpG; trpL	Tryptophan operon	Matsui, K. et al. "Complete nucleotide and deduced amino acid sequences of the <i>Brevibacterium lactofermentum</i> tryptophan operon," <i>Nucleic Acids Res.</i> , 14(24):10113-10114 (1986)
X07563	lys A	DAP decarboxylase (meso-diaminopimelate decarboxylase, EC 4.1.1.20)	Yeh, P. et al. "Nucleic sequence of the <i>lysA</i> gene of <i>Corynebacterium glutamicum</i> and possible mechanisms for modulation of its expression," <i>Mol. Gen. Genet.</i> , 212(1):112-119 (1988)
X14234	EC 4.1.1.31	Phosphoenolpyruvate carboxylase	Eikmanns, B.J. et al. "The Phosphoenolpyruvate carboxylase gene of <i>Corynebacterium glutamicum</i> : Molecular cloning, nucleotide sequence, and expression," <i>Mol. Gen. Genet.</i> , 218(2):330-339 (1989); Lepiniec, L. et al. "Sorghum Phosphoenolpyruvate carboxylase gene family: structure, function and molecular evolution," <i>Plant. Mol. Biol.</i> , 21 (3):487-502 (1993)
X17313	fda	Fructose-bisphosphate aldolase	Von der Osten, C.H. et al. "Molecular cloning, nucleotide sequence and fine-structural analysis of the <i>Corynebacterium glutamicum</i> fda gene: structural comparison of <i>C. glutamicum</i> fructose-1, 6-bisphosphate aldolase to class I and class II aldolases," <i>Mol. Microbiol.</i> ,
X53993	dapA	L-2, 3-dihydrodipicolinate synthetase (EC 4.2.1.52)	Bonnassie, S. et al. "Nucleic sequence of the <i>dapA</i> gene from <i>Corynebacterium glutamicum</i> ," <i>Nucleic Acids Res.</i> , 18(21):6421 (1990)

GenBank™ Accession No.	Gene Name	Gene Function	Reference
X54223		AttB-related site	Cianciotto, N. et al. "DNA sequence homology between att B-related sites of <i>Corynebacterium diphtheriae</i> , <i>Corynebacterium ulcerans</i> , <i>Corynebacterium glutamicum</i> , and the attP site of <i>lambdacorynephage</i> ," <i>FEMS. Microbiol. Lett.</i> , 66:299-302 (1990)
X54740	argS; lysA	Arginyl-tRNA synthetase; Diaminopimelate decarboxylase	Marcel, T. et al. "Nucleotide sequence and organization of the upstream region of the <i>Corynebacterium glutamicum</i> lysA gene," <i>Mol. Microbiol.</i> , 4(11):1819-1830 (1990)
X55994	trpL; trpE	Putative leader peptide; anthranilate synthase component 1	Heery, D.M. et al. "Nucleotide sequence of the <i>Corynebacterium glutamicum</i> trpE gene," <i>Nucleic Acids Res.</i> , 18(23):7138 (1990)
X6037	thrC	Threonine synthase	Han, K.S. et al. "The molecular structure of the <i>Corynebacterium glutamicum</i> threonine synthase gene," <i>Mol. Microbiol.</i> , 4(10):1693-1702 (1990)
X56075	attB-related site	Attachment site	Cianciotto, N. et al. "DNA sequence homology between att B-related sites of <i>Corynebacterium diphtheriae</i> , <i>Corynebacterium ulcerans</i> , <i>Corynebacterium glutamicum</i> , and the attP site of <i>lambdacorynephage</i> ," <i>FEMS. Microbiol. Lett.</i> , 66:299-302 (1990)
X57226	lysC-alpha; lysC-beta; asd	Aspartokinase-alpha subunit; Aspartokinase-beta subunit; aspartate beta semialdehyde dehydrogenase	Kalinowski, J. et al. "Genetic and biochemical analysis of the Aspartokinase from <i>Corynebacterium glutamicum</i> ," <i>Mol. Microbiol.</i> , 5(5):1197-1204 (1991); Kalinowski, J. et al. "Aspartokinase genes lysC alpha and lysC beta overlap and are adjacent to the aspartate beta-semialdehyde dehydrogenase gene asd in <i>Corynebacterium glutamicum</i> ," <i>Mol. Gen. Genet.</i> , 224(3):317-324 (1990)
X59403	gap;pgk; tpi	Glyceraldehyde-3-phosphate; phosphoglycerate kinase; triosephosphate isomerase	Eikmanns, B.J. "Identification, sequence analysis, and expression of a <i>Corynebacterium glutamicum</i> gene cluster encoding the three glycolytic enzymes glyceraldehyde-3-phosphate dehydrogenase, 3-phosphoglycerate kinase, and triosephosphate isomerase," <i>J. Bacteriol.</i> , 174(19):6076-6086 (1992)
X59404	gdh	Glutamate dehydrogenase	Bormann, E.R. et al. "Molecular analysis of the <i>Corynebacterium glutamicum</i> gdh gene encoding glutamate dehydrogenase," <i>Mol. Microbiol.</i> , 6(3):317-326 (1992)
X60312	lysI	L-lysine permease	Seep-Feldhaus, A.H. et al. "Molecular analysis of the <i>Corynebacterium glutamicum</i> lysI gene involved in lysine uptake," <i>Mol. Microbiol.</i> , 5(12):2995-3005 (1991)

GenBank™ Accession No.	Gene Name	Gene Function	Reference
X66078	copI	PsI protein	Joliff, G. et al. "Cloning and nucleotide sequence of the cspI gene encoding PS1, one of the two major secreted proteins of <i>Corynebacterium glutamicum</i> : The deduced N-terminal region of PS1 is similar to the <i>Mycobacterium</i> antigen 85 complex," <i>Mol. Microbiol.</i> , 6(16):2349-2362 (1992)
X66112	glt	Citrate synthase	Eikmanns, B. J. et al. "Cloning sequence, expression and transcriptional analysis of the <i>Corynebacterium glutamicum</i> gltA gene encoding citrate synthase," <i>Microbiol.</i> , 140:1817-1828 (1994)
X67737	dapB	Dihydrodipicolinate reductase	
X69103	csp2	Surface layer protein PS2	Peyret, J.L. et al. "Characterization of the cspB gene encoding PS2, an ordered surface-layer protein in <i>Corynebacterium glutamicum</i> ," <i>Mol. Microbiol.</i> , 9(1):97-109 (1993)
X69104		IS3 related insertion element	Bonamy, C. et al. "Identification of IS1206, a <i>Corynebacterium glutamicum</i> IS3-related insertion sequence and phylogenetic analysis," <i>Mol. Microbiol.</i> , 14(3):571-581 (1994)
X70959	leuA	Isopropylmalate synthase	Patek, M. et al. "Leucine synthesis in <i>Corynebacterium glutamicum</i> : enzyme activities, structure of leuA, and effect of leuA inactivation on lysine synthesis," <i>Appl. Environ. Microbiol.</i> , 60(1):133-140 (1994)
X71489	icd	Isocitrate dehydrogenase (NADP+)	Eikmanns, B. J. et al. "Cloning sequence analysis, expression, and inactivation of the <i>Corynebacterium glutamicum</i> icd gene encoding isocitrate dehydrogenase and biochemical characterization of the enzyme," <i>J. Bacteriol.</i> , 177(3):774-782 (1995)
X72855	GDHA	Glutamate dehydrogenase (NADP+)	
X75083, X70584	mtxA	5-methyltryptophan resistance	Heery, D.M. et al. "A sequence from a tryptophan-hyperproducing strain of <i>Corynebacterium glutamicum</i> encoding resistance to 5-methyltryptophan," <i>Biochem. Biophys. Res. Commun.</i> , 201(3):1255-1262 (1994)
X75085	recA		Fitzpatrick, R. et al. "Construction and characterization of recA mutant strains of <i>Corynebacterium glutamicum</i> and <i>Brevibacterium lactofermentum</i> ," <i>Appl. Microbiol. Biotechnol.</i> , 42(4):575-580 (1994)
X75504	aceA; thiX	Partial Isocitrate lyase; ?	Reinscheid, D.J. et al. "Characterization of the isocitrate lyase gene from <i>Corynebacterium glutamicum</i> and biochemical analysis of the enzyme," <i>J. Bacteriol.</i> , 176(12):3474-3483 (1994)
X76875		ATPase beta-subunit	Ludwig, W. et al. "Phylogenetic relationships of bacteria based on comparative sequence analysis of elongation factor Tu and ATP-synthase beta-subunit genes," <i>Antonie Van Leeuwenhoek</i> , 64:285-305 (1993)

GenBank™ Accession No.	Gene Name	Gene Function	Reference
X77034	tuf	Elongation factor Tu	Ludwig, W. et al. "Phylogenetic relationships of bacteria based on comparative sequence analysis of elongation factor Tu and ATP-synthase beta-subunit genes," <i>Antonie Van Leeuwenhoek</i> , 64:285-305 (1993)
X77384	recA		Billman-Jacobe, H. "Nucleotide sequence of a recA gene from <i>Corynebacterium glutamicum</i> ," <i>DNA Seq.</i> , 4(6):403-404 (1994)
X78491	aceB	Malate synthase	Reinscheid, D.J. et al. "Malate synthase from <i>Corynebacterium glutamicum</i> pta-ack operon encoding phosphotransacetylase: sequence analysis," <i>Microbiology</i> , 140:3099-3108 (1994)
X80629	16S rDNA	16S ribosomal RNA	Rainey, F.A. et al. "Phylogenetic analysis of the genera <i>Rhodococcus</i> and <i>Norcardia</i> and evidence for the evolutionary origin of the genus <i>Norcardia</i> from within the radiation of <i>Rhodococcus</i> species," <i>Microbiol.</i> , 141:523-528 (1995)
X81191	gluA; gluD; gluC; gluD	Gluamate uptake system	Kronmeyer, W. et al. "Structure of the gluABCD cluster encoding the glutamate uptake system of <i>Corynebacterium glutamicum</i> ," <i>J. Bacteriol.</i> , 177(5):1152-1158 (1995)
X81379	dapE	Succinyl/diaminopimelate desuccinylase	Wehrmann, A. et al. "Analysis of different DNA fragments of <i>Corynebacterium glutamicum</i> complementing dapE of <i>Escherichia coli</i> ," <i>Microbiology</i> , 40:3349-56 (1994)
X82061	16S rDNA	16S ribosomal RNA	Ruimy, R. et al. "Phylogeny of the genus <i>Corynebacterium</i> deduced from analyses of small-subunit ribosomal DNA sequences," <i>Int. J. Syst. Bacteriol.</i> , 45(4):740-746 (1995)
X82928	asd; lysC	Aspartate-semialdehyde dehydrogenase; ?	Serebrijski, I. et al. "Multicopy suppression by asd gene and osmotic stress-dependent complementation by heterologous proA in proA mutants," <i>J. Bacteriol.</i> , 177(24):7255-7260 (1995)
X82929	proA	Gamma-glutamyl phosphate reductase	Serebrijski, I. et al. "Multicopy suppression by asd gene and osmotic stress-dependent complementation by heterologous proA in proA mutants," <i>J. Bacteriol.</i> , 177(24):7255-7260 (1995)
X8257	16S rDNA	16S ribosomal RNA	Pascual, C. et al. "Phylogenetic analysis of the genus <i>Corynebacterium</i> based on 16S rRNA gene sequences," <i>Int. J. Syst. Bacteriol.</i> , 45(4):724-728 (1995)
X85965	aroP; dapE	Aromatic amino acid permease; ?	Wehrmann, A. et al. "Functional analysis of sequences adjacent to dapE of <i>Corynebacterium glutamicum</i> reveals the presence of aroP, which encodes the aromatic amino acid transporter," <i>J. Bacteriol.</i> , 177(20):5991-5993 (1995)

GenBank™ Accession No.	Gene Name	Gene Function	Reference
X86157	argB; argC; argD; argF; argJ	Acetylglutamate kinase; N-acetyl-gamma-glutamyl-phosphate reductase; acetylornithine aminotransferase; ornithine carbamoyltransferase; glutamate N-acetyltransferase	Sakanyan, V. et al. "Genes and enzymes of the acetyl cycle of arginine biosynthesis in <i>Corynebacterium glutamicum</i> : enzyme evolution in the early steps of the arginine pathway," <i>Microbiology</i> , 142:99-108 (1996)
X89084	pta; ackA	Phosphate acetyltransferase; acetate kinase	Reinscheid, D.J. et al. "Cloning, sequence analysis, expression and inactivation of the <i>Corynebacterium glutamicum</i> pta-ack operon encoding phosphotransacetylase and acetate kinase," <i>Microbiology</i> , 145:503-513 (1999)
X8850	attB	Attachment site	Le Marrec, C. et al. "Genetic characterization of site-specific integration functions of phi AAU2 infecting "Arthrobacter aureus C70," <i>J. Bacteriol.</i> , 178(7):1996-2004 (1996)
X90356		Promoter fragment F1	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90357		Promoter fragment F2	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90358		Promoter fragment F10	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90359		Promoter fragment F13	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90360		Promoter fragment F22	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90361		Promoter fragment F34	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90362		Promoter fragment F37	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)

GenBank™ Accession No.	Gene Name	Gene Function	Reference
X90363		Promoter fragment F45	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90364		Promoter fragment F64	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90365		Promoter fragment F75	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90366		Promoter fragment PF101	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90367		Promoter fragment PF104	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X90368		Promoter fragment PF109	Patek, M. et al. "Promoters from <i>Corynebacterium glutamicum</i> : cloning, molecular analysis and search for a consensus motif," <i>Microbiology</i> , 142:1297-1309 (1996)
X93513	amt	Ammonium transport system	Siewe, R.M. et al. "Functional and genetic characterization of the (methyl) ammonium uptake carrier of <i>Corynebacterium glutamicum</i> ," <i>J. Biol. Chem.</i> , 271(10):5398-5403 (1996)
X93514	betP	Glycine betaine transport system	Peter, H. et al. "Isolation, characterization, and expression of the <i>Corynebacterium glutamicum</i> betP gene, encoding the transport system for the compatible solute glycine betaine," <i>J. Bacteriol.</i> , 178(17):5229-5234 (1996)
X95649	orf4		Patek, M. et al. "Identification and transcriptional analysis of the dapB-ORF2-dapA-ORF4 operon of <i>Corynebacterium glutamicum</i> , encoding two enzymes involved in L-lysine synthesis," <i>Biotechnol. Lett.</i> , 19:1113-1117 (1997)
X95671	lysE; lysG	Lysine exporter protein; Lysine export regulator protein	Vrijje, M. et al. "A new type of transporter with a new type of cellular function: L-lysine export from <i>Corynebacterium glutamicum</i> ," <i>Mol. Microbiol.</i> , 22(5):815-826 (1996)

GenBank™ Accession No.	Gene Name	Gene Function	Reference
X96580	panB; panC; xylB	3-methyl-2-oxobutanoate hydroxymethyltransferase; pantoate-beta-alanine ligase; xylulokinase	Sahm, H. et al. "D-pantothenate synthesis in Corynebacterium glutamicum and use of panBC and genes encoding L-valine synthesis for D-pantothenate overproduction," <i>Appl. Environ. Microbiol.</i> , 65(5):1973-1979 (1999)
X96962		Insertion sequence IS1207 and transposase	
X99289		Elongation factor P	Ramos, A. et al. "Cloning, sequencing and expression of the gene encoding elongation factor P in the amino-acid producer Brevibacterium lactofermentum (Corynebacterium glutamicum ATCC 13869)," <i>Gene</i> , 198:217-222 (1997)
Y00140	thrB	Homoserine kinase	Mateos, L.M. et al. "Nucleotide sequence of the homoserine kinase (thrB) gene of the Brevibacterium lactofermentum," <i>Nucleic Acids Res.</i> , 15(9):3922 (1987)
Y0151	dhh	Meso-diaminopimelate D-dehydrogenase (EC 1.4.1.16)	Ishino, S. et al. "Nucleotide sequence of the meso-diaminopimelate D-dehydrogenase gene from Corynebacterium glutamicum," <i>Nucleic Acids Res.</i> , 15(9):3917 (1987)
Y00476	thrA	Homoserine dehydrogenase	Mateos, L.M. et al. "Nucleotide sequence of the homoserine dehydrogenase (thrA) gene of the Brevibacterium lactofermentum," <i>Nucleic Acids Res.</i> , 15(24):10598 (1987)
Y00546	hom; thrB	Homoserine dehydrogenase; homoserine kinase	Peoples, O.P. et al. "Nucleotide sequence and fine structural analysis of the Corynebacterium glutamicum hom-thrB operon," <i>Mol. Microbiol.</i> , 2(1):63-72 (1988)
Y08964	murC; ftsQ/divD; ftsZ	UPD-N-acetylmuramate-alanine ligase; division initiation protein or cell division protein; cell division protein	Honrubia, M.P. et al. "Identification, characterization, and chromosomal organization of the ftsZ gene from Brevibacterium lactofermentum," <i>Mol. Gen. Gene.</i> , 259(1):97-104 (1998)
Y09163	putP	High affinity proline transport system	Peter, H. et al. "Isolation of the putP gene of Corynebacterium glutamicumproline and characterization of a low-affinity uptake system for compatible solutes," <i>Arch. Microbiol.</i> , 168(2):143-151 (1997)
Y09548	pyc	Pyruvate carboxylase	Peters-Wendisch, P.G. et al. "Pyruvate carboxylase from Corynebacterium glutamicum: characterization, expression and inactivation of the pyc gene," <i>Microbiology</i> , 144:915-927 (1998)
Y0578	leuB	3-isopropylmalate dehydrogenase	Patek, M. et al. "Analysis of the leuB gene from Corynebacterium glutamicum," <i>Appl. Microbiol. Biotechnol.</i> , 50(1):42-47 (1998)
Y12472		Attachment site bacteriophage Phi-16	Moreau, S. et al. "Site-specific integration of corynephage Phi-16: The construction of an integration vector," <i>Microbiol.</i> , 145:539-548 (1999)

GenBank™ Accession No.	Gene Name	Gene Function	Reference
Y12537	proP	Proline/ectoine uptake system protein	Peter, H. et al. "Corynebacterium glutamicum is equipped with four secondary carriers for compatible solutes: Identification, sequencing, and characterization of the proline/ectoine uptake system, ProP, and the ectoine/proline/glycine betaine carrier, EctP," <i>J. Bacteriol.</i> , 180(22):6005-6012 (1998)
Y13221	glnA	Glutamine synthetase I	Jakoby, M. et al. "Isolation of Corynebacterium glutamicum glnA gene encoding glutamine synthetase I," <i>FEMS Microbiol. Lett.</i> , 154(1):81-88 (1997)
Y16642	lpd	Dihydrolipoamide dehydrogenase	
Y18059		Attachment site Corynephage 304L	Moreau, S. et al. "Analysis of the integration functions of φhi304L: An integrase module among corynephages," <i>Virology</i> , 255(1):150-159 (1999)
501	args, lysA	Arginyl-tRNA synthetase; diaminopimelate decarboxylase (partial)	Oguiza, J.A. et al. "A gene encoding arginyl-tRNA synthetase is located in the upstream region of the lysA gene in Brevibacterium lactofermentum: Regulation of args-lysA cluster expression by arginine," <i>J. Bacteriol.</i> , 175(22):7356-7362 (1993)
Z21502	dapA, dapB	Dihydrodipicolinate synthase; dihydrodipicolinate reductase	Pisabarro, A. et al. "A cluster of three genes (dapA, orf2, and dapB) of Brevibacterium lactofermentum encodes dihydrodipicolinate reductase, and a third polypeptide of unknown function," <i>J. Bacteriol.</i> , 175(9):2743-2749 (1993)
Z29563	thrC	Threonine synthase	Malumbres, M. et al. "Analysis and expression of the thrC gene of the encoded threonine synthase," <i>Appl. Environ. Microbiol.</i> , 60(7):2209-2219 (1994)
Z46753	16S rDNA	Gene for 16S ribosomal RNA	
Z49822	sigA	SigA sigma factor	Oguiza, J.A. et al. "Multiple sigma factor genes in Brevibacterium lactofermentum: Characterization of sigA and sigB," <i>J. Bacteriol.</i> , 178(2):550-553 (1996)
Z49823	galE, dtxR	Catalytic activity UDP-galactose 4-epimerase; diphtheria toxin regulatory protein	Oguiza, J.A. et al. "The galE gene encoding the UDP-galactose 4-epimerase of Brevibacterium lactofermentum is coupled transcriptionally to the dmdR gene," <i>Gene</i> , 177:103-107 (1996)
824	orf1, sigB	?, SigB sigma factor	Oguiza, J.A. et al. "Multiple sigma factor genes in Brevibacterium lactofermentum: Characterization of sigA and sigB," <i>J. Bacteriol.</i> , 178(2):550-553 (1996)
Z66534		Transposase	Correia, A. et al. "Cloning and characterization of an IS-like element present in the genome of Brevibacterium lactofermentum ATCC 13869," <i>Gene</i> , 170(1):91-94 (1996)

A sequence for this gene was published in the indicated reference. However, the sequence obtained by the inventors of the present application is significantly longer than the published version. It is believed that the published version relied on an incorrect start codon, and thus represents only a fragment of the actual coding region.

TABLE 3: Corynebacterium and Brevibacterium Strains Which May be Used in the Practice of the Invention

Genus	Species	ATCC	FERM	NRRL	CECT	NCIMB	CBS	NGIC	DSMZ
Brevibacterium	ammoniaenes	21054							
Brevibacterium	ammoniaenes	19350							
Brevibacterium	ammoniaenes	19351							
Brevibacterium	ammoniaenes	19352							
Brevibacterium	ammoniaenes	19353							
Brevibacterium	ammoniaenes	19354							
Brevibacterium	ammoniaenes	19355							
Brevibacterium	ammoniaenes	19356							
Brevibacterium	ammoniaenes	21055							
Brevibacterium	ammoniaenes	21077							
Brevibacterium	ammoniaenes	21553							
Brevibacterium	ammoniaenes	21580							
Brevibacterium	ammoniaenes	39101							
Brevibacterium	butanicum	21196							
Brevibacterium	divaricatum	21792	P928						
Brevibacterium	flavum	21474							
Brevibacterium	flavum	21129							
Brevibacterium	flavum	21518							
Brevibacterium	flavum			B11474					
Brevibacterium	flavum			B11472					
Brevibacterium	flavum	21127							
Brevibacterium	flavum	21128							
Brevibacterium	flavum	21427							
Brevibacterium	flavum	21475							
Brevibacterium	flavum	21517							
Brevibacterium	flavum	21528							
Brevibacterium	flavum	21529							

Brevibacterium	flavum			B11477					
Brevibacterium	flavum			B11478					
Brevibacterium	flavum	21127							
Brevibacterium	flavum			B11474					
Brevibacterium	healii	15527							
Brevibacterium	ketoglutamicum	21004							
Brevibacterium	ketoglutamicum	21089							
Brevibacterium	ketosoreductum	21914							
Brevibacterium	lactofermentum				70				
Brevibacterium	lactofermentum				74				
Brevibacterium	lactofermentum				77				
Brevibacterium	lactofermentum	21798							
Brevibacterium	lactofermentum	21799							
Brevibacterium	lactofermentum	21800							
Brevibacterium	lactofermentum	21801							
Brevibacterium	lactofermentum			B11470					
Brevibacterium	lactofermentum			B11471					
Brevibacterium	lactofermentum	21086							
Brevibacterium	lactofermentum	21420							
Brevibacterium	lactofermentum	21086							
Brevibacterium	lactofermentum	31269							
Brevibacterium	linens	9174							
Brevibacterium	linens	19391							
Brevibacterium	linens	8377							
Brevibacterium	paraffinolyticum					11160			
Brevibacterium	spec.						717.73		
Brevibacterium	spec.						717.73		
Brevibacterium	spec.	14604							
Brevibacterium	spec.	21860							
Brevibacterium	spec.	21864							
Brevibacterium	spec.	21865							

Corynebacterium	glutamicum	19051																	
Corynebacterium	glutamicum	19052																	
Corynebacterium	glutamicum	19053																	
Corynebacterium	glutamicum	19054																	
Corynebacterium	glutamicum	19055																	
Corynebacterium	glutamicum	19056																	
Corynebacterium	glutamicum	19057																	
Corynebacterium	glutamicum	19058																	
Corynebacterium	glutamicum	19059																	
Corynebacterium	glutamicum	19060																	
Corynebacterium	glutamicum	19185																	
Corynebacterium	glutamicum	13286																	
Corynebacterium	glutamicum	21515																	
Corynebacterium	glutamicum	21527																	
Corynebacterium	glutamicum	21544																	
Corynebacterium	glutamicum	21492																	
Corynebacterium	glutamicum				B8183														
Corynebacterium	glutamicum				B8182														
Corynebacterium	glutamicum				B12416														
Corynebacterium	glutamicum				B12417														
Corynebacterium	glutamicum				B12418														
Corynebacterium	glutamicum				B11476														
Corynebacterium	glutamicum	21608																	
Corynebacterium	lilium			P973															
Corynebacterium	nitriophilus	21419											11594						
Corynebacterium	spec.			P4445															
Corynebacterium	spec.			P4446															
Corynebacterium	spec.	31088																	
Corynebacterium	spec.	31089																	
Corynebacterium	spec.	31090																	
Corynebacterium	spec.	31090																	

Corynebacterium	spec.	31090								
Corynebacterium	spec.	15954							20145	
Corynebacterium	spec.	21857								
Corynebacterium	spec.	21862								
Corynebacterium	spec.	21863								

ATCC: American Type Culture Collection, Rockville, MD, USA

FERM: Fermentation Research Institute, Chiba, Japan

NRRL: ARS Culture Collection, Northern Regional Research Laboratory, Peoria, IL, USA

CECT: Coleccion Espanola de Cultivos Tipo, Valencia, Spain

NCIMB: National Collection of Industrial and Marine Bacteria Ltd., Aberdeen, UK

CBS: Centraalbureau voor Schimmelcultures, Baarn, NL

NCTC: National Collection of Type Cultures, London, UK

DSMZ: Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany

For reference see Sugawara, H. et al. (1993) World directory of collections of microorganisms: Bacteria, fungi and yeasts (4th edn), World federation for culture collections world data center on microorganisms, Saimata, Japen.

Table 4, Page 1

TABLE 4: ALIGNMENT RESULTS

ra00341 1530	GB_HTG3:AC008391	40119	AC008391	Homo sapiens chromosome 5 clone CIT-HSPC_236F12, *** SEQUENCING IN PROGRESS *** , 64 unordered pieces.	Homo sapiens	34,836	3-Aug-99
	GB_EST17:AA645151	427	AA645151	vs72f2.1 Stratagene mouse skin (#937313) Mus musculus cDNA clone IMAGE:1151855 5' similar to gb:X67688 TRANSCRIPTOLASE (HUMAN); gb:U05809 Mus musculus LAF1 transketolase mRNA, complete cds (MOUSE);, mRNA sequence.	Mus musculus	40,376	28-OCT-1997
ra00313 1062	GB_HTG1:HSMX1_4	110000	AL011929	Homo sapiens chromosome 21 clone Cosmids 44C5.Q16H18, 14C10.25D2.87D5 map 21q22.2.D21S349-MX1, *** SEQUENCING IN PROGRESS *** , in ordered pieces.	Homo sapiens	38,462	15-Sep-99
	GB_HTG1:HSMX1_4	110000	AL011929	Homo sapiens chromosome 21 clone Cosmids 44C5.Q16H18, 14C10.25D2.87D5 map 21q22.2.D21S349-MX1, *** SEQUENCING IN PROGRESS *** , in ordered pieces.	Homo sapiens	38,462	15-Sep-99
ra00341 1530	GB_BA1:MTCY369	36850	Z80226	Mycobacterium tuberculosis H37Rv complete genome; segment 36/162.	Mycobacterium tuberculosis	40,401	17-Jun-98
	GB_PL2:ATAC005560	95137	AC005560	Arabidopsis thaliana chromosome II BAC F219 genomic sequence, complete sequence.	Arabidopsis thaliana	36,045	23-OCT-1998
ra00407 2767	GB_PL1:AB010077	77380	AB010077	Arabidopsis thaliana genomic DNA, chromosome 5, P1 clone: MYH19, complete sequence.	Arabidopsis thaliana	36,061	20-Nov-99
	GB_PL2:ATAC006593	79663	AC006593	Arabidopsis thaliana chromosome II BAC F16D14 genomic sequence, complete sequence.	Arabidopsis thaliana	36,936	17-MAR-1999
ra00414 477	GB_BA1:MTV004	69350	AL009198	Mycobacterium tuberculosis H37Rv complete genome; segment 144/162.	Mycobacterium tuberculosis	39,401	18-Jun-98
	GB_STS:AF040123	328	AF040123	Bos taurus microsatellite DVEPC127, sequence tagged site.	Bos taurus	35,168	1-Feb-98
ra00414 477	GB_STS:AF040123	328	AF040123	Bos taurus microsatellite DVEPC127, sequence tagged site.	Bos taurus	35,168	1-Feb-98
	GB_VI:AB024414	110637	AB024414	Gallid herpesvirus 1 (serotype 2) DNA, UL region complete sequence.	Gallid herpesvirus 1 (serotype 2)	40,135	4-Aug-99
ra00460 594	GB_VI:AB012572	16770	AB012572	Gallid herpesvirus 1 (serotype 2) UL41 to UL51 genes, complete cds.	Gallid herpesvirus 1 (serotype 2)	40,135	2-Sep-98
	GB_VI:AB024414	110637	AB024414	Gallid herpesvirus 1 (serotype 2) DNA, UL region complete sequence.	Gallid herpesvirus 1 (serotype 2)	37,107	4-Aug-99
ra00542 798	GB_HTG3:AC008952	71200	AC008952	Homo sapiens chromosome 5 clone CITB-H1_2337D22, *** SEQUENCING IN PROGRESS *** , 69 unordered pieces.	Homo sapiens	34,342	3-Aug-99
	GB_HTG3:AC008952	71200	AC008952	Homo sapiens chromosome 5 clone CITB-H1_2337D22, *** SEQUENCING IN PROGRESS *** , 69 unordered pieces.	Homo sapiens	34,342	3-Aug-99
ra00542 798	GB_HTG2:AC006872	145614	AC006872	Caenorhabditis elegans clone Y53G8Y, *** SEQUENCING IN PROGRESS *** , 5 unordered pieces.	Caenorhabditis elegans	35,112	26-Feb-99
	GB_BA1:MSGY219	38721	AD000013	Mycobacterium tuberculosis sequence from clone Y219.	Mycobacterium tuberculosis	38,668	10-DEC-1996
ra00543 549	GB_BA1:MTCV21D4	20760	Z80775	Mycobacterium tuberculosis H37Rv complete genome; segment 3/262.	Mycobacterium tuberculosis	53,137	24-Jun-99
	GB_BA1:MSGDNAB	40571	L39923	Mycobacterium leprae cosmid L222 DNA sequence, 27 CDS features.	Mycobacterium leprae	38,403	29-Apr-97
ra00544 1653	GB_PL2:ATAC006922	114950	AC006922	Arabidopsis thaliana chromosome II BAC T1J8 genomic sequence, complete sequence.	Arabidopsis thaliana	38,787	21-MAY-1999
	GB_PR4:AC005011	166069	AC005011	Homo sapiens BAC clone GS111G14 from 7q11, complete sequence.	Homo sapiens	38,246	28-Jul-99
ra00544 1653	GB_HTG2:AC007602	95333	AC007602	Homo sapiens chromosome 16 clone 2D4, *** SEQUENCING IN PROGRESS *** , 76 unordered pieces.	Homo sapiens	33,457	20-MAY-1999
	GB_BA1:MLC81913	37750	AL022118	Mycobacterium leprae cosmid B1913.	Mycobacterium leprae	37,339	27-Aug-99
ra00544 1653	GB_BA1:MSGDNAB	40571	L39923	Mycobacterium leprae cosmid L222 DNA sequence, 27 CDS features.	Mycobacterium leprae	40,364	29-Apr-97
	GB_BA2:MSM238027	17973	AJ238027	Mycobacterium smegmatis mps gene.	Mycobacterium smegmatis	37,141	08-OCT-1999

TABLE 4: ALIGNMENT RESULTS

ra00545	390	GB_HTG3:AC009314	20481	AC009314	Homo sapiens clone NH0465K04, *** SEQUENCING IN PROGRESS *** , 12 unordered pieces.	Homo sapiens	35,128	24-Aug-99
		GB_HTG3:AC009314	20481	AC009314	Homo sapiens clone NH0465K04, *** SEQUENCING IN PROGRESS *** , 12 unordered pieces.	Homo sapiens	35,128	24-Aug-99
		GB_EST36:A1920042	696	A1920042	1572 Pine Lambda Zap Xylem library Pinus taeda cDNA clone b12_P13CSUH, mRNA sequence.	Pinus taeda	33,947	29-Jul-99
ra00562	846	GB_PR3:HS470K1	103613	AL031780	Human DNA sequence from clone 470K1 on chromosome 6p22.1-23. Contains ESTs, STSs, GSSs, genomic markers D6S263 and D6S277, and two ca repeat polymorphisms, complete sequence.	Homo sapiens	34,251	23-Nov-99
		GB_HTG1:HSJ976O13	102370	AL117354	Homo sapiens chromosome 1 clone RP5-976O13 map p21.2-22.2, *** SEQUENCING IN PROGRESS *** , in unordered pieces.	Homo sapiens	34,928	25-Nov-99
		GB_HTG1:HSJ976O13	102370	AL117354	Homo sapiens chromosome 1 clone RP5-976O13 map p21.2-22.2, ***SEQUENCING IN PROGRESS *** , in unordered pieces.	Homo sapiens	34,928	25-Nov-99
ra00625	965	GB_PR4:AC005049	106928	AC005049	Homo sapiens clone RG02315, complete sequence.	Homo sapiens	37,446	21-Aug-99
		GB_HTG2:HSDJ319M7	128208	AL079341	Homo sapiens chromosome 6 clone RP1-319M7 map p21.1-21.3, *** SEQUENCING IN PROGRESS *** , in unordered pieces.	Homo sapiens	35,759	30-Nov-99
		GB_HTG2:HSDJ319M7	128208	AL079341	Homo sapiens chromosome 6 clone RP1-319M7 map p21.1-21.3, *** SEQUENCING IN PROGRESS *** , in unordered pieces.	Homo sapiens	35,759	30-Nov-99
ra00670	612	GB_BA1:MTY13E12	43401	Z95390	Mycobacterium tuberculosis H37Rv complete genome; segment 147/162.	Mycobacterium tuberculosis	41,206	17-Jun-98
		GB_BA1:SC6G4	41055	AL031317	Streptomyces coelicolor cosmid 6G4.	Streptomyces coelicolor	55,410	20-Aug-98
		GB_HTG3:AC009422	140233	AC009422	Homo sapiens clone 44_N_8, *** SEQUENCING IN PROGRESS *** , 17 unordered pieces.	Homo sapiens	36,394	22-Aug-99
ra00671	1137	GB_BA1:MTY13E12	43401	Z95390	Mycobacterium tuberculosis H37Rv complete genome; segment 147/162.	Mycobacterium tuberculosis	38,172	17-Jun-98
		GB_BA1:SC6G4	41055	AL031317	Streptomyces coelicolor cosmid 6G4.	Streptomyces coelicolor	67,810	20-Aug-98
		GB_BA1:MLCB1222	34714	AL049491	Mycobacterium leprae cosmid B1222.	Mycobacterium leprae	40,541	27-Aug-99
ra00672	726	GB_BA1:MTY13E12	43401	Z95390	Mycobacterium tuberculosis H37Rv complete genome; segment 147/162.	Mycobacterium tuberculosis	38,187	17-Jun-98
		GB_BA1:MLCB1222	34714	AL049491	Mycobacterium leprae cosmid B1222.	Mycobacterium leprae	37,027	27-Aug-99
		GB_BA1:MBU15140	2136	U15140	Mycobacterium bovis ribosomal proteins IF-1 (infA), L36 (rpmJ), S13 (psfW) and S11 (psk) genes, complete cds, and S4 (psd) gene, partial cds.	Mycobacterium bovis	71,933	28-OCT-1996
ra00673	525	GB_BA1:SC6G4	41055	AL031317	Streptomyces coelicolor cosmid 6G4.	Streptomyces coelicolor	63,238	20-Aug-98
		GB_BA1:MTY13E12	43401	Z95390	Mycobacterium tuberculosis H37Rv complete genome; segment 147/162.	Mycobacterium tuberculosis	33,461	17-Jun-98
		GB_BA1:MLCB1222	34714	AL049491	Mycobacterium leprae cosmid B1222.	Mycobacterium leprae	37,965	27-Aug-99
ra00694	519	GB_BA1:MLSPCOPER	6856	X17524	M.luteus DNA for spectinomycin (spc) operon.	Micrococcus luteus	68,093	07-DEC-1992
		GB_BA1:SCSECYDNA	6154	X83011	S.coelicolor secY locus DNA.	Streptomyces coelicolor	74,611	02-MAR-1998
		GB_BA1:MLCB2492	37144	Z98756	Mycobacterium leprae cosmid B2492.	Mycobacterium leprae	66,408	28-Aug-97
ra00695	657	GB_BA1:MTCY210	36804	Z84395	Mycobacterium tuberculosis H37Rv complete genome; segment 34/162.	Mycobacterium tuberculosis	69,863	17-Jun-98
		GB_BA1:MSGY42	36526	AD000005	Mycobacterium tuberculosis sequence from clone y42.	Mycobacterium tuberculosis	38,880	03-DEC-1996
		GB_BA1:SCSECYDNA	6154	X83011	S.coelicolor secY locus DNA.	Streptomyces coelicolor	67,580	02-MAR-1998
ra00696	525	GB_BA1:MLSPCOPER	6856	X17524	M.luteus DNA for spectinomycin (spc) operon.	Streptomyces coelicolor	65,873	02-MAR-1998
		GB_BA1:MTCY210	36804	Z84395	Mycobacterium tuberculosis H37Rv complete genome; segment 34/162.	Micrococcus luteus	65,145	07-DEC-1992
ra00697	756	GB_BA1:MTCY210	36804	Z84395	Mycobacterium tuberculosis H37Rv complete genome; segment 34/162.	Mycobacterium tuberculosis	65,779	17-Jun-98
		GB_BA1:MSGY42	36526	AD000005	Mycobacterium tuberculosis sequence from clone y42.	Mycobacterium tuberculosis	67,353	17-Jun-98
		GB_BA1:SCSECYDNA	6154	X83011	S.coelicolor secY locus DNA.	Mycobacterium tuberculosis	39,516	03-DEC-1996
ra00698	306	GB_BA1:BSUB0019	212610	Z99122	Bacillus subtilis complete genome (section 19 of 21): from 3597091 to 3809700.	Streptomyces coelicolor	67,764	02-MAR-1998
						Bacillus subtilis	39,465	24-Jun-99

TABLE 4: ALIGNMENT RESULTS

		GB_IN2:AC008370	132171	AC008370	Drosophila melanogaster, chromosome 2R, region 44B-44C, BAC clones BACR09N11 and BACR40A15, complete sequence.	Drosophila melanogaster	32,558	3-Aug-99
		GB_HTG2:AC006878	159941	AC006878	Caenorhabditis elegans clone Y54H5, *** SEQUENCING IN PROGRESS ***, 8 unordered pieces.	Caenorhabditis elegans	36,066	26-Feb-99
ra00699	567	GB_BA1:SCSECYDNA	6154	X83011	S.coelicolor secY locus DNA.	Streptomyces coelicolor	65,009	02-MAR-1998
		GB_BA1:MLSPCOPER	6858	X17524	M.luteus DNA for spectinomycin (spc) operon.	Micrococcus luteus	61,538	07-DEC-1992
ra00706	696	GB_BA1:MTCY210	36804	Z84395	Mycobacterium tuberculosis H37Rv complete genome; segment 34/162.	Mycobacterium tuberculosis	61,989	17-Jun-98
		GB_BA1:MTCY210	36804	Z84395	Mycobacterium tuberculosis H37Rv complete genome; segment 34/162.	Mycobacterium tuberculosis	67,960	17-Jun-98
		GB_BA1:MSGY42	36526	AD000005	Mycobacterium tuberculosis sequence from clone y42.	Mycobacterium tuberculosis	39,757	03-DEC-1996
ra00709	489	GB_BA1:MLSPCOPER	6858	X17524	M.luteus DNA for spectinomycin (spc) operon.	Micrococcus luteus	67,686	07-DEC-1992
		GB_BA1:MTCY210	36804	Z84395	Mycobacterium tuberculosis H37Rv complete genome; segment 34/162.	Mycobacterium tuberculosis	69,897	17-Jun-98
		GB_BA1:MSGY42	36526	AD000005	Mycobacterium tuberculosis sequence from clone y42.	Mycobacterium tuberculosis	69,897	03-DEC-1996
ra00710	435	GB_BA1:MLCB2492	37144	Z98756	Mycobacterium leprae cosmid B2492.	Mycobacterium leprae	68,660	28-Aug-97
		GB_BA1:MLCB2492	36804	Z84395	Mycobacterium tuberculosis H37Rv complete genome; segment 34/162.	Mycobacterium tuberculosis	69,746	17-Jun-98
		GB_BA1:MSGY42	36526	AD000005	Mycobacterium tuberculosis sequence from clone y42.	Mycobacterium tuberculosis	37,709	03-DEC-1996
ra00717	1083	GB_BA1:MLCB2492	37144	Z98756	Mycobacterium leprae cosmid B2492.	Mycobacterium leprae	68,129	28-Aug-97
		GB_PAT:178753	1187	178753	Sequence 9 from patent US 5693781.	Unknown.	37,814	3-Apr-98
		GB_PAT:192042	1187	192042	Sequence 9 from patent US 5726299.	Unknown.	37,814	01-DEC-1998
ra00789	366	GB_BA1:MTCH125	37432	Z98268	Mycobacterium tuberculosis H37Rv complete genome; segment 76/162.	Mycobacterium tuberculosis	50,647	17-Jun-98
		GB_PR4:AC007453	166892	AC007463	Homo sapiens BAC clone NH0244L12 from 2, complete sequence.	Homo sapiens	41,047	22-OCT-1999
		GB_IN2:AC004420	79987	AC004420	Drosophila melanogaster DNA sequence (P1 DS02649 (D132)), complete sequence.	Drosophila melanogaster	34,670	20-Jun-98
ra00790	1185	GB_BA1:MTV012	70287	AL021287	Mycobacterium tuberculosis H37Rv complete genome; segment 132/162.	Mycobacterium tuberculosis	40,331	23-Jun-99
		GB_EST23:AI085588	492	AI085588	oy68d10.x1 NCI_CGAP_CELL1 Homo sapiens cDNA clone IMAGE:1670995 3', mRNA sequence.	Homo sapiens	34,167	24-Sep-98
		GB_HTG4:AC010097	198863	AC010097	Homo sapiens chromosome unknown clone NH0378116, WORKING DRAFT SEQUENCE, in unordered pieces.	Homo sapiens	33,907	29-OCT-1999
ra00798	1278	GB_HTG4:AC010097	198863	AC010097	Homo sapiens chromosome unknown clone NH0378116, WORKING DRAFT SEQUENCE, in unordered pieces.	Homo sapiens	33,907	29-OCT-1999
		GB_BA1:SCHE5	40544	AL035636	Streptomyces coelicolor cosmid H5.	Streptomyces coelicolor	39,294	25-MAR-1999
		GB_BA1:MTY15C10	33050	Z95436	Mycobacterium tuberculosis H37Rv complete genome; segment 154/162.	Mycobacterium tuberculosis	37,619	17-Jun-98
		GB_PAT:AR053877	3107	AR053877	Sequence 3 from patent US 5834279.	Unknown.	62,090	29-Sep-99
ra00807	1365	GB_IN1:CELK07E12	58949	U00054	Caenorhabditis elegans cosmid K07E12.	Caenorhabditis elegans	38,743	11-MAY-1994
		GB_PL1:GYCPR	1179	D83718	Glycyrhiza echninata mRNA for polyketide reductase, complete cds.	Glycyrhiza echninata	41,725	20-Feb-99
		GB_EST31:AU062517	350	AU062517	AU062517 Rice callus Oryza sativa cDNA clone C11644_1A, mRNA sequence.	Oryza sativa	43,386	20-MAY-1999
ra00817	2517	GB_BA1:MTY15C10	33050	Z95436	Mycobacterium tuberculosis H37Rv complete genome; segment 154/162.	Mycobacterium tuberculosis	56,778	17-Jun-98
		GB_GSS11:AQ289275	682	AQ289275	nbxb0034B24r CUGI Rice BAC Library Oryza sativa genomic clone nbxb0034B24r, genomic survey sequence.	Oryza sativa	38,301	03-DEC-1998
ra00823	903	GB_IN1:CELO12469	11025	AJ012469	Caenorhabditis elegans mRNA for DYS-1 protein, partial.	Caenorhabditis elegans	37,981	16-Nov-98
		GB_BA1:MTV025	121125	AL022121	Mycobacterium tuberculosis H37Rv complete genome; segment 155/162.	Mycobacterium tuberculosis	37,753	24-Jun-99
		GB_PL2:ATFCA0	200576	Z97335	Arabidopsis thaliana DNA chromosome 4, ESSA1 FCA contig fragment No. 0.	Arabidopsis thaliana	37,178	28-Jun-99
ra00890	1422	GB_PL2:ATFCA0	200576	Z97335	Arabidopsis thaliana DNA chromosome 4, ESSA1 FCA contig fragment No. 0.	Arabidopsis thaliana	37,016	28-Jun-99
		GB_BA1:MTCY27	27548	Z95208	Mycobacterium tuberculosis H37Rv complete genome; segment 104/162.	Mycobacterium tuberculosis	39,813	17-Jun-98

TABLE 4: ALIGNMENT RESULTS

	GB_BA2:U32716	11618	U32716	Haemophilus influenzae Rd section 31 of 163 of the complete genome.	Haemophilus influenzae Rd	39,588	29-MAY-1998
	GB_HTG2:AC006842	299015	AC006842	Caenorhabditis elegans clone Y104H12X, *** SEQUENCING IN PROGRESS ***, 13 unordered pieces.	Caenorhabditis elegans	36,003	24-Feb-99
ra00898	912						
	GB_BA1:MSGY423	42741	AD000014	Mycobacterium tuberculosis sequence from clone y423.	Mycobacterium tuberculosis	54,945	10-DEC-1996
	GB_BA1:MTCY22G10	35420	Z84724	Mycobacterium tuberculosis H37Rv complete genome; segment 21/162.	Mycobacterium tuberculosis	39,532	17-Jun-98
	GB_IN1:CEC12G8	23674	Z81467	Caenorhabditis elegans cosmid C12C8, complete sequence.	Caenorhabditis elegans	36,170	23-Nov-98
ra00967	411						
	GB_HTG2:AC006244	92079	AC006244	Drosophila melanogaster chromosome 2 clone DS00212 (D463) map 60F1-60F2 strain y, on bw sp, *** SEQUENCING IN PROGRESS ***, 3 unordered pieces.	Drosophila melanogaster	38,765	30-Jul-99
	GB_GSS1:CNS00BE0	1101	AL056856	Drosophila melanogaster genome survey sequence T7 end of BAC # BACR23K12 of RPC1.98 library from Drosophila melanogaster (fruit fly), genomic survey sequence.	Drosophila melanogaster	34,772	4-Jun-99
	GB_HTG2:AC006244	92079	AC006244	Drosophila melanogaster chromosome 2 clone DS00212 (D463) map 60F1-60F2 strain y, on bw sp, *** SEQUENCING IN PROGRESS ***, 3 unordered pieces.	Drosophila melanogaster	38,765	30-Jul-99
ra00990	488						
	GB_GSS8:AQ078675	565	AQ078675	CIT-HSP-2368L22.TF CIT-HSP Homo sapiens genomic clone 2368L22, genomic survey sequence.	Homo sapiens	39,200	20-Aug-98
	GB_GSS8:AQ040280	323	AQ040280	CIT-HSP-2328E18.TR CIT-HSP Homo sapiens genomic clone 2328E18, genomic survey sequence.	Homo sapiens	38,434	11-Jul-98
	GB_PL1:ATF16J13	107600	AL049638	Arabidopsis thaliana DNA chromosome 4, BAC clone F16J13 (ESSA project). Arabidopsis thaliana	Arabidopsis thaliana	43,220	14-Apr-99
ra00994	451						
	GB_EST17:C74578	301	C74578	C74578 Rice panicle shorter than 3cm Oryza sativa cDNA clone E31890_1A, mRNA sequence.	Oryza sativa	51,174	29-Sep-97
	GB_EST36:AF155027	827	AF155027	AF155027 Zebrafish Kidney cDNA random primed, RZPD library no: 576	Danio rerio	35,268	22-Jul-99
	GB_EST8:AA023112	457	AA023112	Danio rerio cDNA clone CHBOP576D06232Q3 T7 primer, mRNA sequence. mth66c12.r1 Soares mouse placenta 4NbMP13.5 14.5 Mus musculus cDNA clone IMAGE:455926 5' similar to PIR:S10960 S10960 hypothetical protein - bovine, mRNA sequence.	Mus musculus	41,869	21-Jan-97
ra01030	1299						
	GB_HTG3:AC011344	127964	AC011344	Homo sapiens chromosome 5 clone CIT-HSPC_287O14, *** SEQUENCING IN PROGRESS ***, 36 unordered pieces.	Homo sapiens	37,718	06-OCT-1999
	GB_HTG3:AC011344	127964	AC011344	Homo sapiens chromosome 5 clone CIT-HSPC_287O14, *** SEQUENCING IN PROGRESS ***, 36 unordered pieces.	Homo sapiens	37,718	06-OCT-1999
	GB_BA1:RPXX04	237523	AJ235273	Rickettsia prowazekii strain Madrid E, complete genome; segment 4/4.	Rickettsia prowazekii	34,752	11-Nov-98
ra01064	759						
	GB_EST16:AA584614	489	AA584614	no08g11.s1 NCI_CGAP_Phe1 Homo sapiens cDNA clone IMAGE:1100132 3', mRNA sequence.	Homo sapiens	39,059	8-Sep-97
	GB_HTG2:AC007720	150070	AC007720	Homo sapiens clone 31_B_4, *** SEQUENCING IN PROGRESS ***, 7 unordered pieces.	Homo sapiens	38,859	3-Jun-99
	GB_HTG2:AC007720	150070	AC007720	Homo sapiens clone 31_B_4, *** SEQUENCING IN PROGRESS ***, 7 unordered pieces.	Homo sapiens	38,859	3-Jun-99
ra01149	381						
	GB_PRA:AC006971	115861	AC006971	Homo sapiens PAC clone DU0791C19 from 7p11.2-q11.21, complete sequence.	Homo sapiens	37,401	08-MAY-1999
	GB_HTG4:AC007347	167025	AC007347	Homo sapiens chromosome 16 clone RPC1.11_488J11, *** SEQUENCING IN PROGRESS ***, 2 ordered pieces.	Homo sapiens	36,364	31-OCT-1999
	GB_HTG4:AC007347	167025	AC007347	Homo sapiens chromosome 16 clone RPC1.11_488J11, *** SEQUENCING IN PROGRESS ***, 2 ordered pieces.	Homo sapiens	36,364	31-OCT-1999
ra01157	1705						
	GB_BA1:MTCV49	39430	Z73966	Mycobacterium tuberculosis H37Rv complete genome; segment 93/162.	Mycobacterium tuberculosis	39,879	24-Jun-99

TABLE 4: ALIGNMENT RESULTS

ra01238	1524	GB_BA2:SAU77894 GB_BA1:SAAJ3310 GB_PR4:AC007367 GB_PR4:AC007367 GB_HTG2:AC008157	2437 2437 197278 197278 171758	U77894 AJ223310 AC007367 AC007367 AC008157	Streptomyces avermitilis hecicase-like protein gene, complete cds. Streptomyces avermitilis sab3 gene, complete CDS. Homo sapiens BAC clone NH0518G12 from 2, complete sequence. Homo sapiens BAC clone NH0518G12 from 2, complete sequence. Homo sapiens clone 45_P_22, *** SEQUENCING IN PROGRESS *** , 9 unordered pieces.	Streptomyces avermitilis Streptomyces avermitilis Homo sapiens Homo sapiens Homo sapiens	57,648 57,648 35,130 38,153 35,762	5-Jan-99 8-Apr-98 22-OCT-1999 22-OCT-1999 28-Jul-99
ra01255	1203	GB_EST37:A1944834 GB_EST1:T16608	388 235	A1944834 T16608	bs06a03.y1 Drosophila melanogaster adult testis library Drosophila melanogaster cDNA clone bs06a03.5, mRNA sequence. NIB1546 Normalized infant brain, Bento Soares Homo sapiens cDNA 3end, mRNA sequence.	Drosophila melanogaster Homo sapiens	40,310 41,277	17-Aug-99 25-Jul-96
ra01279	588	GB_EST10:AA141530 GB_BA1:MLB1790G	515 37617	AA141530 Z14314	CK01913.5prime CK Drosophila melanogaster embryo BlueScript Drosophila melanogaster cDNA clone CK01913.5prime, mRNA sequence. M.leprae genes rpl, rpoB, rpoC, end, rpsL, rpsG, efg, tuf, rpsJ, rplC for ribosomal protein L7, RNA polymerase beta subunit, RNA polymerase beta subunit, endonuclease, ribosomal protein S7, ribosomal protein S12, elongation factor G, elongation factor Tu, ribosomal protein S10, ribosomal protein L3 and mkl gene.	Drosophila melanogaster Mycobacterium leprae	38,477 71,088	29-Nov-98 11-Feb-93
ra01280	489	GB_BA1:MSGRPSLG GB_BA1:MLUSTROA GB_BA1:MLB1790G	1199 5291 37617	L34681 M17788 Z14314	Mycobacterium smegmatis ribosomal protein S12 (rpsL) gene, complete cds; ribosomal protein S7 (rpsG) gene, complete cds. M.luteus str operon encoding ribosomal protein S12 (str or rpsL) ribosomal protein S7 (rpsG) EF-G (fus) and EF-Tu (tuf). M.leprae genes rpl, rpoB, rpoC, end, rpsL, rpsG, efg, tuf, rpsJ, rplC for ribosomal protein L7, RNA polymerase beta subunit, RNA polymerase beta subunit, endonuclease, ribosomal protein S7, ribosomal protein S12, elongation factor G, elongation factor Tu, ribosomal protein S10, ribosomal protein L3 and mkl gene.	Mycobacterium smegmatis Micrococcus luteus Mycobacterium leprae	76,408 71,599 65,644	23-Feb-95 26-Apr-93 11-Feb-93
ra01286	777	GB_BA2:ECOUW67_2 GB_BA1:MTV040 GB_BA1:PRFUSTUF GB_BA1:MLCB2492 GB_BA1:MTCY210 GB_BA1:MTCY210 GB_BA1:MSGY42 GB_BA1:MLB1790G	110000 15100 2742 37144 36804 36804 36526 37617	U18997 AL021943 X98830 Z98756 Z84395 Z84395 AD000005 Z14314	Escherichia coli K-12 chromosomal region from 67.4 to 76.0 minutes. Mycobacterium tuberculosis H37Rv complete genome; segment 33/162. P.rosea fus, tuf, rpsJ and rplC genes. Mycobacterium leprae cosmid B2492. Mycobacterium tuberculosis H37Rv complete genome; segment 34/162. Mycobacterium tuberculosis H37Rv complete genome; segment 34/162. Mycobacterium tuberculosis sequence from clone y42. M.leprae genes rpl, rpoB, rpoC, end, rpsL, rpsG, efg, tuf, rpsJ, rplC for ribosomal protein L7, RNA polymerase beta subunit, RNA polymerase beta subunit, endonuclease, ribosomal protein S7, ribosomal protein S12, elongation factor G, elongation factor Tu, ribosomal protein S10, ribosomal protein L3 and mkl gene.	Escherichia coli Mycobacterium tuberculosis Planobspora rosea Mycobacterium leprae Mycobacterium tuberculosis Mycobacterium tuberculosis Mycobacterium tuberculosis Mycobacterium leprae	37,037 65,849 67,525 67,111 67,021 70,423 35,749 69,104	23-Jan-98 17-Jun-98 19-Nov-96 28-Aug-97 17-Jun-98 17-Jun-98 03-DEC-1996 11-Feb-93
ra01305	1989	GB_GSS10:AQ242866	511	AQ242866	HS_2041_A2_E10_T7 CIT Approved Human Genomic Sperm Library D Homo sapiens genomic clone Plate=2041 Col=20 Row=1, genomic survey sequence.	Homo sapiens	38,735	03-OCT-1998
ra01334	507	GB_PR2:HSU29874 GB_PR2:HSU29874 GB_BA1:MTY20H10	6155 6155 35980	U29874 U29874 Z92772	Human FIT3 ligand gene and FIT3 ligand alternatively spliced isoform gene, complete cds. Human FIT3 ligand gene and FIT3 ligand alternatively spliced isoform gene, complete cds. Mycobacterium tuberculosis H37Rv complete genome; segment 31/162.	Homo sapiens Homo sapiens Mycobacterium tuberculosis	38,791 36,655 66,075	29-Feb-96 29-Feb-96 17-Jun-98

TABLE 4: ALIGNMENT RESULTS

	GB_BA1:MLB1790G	37617	Z14314	M. leprae genes rplL, rpoB, rpoC, end, rpsL, rpsG, efg, tuf, rpsJ, rplC for ribosomal protein L7, RNA polymerase beta subunit, RNA polymerase beta' subunit, endonuclease, ribosomal protein S7, ribosomal protein S12, elongation factor G, elongation factor Tu, ribosomal protein S10, ribosomal protein L3 and rnkI gene.	Mycobacterium leprae	64,969	11-Feb-93
				M. bovis rplL gene for ribosomal protein L7/L12.			
ra01335	GB_BA1:MSGRPLL	631	D16310	Streptomyces coelicolor cosmid 5F2A.	Mycobacterium bovis	66,598	4-Feb-99
	GB_BA1:SCSF2A	40105	AL049587	Streptomyces coelicolor cosmid 6A5.	Streptomyces coelicolor	40,362	24-MAY-1999
	GB_BA1:SC6A5	43632	AL049485	AV002771 Mus musculus C57BL/6J kidney Mus musculus cDNA clone 0610020F04, mRNA sequence.	Streptomyces coelicolor	40,362	24-MAR-1999
	GB_EST30:AV002771	289	AV002771	0610020F04, mRNA sequence.	Mus musculus	41,667	24-Aug-99
ra01343	GB_BA1:MTY20H10	35980	Z92772	Mycobacterium tuberculosis H37Rv complete genome; segment 31/162.	Mycobacterium tuberculosis	66,908	17-Jun-98
	GB_BA1:SGNUSG	7235	X72787	S. griseus nusG, rplKAL gene cluster.	Streptomyces griseus	63,177	06-MAY-1998
	GB_BA1:STMVBR1	7409	D50624	Streptomyces virginiae VbrA gene for NusG like protein, SecE like protein and ribosomal protein, aspartate aminotransferase and adenosine deaminase, complete cds.	Streptomyces virginiae	63,329	10-Feb-99
ra01353	GB_BA1:SC2E1	38962	AL023797	Streptomyces coelicolor cosmid 2E1.	Streptomyces coelicolor	65,368	4-Jun-98
	GB_BA2:SKZ86111	7860	Z86111	Streptomyces lividans rpsP, trmD, rpsI, sipV, sipX, sipY, sipZ, mult genes and 4 open reading frames.	Streptomyces lividans	65,368	27-OCT-1999
ra01356	GB_BA1:MTCY274	39991	Z74024	Mycobacterium tuberculosis H37Rv complete genome; segment 126/162.	Mycobacterium tuberculosis	37,013	19-Jun-98
	GB_BA1:BSUB0009	208780	Z99112	Bacillus subtilis complete genome (section 9 of 21); from 1598421 to 1807200.	Bacillus subtilis	44,851	26-Nov-97
	GB_PL2:CRE132478	16445	AJ132478	Chlamydomonas reinhardtii STF1 gene, partial.	Chlamydomonas reinhardtii	37,200	29-Sep-99
	GB_GSS4:AQ701168	552	AQ701168	HS_2129_A2_B06_TTC CIT Approved Human Genomic Sperm Library D Homo sapiens genomic clone Plate=2129 Col=12 Row=C, genomic survey sequence.	Homo sapiens	40,541	6-Jul-99
ra01374	GB_OV:FR24G11	34807	Z93780	Fugu rubripes genes encoding carbanoyl phosphate synthetase III, myosin light chain, MAP2.	Fugu rubripes	37,936	22-Nov-99
	GB_EST36:A1881479	601	A1881479	606069F03.y1 606 - Ear tissue cDNA library from Schmidt lab Zea mays cDNA, mRNA sequence.	Zea mays	38,963	21-Jul-99
ra01423	GB_BA2:AE000733	15569	AE000733	Aquifex aeolicus section 65 of 109 of the complete genome.	Aquifex aeolicus	35,421	25-MAR-1998
	GB_BA1:SCH24	41625	AL049826	Streptomyces coelicolor cosmid H24.	Streptomyces coelicolor	57,854	11-MAY-1999
	GB_BA1:MSGDNAB	40571	L39923	Mycobacterium leprae cosmid L222 DNA sequence, 27 CDS features.	Mycobacterium leprae	41,634	29-Apr-97
	GB_BA1:MSORIREP	10430	X92503	M. smegmatis origin of replication and genes rpmH, dnaA, dnaN, gnd, recF, gyrB, gyrA.	Mycobacterium smegmatis	39,535	26-Aug-97
ra01424	GB_OV:CCU31864	2517	U31864	Cyprinus carpio stearyl-CoA desaturase mRNA, complete cds.	Cyprinus carpio	36,946	13-Sep-99
	GB_JIN1:DME010641	3733	AJ010641	Drosophila melanogaster mRNA for Dof protein, transcript II.	Drosophila melanogaster	36,768	9-Feb-99
	GB_JIN1:DME010642	4044	AJ010642	Drosophila melanogaster mRNA for Dof protein, transcript I, partial.	Drosophila melanogaster	36,768	6-Sep-99
ra01453	GB_BA1:PDENQURF	10425	L02354	Paracoccus denitrificans NADH dehydrogenase (URF4), (NQO8), (NQO9), (URF5), (URF6), (NQO10), (NQO11), (NQO12), (NQO13), and (NQO14) genes, complete cds's; biotin [acetyl-CoA carboxyl] ligase (brrA) gene, complete cds.	Paracoccus denitrificans	41,304	20-MAY-1993

TABLE 4: ALIGNMENT RESULTS

	GB_BA2:AF108766	14548	AF108766	Rhodobacter sphaeroides AsmA (asma) gene, partial cds; YbaU (ybaU), anthranilate synthase component I (trpE), YbaQ (ybaQ), anthranilate synthase component II (trpG), anthranilate phosphoribosyltransferase (trpD), indole-3-glycerol phosphate synthase (trpC), molybdenum cofactor biosynthesis protein C (moaC), molybdenum cofactor biosynthesis protein A (moaA), LexA repressor (lexA), and glutamyl t-RNA synthetase (glus) genes, complete cds; and citrate synthase (cstY) gene, partial cds.	Rhodobacter sphaeroides	41,388	9-Nov-99	
ra01480	2016	GB_BA1:SC0001205 GB_BA2:AF027507	9589 5168	AJ001205 AF027507	Streptomyces coelicolor A3(2) glycogen metabolism cluster1, Mycobacterium smegmatis dGTPase (dgt), and primase (dnaG) genes, complete cds; tRNA-Asn gene, complete sequence.	Streptomyces coelicolor Mycobacterium smegmatis	40,554 58,650	29-MAR-1999 16-Jan-98
ra01481	615	GB_BA1:MTCY98 GB_PL1:AB009053 GB_HTG1:LMFL5628	31225 78145 32914	Z83860 AB009053 AL049187	Mycobacterium tuberculosis H37Rv complete genome; segment 103/162. Arabidopsis thaliana genomic DNA, chromosome 5, P1 clone: MQB2. Leishmania major chromosome 4 clone L5628 strain Freidin, *** SEQUENCING IN PROGRESS ***, in unordered pieces.	Mycobacterium tuberculosis Arabidopsis thaliana Leishmania major	36,959 37,232 38,399	17-Jun-98 13-Feb-99 29-Apr-99
		GB_HTG1:LMFL5628	32914	AL049187	Leishmania major chromosome 4 clone L5628 strain Freidin, *** SEQUENCING IN PROGRESS ***, in unordered pieces.	Leishmania major	38,399	29-Apr-99
		GB_PR3:HSJ182D15	79576	AL049612	Human DNA sequence *** SEQUENCING IN PROGRESS *** from clone dJ182D15, complete sequence.	Homo sapiens	37,438	23-Nov-99
ra01487	390	GB_BA1:MTV002 GB_BA1:SC3C3 GB_BA1:MLCB22	56414 31382 40281	AL008967 AL031231 Z98741	Mycobacterium tuberculosis H37Rv complete genome; segment 122/162. Streptomyces coelicolor cosmid 3C3. Mycobacterium leprae cosmid B22.	Mycobacterium tuberculosis Streptomyces coelicolor Mycobacterium leprae	38,182 56,923 38,021	17-Jun-98 10-Aug-98 22-Aug-97
ra01495	570	GB_PL1:SCSETRP4 GB_PL2:YSCD9476 GB_PL1:SCNUF1G	5020 31184 3522	X73297 U28372 Z11582	S.cerevisiae spacer element. Saccharomyces cerevisiae chromosome IV cosmid 9476. S.cerevisiae nuf1 gene.	Saccharomyces cerevisiae Saccharomyces cerevisiae Saccharomyces cerevisiae	34,921 34,921 34,921	30-DEC-1993 1-Aug-97 27-MAR-1992
ra01563	1332	GB_BA1:AB015023 GB_PR4:HUA004381	2291 213541	AB015023 AC004381	Corynebacterium glutamicum genes for MurC and FtsQ, complete cds. Homo sapiens Chromosome 16 BAC clone CIT987SK-4M2, complete sequence.	Corynebacterium glutamicum Homo sapiens	39,017 36,530	6-Feb-99 23-Nov-99
ra01581	936	GB_BA1:AB015023 GB_BA1:MTV016 GB_EST11:D23343	2291 53662 381	AB015023 AL021841 D23343	Corynebacterium glutamicum genes for MurC and FtsQ, complete cds. Mycobacterium tuberculosis H37Rv complete genome; segment 143/162. RICC2654A Rice callus Oryza sativa cDNA clone C2654_1A, mRNA sequence.	Corynebacterium glutamicum Mycobacterium tuberculosis Oryza sativa	40,463 41,424 37,831	6-Feb-99 23-Jun-99 8-Jul-99
ra01594	942	GB_EST17:C73734 GB_BA1:MLCB1351 GB_BA1:U00021 GB_PL1:AB025606	455 38936 39193 74282	C73734 Z95117 U00021 AB025606	C73734 Rice panicle (longer than 10cm) Oryza sativa cDNA clone E20291_2A, mRNA sequence. Mycobacterium leprae cosmid B1351. Mycobacterium leprae cosmid L247. Arabidopsis thaliana genomic DNA, chromosome 5, BAC clone:F6N7, complete sequence.	Oryza sativa Mycobacterium leprae Mycobacterium leprae Arabidopsis thaliana	39,341 36,237 38,553 35,699	23-Sep-97 24-Jun-97 29-Sep-94 20-Nov-99
ra01637	751	GB_PR3:AF064861 GB_HTG2:AC003656_4 GB_HTG2:AC003656_4	133965 110000 110000	AF064861 AC003656 AC003656	Homo sapiens PAC 128M19 derived from chromosome 21q22.3, containing the HMG-14 and CHD5 genes, complete cds, complete sequence. Homo sapiens clone P1 C124G1, *** SEQUENCING IN PROGRESS ***, 50 unordered pieces. Homo sapiens clone P1 C124G1, *** SEQUENCING IN PROGRESS ***, 50 unordered pieces.	Homo sapiens Homo sapiens Homo sapiens	37,600 41,137 41,137	2-Jun-98 2-Dec-97 2-Dec-97
ra01661	789	GB_BA1:MTV036 GB_BA1:MSGB1970CS	24055 39399	AL021931 L78815	Mycobacterium tuberculosis H37Rv complete genome; segment 19/162. Mycobacterium leprae cosmid B1970 DNA sequence.	Mycobacterium tuberculosis Mycobacterium leprae	40,962 61,370	17-Jun-98 15-Jun-96

TABLE 4: ALIGNMENT RESULTS

	GB_HTG2:AC006169	174288	AC006169	Drosophila melanogaster chromosome 3 clone BACR48E09 (D489) RPCI-98 48.E.9 map 61A1-61A4 strain Y; on bw sp. *** SEQUENCING IN PROGRESS***, 9 unordered pieces.	Drosophila melanogaster	32,737	2-Aug-99
ra01683 2691	GB_BA1:MSGYRBA	6000	X94224	M.smeignatis gyrB and gyrA genes.	Mycobacterium smegmatis	67,476	12-Feb-97
	GB_BA1:MTCY10H4	39160	Z80233	Mycobacterium tuberculosis H37Rv complete genome; segment 2/162.	Mycobacterium tuberculosis	66,828	17-Jun-98
ra01688 953	GB_BA1:MSGYRAB	5119	X84077	M.smeignatis gyrB and gyrA genes.	Mycobacterium smegmatis	67,090	13-MAR-1996
	GB_BA1:MTCY10H4	39160	Z80233	Mycobacterium tuberculosis H37Rv complete genome; segment 2/162.	Mycobacterium tuberculosis	74,397	17-Jun-98
	GB_BA1:MSORIREP	10430	X92503	M.smeignatis origin of replication and genes rpmH, dnaA, gnd, recF, gyrB, gyrA.	Mycobacterium smegmatis	74,711	26-Aug-97
ra01689 1239	GB_BA1:MSGYRAB	5119	X84077	M.smeignatis gyrB and gyrA genes.	Mycobacterium smegmatis	74,711	13-MAR-1996
	GB_BA1:MSORIREP	10430	X92503	M.smeignatis origin of replication and genes rpmH, dnaA, gnd, recF, gyrB, gyrA.	Mycobacterium smegmatis	63,470	26-Aug-97
ra01718 609	GB_BA1:MSGYRBA	6000	X94224	M.smeignatis gyrB and gyrA genes.	Mycobacterium smegmatis	62,969	12-Feb-97
	GB_BA1:MSGYRAB	5119	X84077	M.smeignatis gyrB and gyrA genes.	Mycobacterium smegmatis	62,886	13-MAR-1996
	GB_GSS13:AC473371	688	AC473371	CITBI-E1-2585J18, TR CITBI-E1 Homo sapiens genomic clone 2585J18, genomic survey sequence.	Homo sapiens	36,976	23-Apr-99
	GB_EST33:AV068888	264	AV068888	AV068888 Mus musculus small intestine C57BL/6J adult Mus musculus cDNA Mus musculus clone 2010307A09, mRNA sequence.	Mus musculus	40,000	24-Jun-99
ra01736 2891	GB_HTG3:AC008277	204008	AC008277	Homo sapiens clone NH0311B14, *** SEQUENCING IN PROGRESS *** , 4 unordered pieces.	Homo sapiens	39,130	04-OCT-1999
	GB_BA1:MTV014	58280	AL021646	Mycobacterium tuberculosis H37Rv complete genome; segment 137/162.	Mycobacterium tuberculosis	38,918	18-Jun-98
	GB_PL2:AF156928	2290	AF156928	Candida albicans (olypolyp)glutamate synthetase (fpgs) gene, complete cds.	Candida albicans	34,894	22-Jun-99
	GB_GSS12:AC421204	483	AC421204	RPCI-11-167B4, TJ RPCI-11 Homo sapiens genomic clone RPCI-11-167B4, genomic survey sequence.	Homo sapiens	39,085	23-MAR-1999
ra01739 720	GB_PR3:HS503F6	51476	AL021153	Homo sapiens DNA sequence from BAC 503F6 on chromosome 22q11.2-12.1. Contains EST and STS.	Homo sapiens	35,484	23-Nov-99
	GB_OM:CFU73207	1845	U73207	Canis familiaris beta1 adrenergic receptor (dogbeta1) gene, complete cds.	Canis familiaris	39,818	31-DEC-1997
	GB_PR3:HS503F6	51476	AL021153	Homo sapiens DNA sequence from BAC 503F6 on chromosome 22q11.2-12.1. Contains EST and STS.	Homo sapiens	36,376	23-Nov-99
ra01740 1545	GB_BA1:U00016	42931	U00016	Mycobacterium leprae cosmid B1937.	Mycobacterium leprae	57,820	01-MAR-1994
	GB_BA2:PAU73505	1332	U73505	Pseudomonas aeruginosa dihydroorotase (pyrC) gene, complete cds.	Pseudomonas aeruginosa	39,322	13-Nov-98
	GB_JN1:CEC52G5	42842	Z67881	Caenorhabditis elegans cosmid C52G5, complete sequence.	Caenorhabditis elegans	35,267	2-Sep-99
ra01772 5061	GB_BA2:AE001493	10792	AE001493	Helicobacter pylori, strain J99 section 54 of 132 of the complete genome.	Helicobacter pylori J99	46,571	20-Jan-99
	GB_EST5:N28852	555	N28852	yx5911.1, r1 Soares melanocyte 2NbhM Homo sapiens cDNA clone IMAGE:266061 5, mRNA sequence.	Homo sapiens	38,561	4-Jan-96
	GB_EST5:N28844	628	N28844	yx59d11.1, r1 Soares melanocyte 2NbhM Homo sapiens cDNA clone IMAGE:266037 5, mRNA sequence.	Homo sapiens	38,118	4-Jan-96
ra01786 807	GB_PL1:AB006707	82315	AB006707	Arabidopsis thaliana genomic DNA, chromosome 5, P1 clone: MYC6, complete sequence.	Arabidopsis thaliana	37,641	20-Nov-99
	GB_PR4:AC006324	157310	AC006324	Homo sapiens clone DJ1164F05, complete sequence.	Homo sapiens	36,802	11-Nov-99
	GB_PL2:ATU29168	2692	U29168	Arabidopsis thaliana DNA repair protein homolog (XPBarE) mRNA, complete cds.	Arabidopsis thaliana	38,808	6-Apr-98
ra01824 945	GB_EST19:AA760333	371	AA760333	vv75b10.r1 Stratagene mouse skin (#937313) Mus musculus cDNA clone IMAGE:1228219 5, mRNA sequence.	Mus musculus	44,211	23-Jan-98
	GB_PR2:CNS00VE	34105	AL096807	Homo sapiens genomic region containing hypervariable minisatellites chromosome 8[8q24.3] of Homo sapiens.	Homo sapiens	36,374	11-OCT-1999

TABLE 4: ALIGNMENT RESULTS

ra01832	1017	GB_HTG3:AC008129_0110000	AC008129	Homo sapiens clone RPC11-473H3, *** SEQUENCING IN PROGRESS ***, 136 unordered pieces.	Homo sapiens	38,877	24-Jul-99
		GB_GSS1:CNS006LB	929	AL065711	Drosophila melanogaster	35,589	3-Jun-99
		BACR13L01 of RPC1.98 library from Drosophila melanogaster (fruit fly), genomic survey sequence.					
		GB_RC:MUSIGVCA	153	ME0955	Mus musculus	43,421	27-Apr-93
		GB_BA2:AE001014	10636	AE001014	Archaeoglobus fulgidus	38,377	15-DEC-1997
ra01866	421	GB_IN2:AC008370	132171	AC008370	Drosophila melanogaster	34,845	3-Aug-99
		BACR09N11 and BACR40A15, complete sequence.					
		GB_IN2:AC008370	132171	AC008370	Drosophila melanogaster	37,897	3-Aug-99
		Drosophila melanogaster, chromosome 2R, region 44B-44C, BAC clones BACR09N11 and BACR40A15, complete sequence.					
		GB_HTG1:HSAJ9613	45302	AJ009613	Homo sapiens	38,717	11-Nov-98
		Homo sapiens chromosome 17 clone cosmid 5L5 map p11, *** SEQUENCING IN PROGRESS ***, in unordered pieces.					
ra01867	531	GB_EST15:AA520493	439	AA520493	Toxoplasma gondii	38,413	16-Jul-97
		TgESTz61f08.r1 TgmE49 invivo Bradyzoite cDNA size selected Toxoplasma gondii cDNA clone (gz61f08.r1 5', mRNA sequence.					
		GB_GSS10:AQ225693	448	AQ225693	Homo sapiens	37,374	26-Sep-98
		HS_2009_B2_B08_T7 CIT Approved Human Genomic Sperm Library D Homo sapiens genomic clone Plate=2009 Col=16 Row=D, genomic survey sequence.					
ra01876	1974	GB_PR4:AC005262	44235	AC005262	Homo sapiens	34,345	6-Jul-98
		GB_OV:CHKTN1C	1185	M10013	Gallus gallus	41,674	28-Apr-93
		GB_OV:CHKTN1C	927	K02623	Gallus gallus	40,065	28-Apr-93
		GB_OV:CHKTN1C	1185	M10013	Gallus gallus	42,097	28-Apr-93
ra01893	678	GB_BA1:AB016498	596	AB016498	Thermus thermophilus	53,691	9-Apr-99
		Thermus thermophilus frt gene for ribosome recycling factor gene (RRF), complete cds.					
		GB_PR4:AC002531	197900	AC002531	Homo sapiens	33,628	13-OCT-1999
		GB_HTG5:AC008019	190459	AC008019	Mus musculus	35,022	16-Nov-99
ra01912	861	GB_BA1:SC2E1	38962	AL023797	Streptomyces coelicolor	66,047	4-Jun-98
		GB_BA1:MTCY274	39991	Z74024	Mycobacterium tuberculosis	38,225	19-Jun-98
		GB_BA2:AF034101	2162	AF034101	Streptomyces coelicolor	65,814	15-OCT-1999
		Streptomyces coelicolor ribosomal protein S2 (psb) and elongation factor Ts (sf) genes, complete cds.					
ra01948	626	GB_BA1:MSRP1D	648	Y13226	Mycobacterium smegmatis	68,833	04-DEC-1997
		GB_BA1:MSGY42	36526	AD000005	Mycobacterium tuberculosis	35,313	03-DEC-1996
		GB_BA1:MTCY210	36804	Z84395	Mycobacterium tuberculosis	68,530	17-Jun-98
ra01949	426	GB_BA1:MBS10OPER	5962	Y13228	Mycobacterium bovis BCG	66,197	04-DEC-1997
		GB_BA1:MTCY210	36804	Z84395	Mycobacterium tuberculosis	65,962	17-Jun-98
		GB_BA1:MSGY42	36526	AD000005	Mycobacterium tuberculosis	38,765	03-DEC-1996
ra01951	684	GB_BA1:MTCY210	36804	Z84395	Mycobacterium tuberculosis	71,157	17-Jun-98
		GB_BA1:MSGY42	36526	AD000005	Mycobacterium tuberculosis	38,179	03-DEC-1996
		GB_BA1:MLCB2492	37144	Z98756	Mycobacterium tuberculosis	70,425	28-Aug-97
ra02037	353	GB_PR4:AC004921	150332	AC004921	Mycobacterium leprae	37,822	14-Jan-99
		Homo sapiens PAC clone DU0899E09 from 7q11.23-q21.1, complete sequence.					
		GB_HTG6:AC008076	200000	AC008076	Homo sapiens	41,860	02-DEC-1999
		Homo sapiens chromosome 4, *** SEQUENCING IN PROGRESS ***, 18 unordered pieces.					
		GB_PR4:AC004921	150332	AC004921	Homo sapiens	37,685	14-Jan-99
		Homo sapiens PAC clone DU0899E09 from 7q11.23-q21.1, complete sequence.					

TABLE 4: ALIGNMENT RESULTS

ra02038	492	GB_BA2:SCU43429	1740	U43429	Streptomyces coelicolor ribosomal protein L13 (rplM) and S9 (rpsI) genes, complete cds.	Streptomyces coelicolor	55,876	13-Jan-98
		GB_BA1:SC6G4	41055	AL031317	Streptomyces coelicolor cosmid 6G4.	Streptomyces coelicolor	55,876	20-Aug-98
		GB_BA1:MTCV77	22255	Z95389	Mycobacterium tuberculosis H37Rv complete genome; segment 146/162.	Mycobacterium tuberculosis	38,382	18-Jun-98
ra02041	737	GB_BA1:MTCV210	36804	Z84395	Mycobacterium tuberculosis H37Rv complete genome; segment 34/162.	Mycobacterium tuberculosis	70,041	17-Jun-98
		GB_BA1:MBS100OPER	5962	Y13228	Mycobacterium bovis BCG DNA for ribosomal S10 operon.	Mycobacterium bovis BCG	70,041	04-DEC-1997
		GB_BA1:MSGY42	36526	AD000005	Mycobacterium tuberculosis sequence from clone y42.	Mycobacterium tuberculosis	39,945	03-DEC-1996
ra02042	537	GB_BA1:MSGY42	36526	AD000005	Mycobacterium tuberculosis sequence from clone y42.	Mycobacterium tuberculosis	42,015	03-DEC-1996
		GB_BA1:MTCV210	36804	Z84395	Mycobacterium tuberculosis H37Rv complete genome; segment 34/162.	Mycobacterium tuberculosis	66,541	17-Jun-98
		GB_BA1:MLCB2492	37144	Z98756	Mycobacterium leprae cosmid B2492.	Mycobacterium leprae	66,604	28-Aug-97
ra02043	241	GB_BA1:AB017508	32050	AB017508	Bacillus halodurans C-125 genomic DNA, 32 kb fragment, complete cds.	Bacillus halodurans	48,305	14-Apr-99
		GB_EST1:D41045	356	D41045	RICS3304A Rice shoot Oryza sativa cDNA, mRNA sequence.	Oryza sativa	43,697	11-Nov-94
		GB_BA1:CZA382	42369	AL078635	Amycolatopsis orientalis cosmid pCZA382.	Amycolatopsis orientalis	42,152	17-Aug-99
ra02077	519	GB_RO:RNPLECT	15231	X59601	Rat mRNA for plectin.	Rattus norvegicus	41,468	19-DEC-1996
		GB_BA2:AF148219	1989	AF148219	Nostoc PCC8009 fibrillin and photosystem I protein E (psaE) genes, complete cds; and formamidopyrimidine-DNA glycosylase MutM (mutM) gene, partial cds.	Nostoc PCC8009	36,346	9-Jun-99
		GB_RO:RNPLECT	15231	X59601	Rat mRNA for plectin.	Rattus norvegicus	36,505	19-DEC-1996
ra02145	1740	GB_BA1:MTCV190	34150	Z70283	Mycobacterium tuberculosis H37Rv complete genome; segment 98/162.	Mycobacterium tuberculosis	64,033	17-Jun-98
		GB_BA1:MSGB1554CS	36548	L78814	Mycobacterium leprae cosmid B1554 DNA sequence.	Mycobacterium leprae	37,609	15-Jun-96
		GB_BA1:MSGB1551CS	36548	L78813	Mycobacterium leprae cosmid B1551 DNA sequence.	Mycobacterium leprae	37,609	15-Jun-96
ra02179	951	GB_EST5:X93280	344	X93280	SSVIAE19 S.scrofa ovary Sus scrofa cDNA clone V1ae19 5', mRNA sequence.	Sus scrofa	39,649	14-MAY-1997
		GB_GSS11:AQ324492	859	AQ324492	mgxb0018H12r CUGI Rice Blast BAC Library Magnaporthe grisea genomic clone mgxb0018H12r, genomic survey sequence.	Magnaporthe grisea	36,151	8-Jan-99
		GB_HTG3:AC011395	95036	AC011395	Homo sapiens chromosome 5 clone C17978SKB_18712, *** SEQUENCING IN PROGRESS ***	Homo sapiens	35,263	06-OCT-1999
		GB_HTG3:AC011395	95036	AC011395	PROGRESS *** 6 unordered pieces.			
ra02190	1581	GB_BA1:MTCV01B2	35938	Z95554	Mycobacterium tuberculosis H37Rv complete genome; segment 72/162.	Mycobacterium tuberculosis	76,141	17-Jun-98
		GB_BA1:MLACEA	37049	Z46257	M.leprae aceA gene for isocitrate lyase.	Mycobacterium leprae	72,172	22-MAY-1996
		GB_BA1:SC7H2	42655	AL109732	Streptomyces coelicolor cosmid 7H2.	Streptomyces coelicolor A3(2)	40,627	2-Aug-99
ra02241	584	GB_HTG3:AC010579	157658	AC010579	Drosophila melanogaster chromosome 3 clone BACR09D08 (D1101) RPCI-98 09.D 8 map 96F-96F strain y; cn bw sp, *** SEQUENCING IN PROGRESS ***	Drosophila melanogaster	40,402	24-Sep-99
		GB_HTG3:AC010579	157658	AC010579	*** 121 unordered pieces.			
		GB_HTG3:AC010579	157658	AC010579	Drosophila melanogaster chromosome 3 clone BACR09D08 (D1101) RPCI-98 09.D 8 map 96F-96F strain y; cn bw sp, *** SEQUENCING IN PROGRESS ***	Drosophila melanogaster	40,402	24-Sep-99
		GB_HTG2:AC007946	97610	AC007946	*** 121 unordered pieces.			
		GB_HTG2:AC007946	97610	AC007946	Drosophila melanogaster chromosome 3 clone BACR03003 (D769) RPCI-98 03.O 3 map 96E-96F strain y; cn bw sp, *** SEQUENCING IN PROGRESS ***	Drosophila melanogaster	40,248	2-Aug-99
		GB_HTG2:AC007946	97610	AC007946	*** 70 unordered pieces.			
ra02293	2511	GB_BA1:SC7H2	42655	AL109732	Streptomyces coelicolor cosmid 7H2.	Streptomyces coelicolor A3(2)	40,557	2-Aug-99
		GB_BA2:U49051	2859	U49051	Sinorhizobium meliloti putative DEAH family helicase HeIo gene, complete cds.	Sinorhizobium meliloti	48,002	7-Aug-97
		GB_BA2:U32787	12361	U32787	Haemophilus influenzae Rd section 102 of 163 of the complete genome.	Haemophilus influenzae Rd	36,309	29-MAY-1998
ra02357	6423	GB_EST1:T47370	307	T47370	yb13b07.r1 Striatogene placenta (#937225) Homo sapiens cDNA clone IMAGE:71029 5' similar to contains L1 repetitive element, mRNA sequence.	Homo sapiens	40,850	1-Feb-95
		GB_PR1:HSVMVCLC2	11997	Z15030	H sapiens gene for ventricular myosin light chain 2.	Homo sapiens	40,012	9-Feb-99

TABLE 4: ALIGNMENT RESULTS

ra02359	1992	GB_PR1:HUM/MLC GB_PR3:HS523G1	11997 109885	L01652 AL034375	Human ventricular myosin light chain 2 gene, seven exons. Human DNA sequence from clone 523G1 on chromosome 6p22.3-24.1 Contains part of the mRNA for SCA1 (spino cerebellar ataxia 1 (olivopontocerebellar ataxia 1, autosomal dominant, ataxin 1)) STSs and GSSs, complete sequence. Human DNA sequence from clone 523G1 on chromosome 6p22.3-24.1 Contains part of the mRNA for SCA1 (spino cerebellar ataxia 1 (olivopontocerebellar ataxia 1, autosomal dominant, ataxin 1)) STSs and GSSs, complete sequence.	Homo sapiens Homo sapiens	40,012 37,589	3-Aug-93 23-Nov-99
		GB_PR3:HS523G1	109885	AL034375		Homo sapiens	35,888	23-Nov-99
ra02363	4923	GB_RO:MMU9842 GB_RO:MM/PROCNE GB_OM:PIGPEP GB_BA1:MTCY428 GB_HTG3:AC010371	168 1819 1398 26914 86848	AJ009842 X97399 M20920 Z81451 AC010371	Mus musculus cathepsin E gene, exon 3, partial. M. musculus mRNA for procathepsin E. Swine pepsinogen A mRNA, complete cds. Mycobacterium tuberculosis H37Rv complete genome; segment 107/162. Homo sapiens chromosome 5 clone CITB-H1_2049013, *** SEQUENCING IN PROGRESS *** 29 unordered pieces. Homo sapiens chromosome 5 clone CITB-H1_2049013, *** SEQUENCING IN PROGRESS *** 29 unordered pieces. Leishmania major chromosome 3 clone L712 strain Friedlin, complete sequence.	Mus musculus Mus musculus Sus scrofa Mycobacterium tuberculosis Homo sapiens Homo sapiens Leishmania major	44,643 38,793 37,066 38,568 41,055 41,055	19-Aug-99 3-Jun-97 27-Apr-93 17-Jun-98 15-Sep-99 15-Sep-99
ra02370	915	GB_IN2:AC005930 GB_GSS3:B43984	41284 403	AC005930 B43984	Homo sapiens chromosome 3 clone L712 strain Friedlin, complete sequence. HS-1058-B1-F09-MF:abi CIT Human Genomic Sperm Library C Homo sapiens genomic clone Plate=CT 780 Col=17 Row=L, genomic survey sequence.	Homo sapiens	39,686 39,918	13-Nov-99 21-OCT-1997
		GB_GSS3:B43984	403	B43984		Homo sapiens	39,918	21-OCT-1997
		GB_HTG3:AC010371	86848	AC010371		Homo sapiens	41,055	15-Sep-99
		GB_IN2:AC005930	41284	AC005930		Leishmania major	39,686	13-Nov-99
		GB_GSS3:B43984	403	B43984		Homo sapiens	39,918	21-OCT-1997
		GB_GSS3:AC0108989	192	AQ108989	CIT-HSP-2360J15.TF CIT-HSP Homo sapiens genomic clone 2360J15, genomic survey sequence.	Homo sapiens	39,474	29-Aug-98
ra02371	415	GB_BA1:MTCY428 GB_BA2:AE000749 GB_IN1:DMC63B12 GB_PR4:AC004617 GB_HTG1:HS2705	26914 16033 36401 176552 149932	Z81451 AE000749 AL021106 AC004617 AL033529	Mycobacterium tuberculosis H37Rv complete genome; segment 107/162. Aquifex aeolicus section 81 of 109 of the complete genome. Drosophila melanogaster cosmid clone 63B12. Homo sapiens chromosome Y, clone 264,M,20, complete sequence. Homo sapiens chromosome 1 clone RP1-27O5, *** SEQUENCING IN PROGRESS *** 29 unordered pieces. Homo sapiens chromosome 1 clone RP1-27O5, *** SEQUENCING IN PROGRESS *** 29 unordered pieces.	Mycobacterium tuberculosis Aquifex aeolicus Drosophila melanogaster Homo sapiens Homo sapiens	35,351 38,677 38,592 40,212 40,682	17-Jun-98 25-MAR-1998 29-Apr-99 13-OCT-1999 23-Nov-99
		GB_HTG1:HS2705	149932	AL033529		Homo sapiens	40,682	23-Nov-99
		GB_BA1:MTCY06H11	38000	Z85982	Mycobacterium tuberculosis H37Rv complete genome; segment 73/162.	Mycobacterium tuberculosis	54,341	17-Jun-98
ra02419	315	GB_GSS12:QA410661 GB_BA2:SCAHBAGC2	433 5367	AQ410661 AF131879	HS_5045_B2_E05_SPBE RPCI-11 Human Male BAC Library Homo sapiens genomic clone Plate=621 Col=10 Row=L, genomic survey sequence. Streptomyces collinus anstrelinin AHBA biosynthetic gene cluster region 2, complete sequence.	Homo sapiens Streptomyces collinus	35,505 35,593	17-MAR-1999 24-MAY-1999
		GB_BA1:MTCY06H11	38000	Z85982		Mycobacterium tuberculosis	64,542	17-Jun-98
ra02420	504	GB_BA1:SC135 GB_EST37:A1995529	40909 634	AL031541 A1995529	Streptomyces coelicolor cosmid 135. 701675731 A. thaliana, Columbia Col-0, inflorescence-1 Arabidopsis thaliana cDNA clone 701675731, mRNA sequence.	Streptomyces coelicolor Arabidopsis thaliana	36,439 38,200	9-Sep-98 8-Sep-99
		GB_BA1:MTCY7D11	22070	Z95120	Mycobacterium tuberculosis H37Rv complete genome; segment 136/162.	Mycobacterium tuberculosis	60,654	17-Jun-98
ra02468	1347	GB_HTG4:AC008754	86446	AC008754	Homo sapiens chromosome 19 clone CITB-E1_3023J11, *** SEQUENCING IN PROGRESS *** 73 unordered pieces.	Homo sapiens	35,634	31-OCT-1999

TABLE 4: ALIGNMENT RESULTS

ra02522	666	GB_PL2:AC004135	73805	AC004135	Genomic sequence for Arabidopsis thaliana BAC T17H7 from Chromosome 1, Arabidopsis thaliana complete sequence.	38,052	29-MAY-1999
		GB_PL2:AC004135	73805	AC004135	Genomic sequence for Arabidopsis thaliana BAC T17H7 from Chromosome 1, Arabidopsis thaliana complete sequence.	36,157	29-MAY-1999
ra02533		GB_RO:MUSTRAA	6149	M36386	Mouse tumor rejection antigen P815A gene, complete cds.	35,769	27-Apr-93
ra02615	759	GB_BA1:MSKATG	2307	X98718	M. smegmatis katG gene.	37,349	16-Jan-97
		GB_BA2:MSU46844	16951	U46844	Mycobacterium smegmatis catalase-peroxidase (katG), putative arabinosyl transferase (embC, embA, embB), genes complete cds and putative propionyl-coA carboxylase beta chain (pccB) genes, partial cds.	39,783	12-MAY-1997
		GB_BA2:AF124600	4115	AF124600	Corynebacterium glutamicum chorismate synthase (aroC), shikimate kinase (aroK), and 3-dehydroquinate synthase (aroB) genes, complete cds, and putative cytoplasmic peptidase (pepC) gene, partial cds.	39,893	04-MAY-1999
ra02633	387	GB_RO:RNV09164	6556	Y09164	R. norvegicus mRNA for sodium channel.	34,204	8-Jan-97
		GB_RO:RNV09164	6556	Y09164	R. norvegicus mRNA for sodium channel.	38,298	8-Jan-97
ra02635	357	GB_BA1:MTV018	53450	AL021899	Mycobacterium tuberculosis H37Rv complete genome; segment 90/162.	37,464	18-Jun-98
		GB_GSS1:MTAF0013813045		AF001381	Mycobacterium tuberculosis strain KIT10218 cosmid 10R, partial sequence, genomic survey sequence.	36,667	9-Aug-97
ra02636	285	GB_BA1:SC6C5	18160	AL034492	Streptomyces coelicolor cosmid 6C5.	42,938	14-DEC-1998
		GB_BA1:MTV018	53450	AL021899	Mycobacterium tuberculosis H37Rv complete genome; segment 90/162.	41,036	18-Jun-98
		GB_GSS1:MTAF0013813045		AF001381	Mycobacterium tuberculosis strain KIT10218 cosmid 10R, partial sequence, genomic survey sequence.	40,206	9-Aug-97
		GB_GSS1:MTAF0013813045		AF001381	Mycobacterium tuberculosis strain KIT10218 cosmid 10R, partial sequence, genomic survey sequence.	45,091	9-Aug-97
ra02637	426	GB_PR4:AC006602	93610	AC006602	Homo sapiens Chromosome 15q11-q13 PAC clone pDJ47619 from the Prader-Homo sapiens Williams/Angelman Syndrome region, complete sequence.	37,441	23-Feb-99
		GB_PR4:AC007275	169904	AC007275	Homo sapiens clone NH0109F19, complete sequence.	36,170	29-Jul-99
		GB_PR4:AC007275	169904	AC007275	Homo sapiens clone NH0109F19, complete sequence.	34,783	29-Jul-99
ra02657	3705	GB_BA1:MTCV48	35377	Z74020	Mycobacterium tuberculosis H37Rv complete genome; segment 69/162.	63,678	17-Jun-98
		GB_BA1:MLCL458	43839	AL049478	Mycobacterium leprae cosmid L458.	63,716	27-Aug-99
		GB_BA1:MSG813GS	42923	L78823	Mycobacterium leprae cosmid B13 DNA sequence.	37,939	15-Jun-96
ra02682	450	GB_PR2:AC002379	118595	AC002379	Human BAC clone GS165104 from Tgq21, complete sequence.	36,552	23-Jul-97
		GB_EST18:T44994	452	T44994	8257 Lambda-PR12 Arabidopsis thaliana cDNA clone 127P2377, mRNA sequence.	34,247	7-Jan-98
		GB_EST14:AA395030	444	AA395030	26827 Lambda-PR12 Arabidopsis thaliana cDNA clone 111K20XP3, mRNA sequence.	31,806	30-OCT-1997
ra02752	618	GB_BA1:MTCV274	39991	Z74024	Mycobacterium tuberculosis H37Rv complete genome; segment 126/162.	38,715	19-Jun-98
		GB_BA1:SC2E1	38962	AL023797	Streptomyces coelicolor cosmid 2E1.	53,300	4-Jun-98
		GB_BA2:SKZ86111	7860	Z86111	Streptomyces lividans rpsP, trmD, rpsJ, sipV, sipX, sipY, sipZ, mult genes and 4 open reading frames.	52,970	27-OCT-1999
ra02755	2118	GB_BA1:MSGY151	37036	AD000018	Mycobacterium tuberculosis sequence from clone Y151.	56,905	10-DEC-1996

TABLE 4: ALIGNMENT RESULTS

ra02764	GB_BA1:MTCY130	32514	Z73902	Mycobacterium tuberculosis H37Rv complete genome; segment 59/162.	Mycobacterium tuberculosis	39,419	17-Jun-98
	GB_BA1:SC4H2	38400	AL022268	Streptomyces coelicolor cosmid 4H2.	Streptomyces coelicolor	56,729	6-Apr-98
ra02819	GB_GSS14:AQ549674	479	AQ549674	RPCI-11-413C1.TV RPCI-11 Homo sapiens genomic clone RPCI-11-413C1, genomic survey sequence.	Homo sapiens	40,705	28-MAY-1999
	GB_GSS14:AQ549674	479	AQ549674	RPCI-11-413C1.TV RPCI-11 Homo sapiens genomic clone RPCI-11-413C1, genomic survey sequence.	Homo sapiens	38,696	28-MAY-1999
ra02826	GB_BA1:MTY20H10	35980	Z92772	Mycobacterium tuberculosis H37Rv complete genome; segment 31/162.	Mycobacterium tuberculosis	67,387	17-Jun-98
	GB_BA1:SGNUSG	7235	X72787	S. griseus nusG, rplKAL gene cluster.	Streptomyces griseus	65,946	06-MAY-1998
	GB_BA1:STMVBR41	7409	D50624	Streptomyces virginiae VbrA gene for NusG like protein, SecE like protein and ribosomal protein, aspartate aminotransferase and adenosine deaminase, complete cds.	Streptomyces virginiae	65,766	10-Feb-99
ra02833	EM_PAT:E11161	3521	E11161	Genomic DNA including an autonomous replication sequences (ars)	Corynebacterium glutamicum	98,343	08-OCT-1997 (Rel. 52, Created)
	GB_BA2:MAU19185	3952	U19185	Mycobacterium avium RpmH (rpmH) and DnaA (dnaA) genes, complete cds, and DnaN (dnan) gene, partial cds.	Mycobacterium avium	46,333	08-DEC-1998
	GB_BA1:MLUDNAA	4171	M34006	M. luteus ribonuclease P (rnpA), 50S ribosomal subunit protein L34 (rpmH), DNA biosynthesis initiation protein (dnaA), and DNA polymerase III beta subunit (dnan) genes, complete cds.	Micrococcus luteus	46,540	16-Feb-94